AB 1774: Clinical laboratories: licensure.
- Session Year: 2015-2016
- House: Assembly
- Latest Version Date: 2016-05-11
Existing federal law, the Clinical Laboratory Improvement Amendments of 1988 (CLIA) requires the federal Centers for Medicare and Medicaid Services to certify and regulate clinical laboratories that perform testing on humans. Complaints against individual laboratories are directed to the state.
Existing law provides for the licensure, registration, and regulation of clinical laboratories and various clinical laboratory personnel by the State Department of Public Health. Under existing law the department inspects clinical laboratories and assesses a fee for licensure of those facilities.
This bill would repeal the laws requiring a clinical laboratory to be licensed by the department, including the licensing fee, and would recast the inspection role of the department to involve inspection and monitoring of specified issues for clinical laboratories that are not accredited by an accrediting organization approved under CLIA, investigation upon complaint, and sanctions, as provided. The bill would authorize the department, after the balance in the Clinical Laboratory Improvement Fund that is attributable to licensing fees previously assessed on clinical laboratories is less than $1,000,000, to assess a fee, upon inspection, for clinical laboratories that are not accredited by an agency approved under federal law. The bill would also make conforming changes.
Existing federal law, the Clinical Laboratory Improvement Amendments of 1988 (CLIA) requires the federal Centers for Medicare and Medicaid Services to certify and regulate clinical laboratories that perform testing on humans. Complaints against individual laboratories are directed to the state.
Existing law provides for the licensure, registration, and regulation of clinical laboratories and various clinical laboratory personnel by the State Department of Public Health. Under existing law the department inspects clinical laboratories and assesses a fee for licensure of those facilities.
This bill would repeal the laws requiring a clinical laboratory to be licensed and inspected by the department, including the licensing fee. fee, and would recast the inspection role of the department to involve inspection and monitoring of specified issues for clinical laboratories that are not accredited by an accrediting organization approved under CLIA, investigation upon complaint, and sanctions, as provided. The bill would also make conforming changes.
Existing federal law, the Clinical Laboratory Improvement Amendments of 1988 (CLIA) requires the federal Centers for Medicare and Medicaid Services to certify and regulate clinical laboratories that perform testing on humans. Complaints against individual laboratories are directed to the state.
Existing law provides for the licensure, registration, and regulation of clinical laboratories and various clinical laboratory personnel by the State Department of Public Health. Under existing law the department inspects clinical laboratories and assesses a fee for licensure of those facilities.
This bill would repeal the laws requiring a clinical laboratory to be licensed and inspected by the department, including the licensing fee. The bill would also make conforming changes.
(a)A person licensed under Chapter 4 (commencing with Section 1600) of this division or licensed under Chapter 5 (commencing with Section 2000) of this division or licensed under any initiative act referred to in this division relating to osteopaths may not refer patients, clients, or customers to a clinical laboratory in which the licensee has a membership, proprietary interest, or coownership in any form, or has a profit-sharing arrangement, unless the licensee at the time of making the referral discloses in writing the interest to the patient, client, or customer. The written disclosure shall indicate that the patient may choose any clinical laboratory for purposes of having laboratory work or assignment performed.
(b)This does shall not apply to persons who are members of a medical group that contracts to provide medical care to members of a group practice prepayment plan registered under the Knox-Keene Health Care Service Act of 1975 (Chapter 2.2 (commencing with Section 1340) of Division 2 of the Health and Safety Code).
(c)This does shall not apply to a referral to a clinical laboratory that is owned and operated by a health facility licensed pursuant to Chapter 2 (commencing with Section 1250) of Division 2 of the Health and Safety Code.
(d)This section does not prohibit the acceptance of evaluation specimens for proficiency testing or referral of specimens or the assignment from one clinical laboratory to another clinical laboratory, either licensed or exempt under this chapter, providing the report indicates clearly the laboratory performing the test.
(e)Proprietary interest does not include ownership of a building where space is leased to a clinical laboratory at the prevailing rate under a straight lease arrangement.
(f)A violation of this section is a public offense and is punishable upon a first conviction by imprisonment in a county jail for not more than one year, or by imprisonment pursuant to subdivision (h) of Section 1170 of the Penal Code, or by a fine not exceeding ten thousand dollars ($10,000), or by both that imprisonment and fine. A second or subsequent conviction shall be punishable by imprisonment pursuant to subdivision (h) of Section 1170 of the Penal Code.
SEC. 2.Section 655.5 of the Business and Professions Code is amended to read:655.5.(a)It is unlawful for a person licensed under this division or under an initiative act referred to in this division, or a clinical laboratory, or a health facility when billing for a clinical laboratory of the facility, to charge, bill, or otherwise solicit payment from a patient, client, or customer for a clinical laboratory service not actually rendered by the person or clinical laboratory or under his, her her, or its direct supervision unless the patient, client, or customer is apprised at the first time of the charge, billing, or solicitation of the name, address, and charges of the clinical laboratory performing the service. The first written charge, bill, or other solicitation of payment shall separately set forth the name, address, and charges of the clinical laboratory concerned and shall clearly show whether or not the charge is included in the total of the account, bill, or charge. This subdivision is satisfied if the required disclosures are made to the third-party payer of the patient, client, or customer. If the patient is responsible for submitting the bill for the charges to the third-party payer, the bill provided to the patient for that purpose shall include the disclosures required by this section. This subdivision does not apply to a clinical laboratory of a health facility or a health facility when billing for a clinical laboratory of the facility nor to a person licensed under this division or under any initiative act referred to in this division if the standardized billing form used by the facility or person requires a summary entry for all clinical laboratory charges. For purposes of this subdivision, health facility has the same meaning as defined in Section 1250 of the Health and Safety Code.
(b)A clinical laboratory shall provide to each of its referring providers, upon request, a schedule of fees for services provided to patients of the referring provider. The schedule shall be provided within two working days after the clinical laboratory receives the request. For the purposes of this subdivision, a referring provider means a provider who has referred a patient to the clinical laboratory in the preceding six-month period. A clinical laboratory that provides a list of laboratory services to a referring provider or to a potential referring provider shall include a schedule of fees for the laboratory services listed.
(c)It is also unlawful for a person licensed under this division or under any initiative act referred to in this division to charge additional charges for a clinical laboratory service that is not actually rendered by the licensee to the patient and itemized in the charge, bill, or other solicitation of payment. This section shall not be construed to prohibit any of the following:
(1)An itemized charge for a service actually rendered to the patient by the licensee.
(2)A summary charge for services actually rendered to a patient by a health facility, as defined in Section 1250 of the Health and Safety Code, or by a person licensed under this division or under any initiative act referred to in this division if the standardized billing form used by the facility or person requires a summary entry for all clinical laboratory charges.
(d)As used in this section, the term a person licensed under this division includes a registered laboratory, as defined in Section 1206, all wholly owned subsidiaries of the person, a parent company that wholly owns the person, and any subsidiaries wholly owned by the same parent that wholly owns the person. Wholly owned means ownership directly or through one or more subsidiaries. This section shall not apply to billings by a registered laboratory when the registered laboratory bills for services performed by a laboratory owned or operated by the registered laboratory.
(e)This section does not apply to a person or clinical laboratory who or which contracts directly with a health care service plan licensed pursuant to Section 1349 of the Health and Safety Code, if the services are to be provided to members of the plan on a prepaid basis and without additional charge or liability on account thereof.
(f)A violation of this section is a public offense and is punishable upon a first conviction by imprisonment in a county jail for not more than one year, or by imprisonment pursuant to subdivision (h) of Section 1170 of the Penal Code, or by a fine not exceeding ten thousand dollars ($10,000), or by both that imprisonment and fine. A second or subsequent conviction is punishable by imprisonment pursuant to subdivision (h) of Section 1170 of the Penal Code.
(g)(1)Notwithstanding subdivision (f), a violation of this section by a physician and surgeon for a first offense shall be subject to the exclusive remedy of reprimand by the Medical Board of California if the transaction that is the subject of the violation involves a charge for a clinical laboratory service that is less than the charge would have been if the clinical laboratory providing the service billed a patient, client, or customer directly for the clinical laboratory service, and if that clinical laboratory charge is less than the charge listed in the clinical laboratorys schedule of fees pursuant to subdivision (b).
(2)This subdivision does not permit a physician and surgeon to charge more than he or she was charged for the laboratory service by the clinical laboratory providing the service unless the additional charge is for service actually rendered by the physician and surgeon to the patient.
SEC. 3.Section 1206 of the Business and Professions Code is amended to read:1206.(a)For the purposes of this chapter the following definitions are applicable:
(1)Analyte means the substance or constituent being measured, including, but not limited to, glucose, sodium, or theophylline, or any substance or property whose presence or absence, concentration, activity, intensity, or other characteristics are to be determined.
(2)Biological specimen means any material that is derived from the human body.
(3)Blood electrolyte analysis means the measurement of electrolytes in a blood specimen by means of ion selective electrodes on instruments specifically designed and manufactured for blood gas and acid-base analysis.
(4)Blood gas analysis means a clinical laboratory test or examination that deals with the uptake, transport, and metabolization of oxygen and carbon dioxide in the human body.
(5)Clinical laboratory test or examination means the detection, identification, measurement, evaluation, correlation, monitoring, and reporting of any particular analyte, entity, or substance within a biological specimen for the purpose of obtaining scientific data that may be used as an aid to ascertain the presence, progress, and source of a disease or physiological condition in a human being, or used as an aid in the prevention, prognosis, monitoring, or treatment of a physiological or pathological condition in a human being, or for the performance of nondiagnostic tests for assessing the health of an individual.
(6)Clinical laboratory science means any of the sciences or scientific disciplines used to perform a clinical laboratory test or examination.
(7)Clinical laboratory practice means the application of clinical laboratory sciences or the use of any means that applies the clinical laboratory sciences within or outside of a licensed or registered clinical laboratory. Clinical laboratory practice includes consultation, advisory, and other activities inherent to the profession.
(8)Clinical laboratory means a place used, or an establishment or institution organized or operated, for the performance of clinical laboratory tests or examinations or the practical application of the clinical laboratory sciences. That application may include any means that applies the clinical laboratory sciences.
(9)Direct and constant supervision means personal observation and critical evaluation of the activity of unlicensed laboratory personnel by a physician and surgeon, or by a person licensed under this chapter other than a trainee, during the entire time that the unlicensed laboratory personnel are engaged in the duties specified in Section 1269.
(10)Direct and responsible supervision means both of the following:
(A)Personal observation and critical evaluation of the activity of a trainee by a physician and surgeon, or by a person licensed under this chapter other than a trainee, during the entire time that the trainee is performing clinical laboratory tests or examinations.
(B)Personal review by the physician and surgeon or the licensed person of all results of clinical laboratory testing or examination performed by the trainee for accuracy, reliability, and validity before the results are reported from the laboratory.
(11)Licensed laboratory means a clinical laboratory licensed pursuant to the federal Clinical Laboratory Improvement Amendments of 1988 (CLIA).
(12)Location means either a street and city address, or a site or place within a street and city address, where any of the clinical laboratory sciences or scientific disciplines are practiced or applied, or where clinical laboratory tests or examinations are performed.
(13)Physician office laboratory means a clinical laboratory that is either: (A) owned and operated by a partnership or professional corporation that performs clinical laboratory tests or examinations only for patients of five or fewer physicians and surgeons or podiatrists who are shareholders, partners, or employees of the partnership or professional corporation that owns and operates the clinical laboratory; or (B) owned and operated by an individual licensed physician and surgeon or a podiatrist, and that performs clinical laboratory tests or examinations only for patients of the physician and surgeon or podiatrist who owns and operates the clinical laboratory.
(14)Point-of-care laboratory testing device means a portable laboratory testing instrument to which the following applies:
(A)It is used within the proximity of the patient for whom the test or examination is being conducted.
(B)It is used in accordance with the patient test management system, the quality control program, and the comprehensive quality assurance program established and maintained by the laboratory pursuant to paragraph (2) of subdivision (d) of Section 1220.
(C)It meets the following criteria:
(i)Performs clinical laboratory tests or examinations classified as waived or of moderate complexity under the federal Clinical Laboratory Improvement Amendments of 1988 (CLIA) (42 U.S.C. Sec. 263a).
(ii)Performs clinical laboratory tests or examinations on biological specimens that require no preparation after collection.
(iii)Provides clinical laboratory tests or examination results without calculation or discretionary intervention by the testing personnel.
(iv)Performs clinical laboratory tests or examinations without the necessity for testing personnel to perform calibration or maintenance, except resetting pursuant to the manufacturers instructions or basic cleaning.
(15)Public health laboratory means a laboratory that is operated by a city or county in conformity with Article 5 (commencing with Section 101150) of Chapter 2 of Part 3 of Division 101 of the Health and Safety Code and the regulations adopted thereunder.
(16)Registered laboratory means a clinical laboratory that performs clinical laboratory tests or examinations subject to a certificate of waiver or a certificate of provider-performed microscopy under CLIA.
(17)Specialty means histocompatibility, microbiology, diagnostic immunology, chemistry, hematology, immunohematology, pathology, genetics, or other specialty specified by regulation adopted by the department.
(18)Subspecialty for purposes of microbiology, means bacteriology, mycobacteriology, mycology, parasitology, virology, molecular biology, and serology for diagnosis of infectious diseases, or other subspecialty specified by regulation adopted by the department; for purposes of diagnostic immunology, means syphilis serology, general immunology, or other subspecialty specified by regulation adopted by the department; for purposes of chemistry, means routine chemistry, clinical microscopy, endocrinology, toxicology, or other subspecialty specified by regulation adopted by the department; for purposes of immunohematology, means ABO/Rh Type and Group, antibody detection for transfusion, antibody detection nontransfusion, antibody identification, compatibility, or other subspecialty specified by regulation adopted by the department; for pathology, means tissue pathology, oral pathology, diagnostic cytology, or other subspecialty specified by regulation adopted by the department; for purposes of genetics, means molecular biology related to the diagnosis of human genetic abnormalities, cytogenetics, or other subspecialty specified by regulation adopted by the department.
(b)This chapter does not restrict, limit, or prevent a person licensed to provide health care services under the laws of this state, including, but not limited to, licensed physicians and surgeons and registered nurses, from practicing the profession or occupation for which he or she is licensed.
(c)This chapter does not authorize a person to perform or order health care services, or utilize the results of the clinical laboratory test or examination, unless the person is otherwise authorized to provide that care or utilize the results. The inclusion of a person in Section 1206.5 for purposes of performing a clinical laboratory test or examination shall not be interpreted to authorize a person, who is not otherwise authorized, to perform venipuncture, arterial puncture, or skin puncture.
SEC. 4.Section 1206.6 of the Business and Professions Code is amended to read:1206.6.Subdivision (a) of Section 1206.5 does not apply to a pharmacist at a community pharmacy who, upon customer request, performs only blood glucose, hemoglobin A1c, or cholesterol tests that are classified as waived under CLIA and are approved by the federal Food and Drug Administration for sale to the public without a prescription in the form of an over-the-counter test kit, provided that all of the following requirements are satisfied:
(a)The pharmacy obtains a valid CLIA certificate of waiver and complies with all other requirements for the performance of waived clinical laboratory tests under applicable federal regulations. For purposes of CLIA, the person identified as responsible for directing and supervising testing oversight and decisionmaking shall be the pharmacist-in-charge, as defined in Section 4036.5.
(b)The pharmacy complies with this chapter.
(c)The tests are performed only by a pharmacist, as defined in Section 4036, in the course of performing routine patient assessment procedures in compliance with Section 4052.4.
SEC. 5.Section 1220 of the Business and Professions Code is amended to read:1220.(a)(1)Each clinical laboratory shall maintain records, equipment, and facilities that are adequate and appropriate for the services rendered.
(2)(A)Except for tests or examinations classified as waived under CLIA, each clinical laboratory shall enroll, and demonstrate successful participation, as defined under CLIA, for each specialty and subspecialty in which it performs clinical laboratory tests or examinations, in a proficiency testing program approved by the department or by CMS, to the same extent as required by CLIA in Subpart H (commencing with Section 493.801) of Title 42 of the Code of Federal Regulations. This requirement does not prohibit a clinical laboratory from performing clinical laboratory tests or examinations in a specialty or subspecialty for which there is no department or CMS approved CMS-approved proficiency testing program.
(B)Each clinical laboratory shall authorize its proficiency test results to be reported to the department in an electronic format that is compatible with the departments proficiency testing data monitoring system and shall authorize the release of proficiency tests results to the public to the same extent required by CLIA.
(b)Each clinical laboratory shall be conducted, maintained, and operated without injury to the public health.
(c)The department shall conduct an investigation of complaints received concerning a clinical laboratory that may include an inspection of the laboratory.
(d)(1)Each clinical laboratory shall perform all clinical laboratory tests or examinations classified as waived under CLIA in conformity with the manufacturers instructions.
(2)Except for those clinical laboratories performing only tests or examinations classified as waived under CLIA, each clinical laboratory shall establish and maintain all of the following:
(A)A patient test management system that meets the standards of CLIA in Subpart J (commencing with Section 493.1100) of Title 42 of the Code of Federal Regulations.
(B)A quality control program that meets the requirements of CLIA in Subpart K (commencing with Section 493.1200) of Title 42 of the Code of Federal Regulations as in effect on January 1, 2015, and that may include the clinical laboratorys use of an Individualized Quality Control Plan, as incorporated into Appendix C of the State Operations Manual adopted by the federal Centers for Medicare and Medicaid Services (CMS).
(C)A comprehensive quality assurance program that meets the standards of CLIA in Subpart P (commencing with Section 493.1701) of Title 42 of the Code of Federal Regulations.
SEC. 6.Section 1223 of the Business and Professions Code is repealed.SEC. 7.Section 1223 is added to the Business and Professions Code, to read:1223.(a)Clinical laboratories shall choose to be overseen select to be regulated by the department, pursuant to subdivision (a), paragraph (1), or may seek certification of deemed status by an accrediting organization approved under CLIA, pursuant to subdivision (b). paragraph (2). The accrediting organization may issue certificates of deemed status and may provide continued oversight to ensure compliance with state law.
(a)
(1)The department shall monitor, inspect, and investigate all clinical laboratories that are not accredited by an organization approved under CLIA for compliance with state standards that are in excess of federal standards.
(b)(1)
(2)(A)A clinical laboratory that is accredited by an organization approved under CLIA shall be deemed to meet all state standards and shall not require monitoring, inspection, or investigation pursuant to subdivision (a), paragraph (1) but may be subject to investigation by the department under other provisions of law.
(2)
(B)An accrediting organization shall provide the department with documentation of approval by the federal Centers for Medicare & Medicaid Services as an accrediting body under CLIA, a detailed comparison of the individual accreditation or approval requirements, with the comparable California condition-level requirements, including standards that are in excess of federal law, and a list of all of the clinical laboratories that operate in California, including the CLIA number and the expiration date of their accreditation, as applicable.
(c)
(b)The department may concentrate its resources on upholding personnel standards.
(c)(1)The department may charge a fee to inspect clinical laboratories that are regulated by the department pursuant to paragraph (1) of subdivision (a). The fee shall be assessed upon inspection and shall be set at the reasonable cost of inspection, but in no case shall the fee exceed one thousand fifty dollars ($1,050).
(2)The department shall not assess a fee pursuant to this subdivision until the balance in the Clinical Laboratory Improvement Fund that is attributable to fees assessed on clinical laboratories under Section 1300, as it existed prior to January 1, 2017, is less than one million dollars ($1,000,000).
SEC. 8.Section 1227 of the Business and Professions Code is repealed.SEC. 9.Section 1227 is added to the Business and Professions Code, to read:1227.The department shall post on its Internet Web site a comprehensive list of the differences between state law and CLIA.
SEC. 10.Section 1241.1 of the Business and Professions Code is repealed.SEC. 11.Section 1244 of the Business and Professions Code is amended to read:1244.(a)This chapter does not restrict, limit, or prevent a program of nondiagnostic general health assessment provided that:
(1)The program complies with the requirements of CLIA for waived testing.
(2)The purpose of the program is to screen asymptomatic individuals for chronic health disorders and to refer individuals to licensed sources of care as indicated.
(3)The program does not test for human immunodeficiency virus or any reportable disease or condition identified in Section 120130 of the Health and Safety Code or the regulations adopted under that section.
(4)The program utilizes only those devices that comply with all of the following:
(A)Meet all applicable state and federal performance standards pursuant to Section 111245 of the Health and Safety Code.
(B)Are not adulterated as specified in Article 2 (commencing with Section 111250) of Chapter 6 of Part 5 of Division 104 of the Health and Safety Code.
(C)Are not misbranded as specified in Article 3 (commencing with Section 111330) of Chapter 6 of Part 5 of Division 104 of the Health and Safety Code.
(D)Are not new devices unless they meet the requirements of Section 111550 of the Health and Safety Code.
(E)Are approved as waived tests and are used according to the manufacturers instructions.
(5)Blood collection is performed by skin puncture only.
(6)Testing of a urine specimen is performed by the dipstick method only.
(7)Testing is performed on site on-site and reported directly to the person requesting the test.
(8)The program maintains a supervisory committee consisting of, at a minimum, a licensed physician and surgeon and a clinical laboratory scientist licensed pursuant to this code.
(9)The supervisory committee for the program adopts written protocols that shall be followed in the program and that shall contain all of the following:
(A)Provision of written information to individuals to be assessed that shall include, but not be limited to, the following:
(i)The potential risks and benefits of assessment procedures to be performed in the program.
(ii)The limitations, including the nondiagnostic nature, of assessment examinations of biological specimens performed in the program.
(iii)Information regarding the risk factors or markers targeted by the program.
(iv)The need for followup with licensed sources of care for confirmation, diagnosis, and treatment as appropriate.
(B)Proper use of each device utilized in the program including the operation of analyzers, maintenance of equipment and supplies, and performance of quality control procedures including the determination of both accuracy and reproducibility of measurements in accordance with instructions provided by the manufacturer of the assessment device used.
(C)Proper procedures to be employed when collecting blood, if blood specimens are to be obtained.
(D)Proper procedures to be employed in handling and disposing of all biological specimens to be obtained and material contaminated by those biological specimens. These procedures shall comply with all county and city ordinances for medical waste management and blood-borne pathogen control that apply to the location where the program operates.
(E)Proper procedures to be employed in response to fainting, excessive bleeding, or other medical emergencies.
(F)Documentation that the testing personnel are following the instructions of the instruments manufacturer, are trained in the performance of the test, and are competent to perform the testing without supervision.
(G)Reporting of assessment results to the individual being assessed.
(H)Referral and followup to licensed sources of care as indicated.
(10)(a)The written protocols adopted by the supervisory committee shall be maintained for at least one year following completion of the assessment program, during which period they shall be subject to review by department personnel and the local health officer or his or her designee, including the public health laboratory director.
(b)If skin puncture to obtain a blood specimen is to be performed in a program of nondiagnostic general health assessment, the individual performing the skin puncture shall be authorized to perform skin puncture under this chapter.
(c)A program of nondiagnostic general health assessment that fails to meet the requirements set forth in subdivisions (a) and (b) shall not operate.
(d)For purposes of this section, skin puncture means the collection of a blood specimen by the finger prick method only and does not include venipuncture, arterial puncture, or any other procedure for obtaining a blood specimen.
(e)This chapter does not prohibit a licensed clinical laboratory from operating a program of nondiagnostic general health assessment provided that the clinical laboratory complies with the requirements of this section.
(f)A program for a health fair providing diagnostic or screening tests is not a nondiagnostic general health assessment program if all of the requirements of this chapter are met, and the laboratory performing the testing is licensed by federal law or is operating with a waiver for the applicable procedures. For a test that is not authorized for self-ordering pursuant to Section 1246.5 and that is not for a nondiagnostic general health assessment pursuant to this section, the clinical laboratory participating in the health fair shall assure that the test is ordered onsite only by a person licensed under this division who is authorized under his or her scope of practice to order the test or by a person authorized by that licensee. The results of a test performed at a health fair shall be provided to the test subject along with an explanation of the results.
SEC. 12.Section 1246.5 of the Business and Professions Code is amended to read:1246.5.(a)Notwithstanding any other law, a person may request, and a licensed clinical laboratory or public health laboratory may perform, the laboratory tests specified in this section. A registered clinical laboratory may perform the laboratory tests specified in this section if the test is subject to a certificate of waiver under CLIA. A program for nondiagnostic general health assessment that includes a laboratory test specified in this section shall comply with the provisions of Section 1244. The results from any test may be provided directly to the person requesting the test if the test is on or for his or her own body. These test results shall be provided in a manner that presents clear information and that identifies results indicating the need for referral to a physician and surgeon.
(b)The tests that may be conducted pursuant to this section are: pregnancy, glucose level, cholesterol, occult blood, and any other test for which there is a test for a particular analyte approved by the federal Food and Drug Administration for sale to the public without a prescription in the form of an over-the-counter test kit. A test approved only as an over-the-counter collection device may not be conducted pursuant to this section.
SEC. 13.Section 1265 of the Business and Professions Code is repealed.SEC. 14.Section 1265.1 of the Business and Professions Code is repealed.SEC. 15.Section 1266 of the Business and Professions Code is repealed.SEC. 16.Section 1267 of the Business and Professions Code is repealed.SEC. 17.Section 1268 of the Business and Professions Code is repealed.SEC. 18.Section 1271.1 of the Business and Professions Code is amended to read:1271.1.(a)A clinical laboratory that provides cytology services shall, if the laboratory ceases operation, preserve records, reports, cytology slides, and cell blocks as prescribed in subdivision (g) of Section 1271 and Section 1274.
(b)A person injured as a result of the laboratorys abandonment of records may bring an action in a court of competent jurisdiction for the amount of damages suffered as a result. If the laboratory was a corporation or partnership that has been dissolved, the person injured may bring an action against that corporations or partnerships principal officers of record at the time of the dissolution.
(c)For purposes of this section, the following definitions shall apply:
(1)Abandonment of records means violating subdivision (a) and thereby leaving patients and physicians and surgeons without access to information to which they are entitled pursuant to this chapter.
(2)Principal officers means:
(A)In the case of a partnership other than a limited partnership, any partner.
(B)In the case of a limited partnership, any general partner, as defined in Section 15904.02 of the Corporations Code.
(C)In the case of a corporation, the chairperson of the board, the chief executive officer, and the president of the corporation.
SEC. 19.Section 1272 of the Business and Professions Code is amended to read:1272.A clinical laboratory shall participate in a CLIA-approved proficiency testing program and demonstrate satisfactory performance in all of the laboratory specialities that include tests performed in the laboratory. Proficiency shall be tested in the following specialties: microbiology, serology, clinical chemistry, hematology, cytology, and immunohematology.
SEC. 20.Section 1272.1 is added to the Business and Professions Code, to read:1272.1.(a)If a clinical laboratory ceases operations, the laboratory owners, or delegated representatives of the owners, and the laboratory directors shall notify the department of this fact, in writing, within 30 calendar days from the date a clinical laboratory ceases operation. For purposes of this section, a laboratory ceases operations when it suspends the performance of all clinical laboratory tests or examinations for 30 calendar days at the location for which the clinical laboratory is licensed or registered.
(b)(1)Notwithstanding any other law, owners and laboratory directors of all clinical laboratories, including those laboratories that cease operations, shall preserve medical records and laboratory records, as defined in this section, for three years from the date of testing, examination, or purchase, unless a longer retention period is required by any other law, and shall maintain an ability to provide those records when requested by the department or any duly authorized representative of the department.
(2)For purposes of this subdivision, medical records means the test requisition or test authorization, or the patients chart or medical record if used as the test requisition, the final and preliminary test or examination result, and the name of the person contacted if the laboratory test or examination result indicated an imminent life-threatening result or was of panic value.
(3)For purposes of this subdivision, laboratory records means records showing compliance with CLIA and this chapter during a laboratorys operation that are actual or true copies, either photocopies or electronically reproducible copies, of records for patient test management, quality control, quality assurance, and all invoices documenting the purchase or lease of laboratory equipment and test kits, reagents, or media.
(4)Information contained in medical records and laboratory records shall be confidential, and shall be disclosed only to authorized persons in accordance with federal, state, and local laws.
(c)The department or any person injured as a result of a laboratorys abandonment or failure to retain records pursuant to this section may bring an action in a court of proper jurisdiction for any reasonable amount of damages suffered as a result thereof.
SEC. 21.Section 1272.4 of the Business and Professions Code is repealed.SEC. 22.Section 1272.6 of the Business and Professions Code is repealed.SEC. 23.Section 1281 of the Business and Professions Code is repealed.SEC. 24.Section 1300 of the Business and Professions Code is amended to read:1300.The amount of application and license fees under this chapter shall be as follows:
(a)The application fee for a histocompatibility laboratory directors, clinical laboratory bioanalysts, clinical chemists, clinical microbiologists, clinical laboratory toxicologists, clinical cytogeneticists, or clinical genetic molecular biologists license is sixty-three dollars ($63).
(b)The annual renewal fee for a histocompatibility laboratory directors, clinical laboratory bioanalysts, clinical chemists, clinical microbiologists, clinical laboratory toxicologists, clinical cytogeneticists, or clinical genetic molecular biologists license is sixty-three dollars ($63).
(c)The application fee for a clinical laboratory scientists or limited clinical laboratory scientists license is thirty-eight dollars ($38).
(d)The application and annual renewal fee for a cytotechnologists license is fifty dollars ($50).
(e)The annual renewal fee for a clinical laboratory scientists or limited clinical laboratory scientists license is twenty-five dollars ($25).
(f)The application fee for a trainees license is thirteen dollars ($13).
(g)The annual renewal fee for a trainees license is eight dollars ($8).
(h)The application fee for a duplicate license is five dollars ($5).
(i)The personnel licensing delinquency fee is equal to the annual renewal fee.
(j)The director may establish a fee for examinations required under this chapter. The fee shall not exceed the total cost to the department in conducting the examination.
(k)The state, a district, city, county, city and county, or other political subdivision, or a public officer or body shall be subject to the payment of fees established pursuant to this chapter or regulations adopted thereunder.
(l)The department shall establish an application fee and a renewal fee for a medical laboratory technician license, the total fees collected not to exceed the costs of the department for the implementation and operation of the program licensing and regulating medical laboratory technicians pursuant to Section 1260.3.
SEC. 25.Section 1300.1 of the Business and Professions Code is repealed.SEC. 26.Section 1301 of the Business and Professions Code is amended to read:1301.(a)The department shall give written notice to all persons licensed pursuant to Section 1260, 1260.1, 1261, 1261.5, 1262, 1264, or 1270 at least 30 days in advance of the regular renewal date that a renewal fee has not been paid. In addition, the department shall give written notice to licensed clinical laboratory bioanalysts or doctoral degree specialists and clinical laboratory scientists or limited clinical laboratory scientists by registered or certified mail 90 days in advance of the expiration of the fifth year that a renewal fee has not been paid and, if not paid before the expiration of the fifth year of delinquency, the licensee may be subject to reexamination.
(b)If the renewal fee is not paid for five or more years, the department may require an examination before reinstating the license, except that an examination shall not be required as a condition for reinstatement if the original license was issued without an examination. An examination shall not be required for reinstatement if the license was forfeited solely by reason of nonpayment of the renewal fee if the nonpayment was for less than five years.
(c)If the license is not renewed within 60 days after its expiration, the licensee, as a condition precedent to renewal, shall pay the delinquency fee identified in subdivision (i) of Section 1300, in addition to the renewal fee in effect on the last preceding regular renewal date. Payment of the delinquency fee is not necessary if, within 60 days of the license expiration date, the licensee files an application for inactive status.
SEC. 27.Section 1310 of the Business and Professions Code is repealed.SEC. 28.Section 1310 is added to the Business and Professions Code, to read:1310.(a)If the department determines that a clinical laboratory does not substantially meet the requirements of this chapter or federal law, the department may impose any of the following:
(1)Directed plans of correction, as defined under CLIA.
(2)Civil money penalties in an amount ranging from fifty dollars ($50) to three thousand dollars ($3,000) per day of noncompliance, or per violation, for a condition-level deficiency that does not pose immediate jeopardy, to an amount ranging from three thousand fifty dollars ($3,050) to ten thousand dollars ($10,000) per day of noncompliance, or per violation, for a condition-level deficiency that poses immediate jeopardy, but only after notice and an opportunity to respond in accordance with Section 100171 of the Health and Safety Code, and consideration of facts enumerated in CLIA in Section 493.1834 of Title 42 of the Code of Federal Regulations.
(3)Civil money penalties in an amount ranging from fifty dollars ($50) to three thousand dollars ($3,000) per day of noncompliance, or per violation, for failure to comply with disease reporting requirements, but only after notice and an opportunity to respond in accordance with Section 100171 of the Health and Safety Code.
(4)Onsite monitoring, as defined under CLIA, and payment for the costs of onsite monitoring.
(5)Any combination of the actions described in paragraphs (1) to (4), inclusive.
(b)The department or its agents may enter and inspect a clinical laboratory at any time to enforce state laws and regulations, including, but not limited to, state standards that are more stringent than federal standards.
(c)The costs to the department in conducting a complaint investigation, imposing sanctions, or conducting a hearing under this chapter shall be paid by the clinical laboratory. The fee shall not exceed the fee that the clinical laboratory would pay under CLIA for the same type of activity and shall not be payable if the clinical laboratory would not be required to pay those fees under CLIA.
SEC. 29.Section 1320 of the Business and Professions Code is amended to read:1320.The department may deny, suspend, or revoke a license issued pursuant to this chapter for any of the following reasons:
(a)Conduct involving moral turpitude or dishonest reporting of tests.
(b)Violation by the applicant or licensee of this chapter or a rule or regulation adopted pursuant thereto.
(c)Aiding, abetting, or permitting the violation of this chapter, the rules or regulations adopted pursuant to this chapter, or the Medical Practice Act (Chapter 5 (commencing with Section 2000) of Division 2).
(d)Permitting a licensed trainee to perform tests or procure specimens unless under direct and responsible supervision.
(e)Violation of any provision of this code governing the practice of medicine and surgery.
(f)Proof that an applicant or licensee has made false statements in any material regard on the application for a license or renewal issued pursuant to this chapter.
(g)Conduct inimical to the public health, morals, welfare, or safety of the people of the State of California in the provision of services for which a license is issued pursuant to this chapter.
(h)Proof that the applicant or licensee has used a degree or certificate as a means of qualifying for licensure that has been purchased or procured by barter or by any unlawful means or obtained from an institution that, at the time the degree, certificate, or title was obtained, was not recognized or accredited by the department of education of the state where the institution is or was located to give training in the field of study in which the degree, certificate, or title is claimed.
(i)Violation of any of the prenatal laws or regulations pertaining thereto in Chapter 2 (commencing with Section 120675) of Part 3 of Division 105 of the Health and Safety Code and Article 1 (commencing with Section 1125) of Group 4 of Subchapter 1 of Chapter 2 of Part 1 of Title 17 of the California Code of Regulations.
(j)Knowingly accepting an assignment for clinical laboratory tests or specimens from, and the rendering of a report thereon to, persons not authorized by law to submit those specimens or assignments.
(k)Rendering a report on clinical laboratory work actually performed in another clinical laboratory without designating clearly the name and address of the laboratory in which the test was performed.
(l)Conviction of a felony or misdemeanor involving moral turpitude under the laws of any state or of the United States arising out of or in connection with the practice of clinical laboratory technology. The record of conviction or a certified copy thereof shall be conclusive evidence of that conviction.
(m)Unprofessional conduct.
(n)The use of drugs or alcoholic beverages to the extent or in a manner as to be dangerous to a person licensed under this chapter, or any other person to the extent that use impairs the ability of the licensee to conduct, with safety to the public, the practice of clinical laboratory technology.
(o)Misrepresentation in obtaining a license.
(p)Performance of a clinical laboratory test or examination or other procedure that is not within the specialties or subspecialties, or category of laboratory procedures authorized by the license.
SEC. 30.Section 1324 of the Business and Professions Code is repealed.SEC. 31.Section 1325 of the Business and Professions Code is repealed.SEC. 32.Section 9272 of the Food and Agricultural Code is amended to read:9272.The provisions of this chapter shall not apply (1) to facilities primarily engaged in the collection, preparation, testing, processing, storage, or distribution of human blood or blood products, provided the facility is licensed pursuant to Chapter 4 (commencing with Section 1600) of Division 2 of the Health and Safety Code and any biologic, as defined in Section 9203, produced by the facility is sold or distributed only to an establishment licensed by this chapter or (2) to clinical laboratories whose only biologics are autogenous bacterins prepared at the request of licensed veterinarians.
SEC. 33.Section 1206 of the Health and Safety Code is amended to read:1206.This chapter does not apply to the following:
(a)Except with respect to the option provided with regard to surgical clinics in paragraph (1) of subdivision (b) of Section 1204 and, further, with respect to specialty clinics specified in paragraph (2) of subdivision (b) of Section 1204, a place or establishment owned or leased and operated as a clinic or office by one or more licensed health care practitioners and used as an office for the practice of their profession, within the scope of their license, regardless of the name used publicly to identify the place or establishment.
(b)A clinic directly conducted, maintained, or operated by the United States or by any of its departments, officers, or agencies, and any primary care clinic specified in subdivision (a) of Section 1204 that is directly conducted, maintained, or operated by this state or by any of its political subdivisions or districts, or by any city. Nothing in this subdivision precludes the department from adopting regulations that utilize clinic licensing standards as eligibility criteria for participation in programs funded wholly or partially under Title XVIII or XIX of the federal Social Security Act.
(c)(1)A clinic conducted, maintained, or operated by a federally recognized Indian tribe or tribal organization, as defined in Section 450 or 1603 of Title 25 of the United States Code, that is located on land recognized as tribal land by the federal government.
(2)A clinic conducted, maintained, or operated by a federally recognized Indian tribe or tribal organization, as defined in Section 450 or 1603 of Title 25 of the United States Code, under a contract with the United States pursuant to the Indian Self-Determination and Education Assistance Act (Public Law 93-638), regardless of the location of the clinic, except that if the clinic chooses to apply to the State Department of Public Health for a state facility license, then the State Department of Public Health will retain authority to regulate that clinic as a primary care clinic as defined by subdivision (a) of Section 1204.
(d)Clinics conducted, operated, or maintained as outpatient departments of hospitals.
(e)A facility licensed as a health facility under Chapter 2 (commencing with Section 1250).
(f)A freestanding clinical or pathological laboratory.
(g)A clinic operated by, or affiliated with, an institution of learning that teaches a recognized healing art and is approved by the state board or commission vested with responsibility for regulation of the practice of that healing art.
(h)A clinic that is operated by a primary care community or free clinic and that is operated on separate premises from the licensed clinic and is only open for limited services of no more than 30 hours a week. An intermittent clinic, as described in this subdivision, shall meet all other requirements of law, including administrative regulations and requirements, pertaining to fire and life safety.
(i)The offices of physicians in group practice who provide a preponderance of their services to members of a comprehensive group practice prepayment health care service plan subject to Chapter 2.2 (commencing with Section 1340).
(j)Student health centers operated by public institutions of higher education.
(k)Nonprofit speech and hearing centers, as defined in Section 1201.5. A nonprofit speech and hearing clinic desiring an exemption under this subdivision shall apply to the director, who shall grant the exemption to any facility meeting the criteria of Section 1201.5. Notwithstanding the licensure exemption contained in this subdivision, a nonprofit speech and hearing center shall be deemed to be an organized outpatient clinic for purposes of qualifying for reimbursement as a rehabilitation center under the Medi-Cal Act (Chapter 7 (commencing with Section 14000) of Part 3 of Division 9 of the Welfare and Institutions Code).
(l)A clinic operated by a nonprofit corporation exempt from federal income taxation under paragraph (3) of subsection (c) of Section 501 of the Internal Revenue Code of 1954, as amended, or a statutory successor thereof, that conducts medical research and health education and provides health care to its patients through a group of 40 or more physicians and surgeons, who are independent contractors representing not less than 10 board-certified specialties, and not less than two-thirds of whom practice on a full-time basis at the clinic.
(m)A clinic, limited to in vivo diagnostic services by magnetic resonance imaging functions or radiological services under the direct and immediate supervision of a physician and surgeon who is licensed to practice in California. This shall not be construed to permit cardiac catheterization or any treatment modality in these clinics.
(n)A clinic operated by an employer or jointly by two or more employers for their employees only, or by a group of employees, or jointly by employees and employers, without profit to the operators thereof or to any other person, for the prevention and treatment of accidental injuries to, and the care of the health of, the employees comprising the group.
(o)A community mental health center, as defined in Section 5667 of the Welfare and Institutions Code.
(p)(1)A clinic operated by a nonprofit corporation exempt from federal income taxation under paragraph (3) of subsection (c) of Section 501 of the Internal Revenue Code of 1954, as amended, or a statutory successor thereof, as an entity organized and operated exclusively for scientific and charitable purposes and that satisfied all of the following requirements on or before January 1, 2005:
(A)Commenced conducting medical research on or before January 1, 1982, and continues to conduct medical research.
(B)Conducted research in, among other areas, prostatic cancer, cardiovascular disease, electronic neural prosthetic devices, biological effects and medical uses of lasers, and human magnetic resonance imaging and spectroscopy.
(C)Sponsored publication of at least 200 medical research articles in peer-reviewed publications.
(D)Received grants and contracts from the National Institutes of Health.
(E)Held and licensed patents on medical technology.
(F)Received charitable contributions and bequests totaling at least five million dollars ($5,000,000).
(G)Provides health care services to patients only:
(i)In conjunction with research being conducted on procedures or applications not approved or only partially approved for payment (I) under the Medicare program pursuant to Section 1359y(a)(1)(A) of Title 42 of the United States Code, or (II) by a health care service plan registered under Chapter 2.2 (commencing with Section 1340), or a disability insurer regulated under Chapter 1 (commencing with Section 10110) of Part 2 of Division 2 of the Insurance Code; provided that services may be provided by the clinic for an additional period of up to three years following the approvals, but only to the extent necessary to maintain clinical expertise in the procedure or application for purposes of actively providing training in the procedure or application for physicians and surgeons unrelated to the clinic.
(ii)Through physicians and surgeons who, in the aggregate, devote no more than 30 percent of their professional time for the entity operating the clinic, on an annual basis, to direct patient care activities for which charges for professional services are paid.
(H)Makes available to the public the general results of its research activities on at least an annual basis, subject to good faith protection of proprietary rights in its intellectual property.
(I)Is a freestanding clinic, whose operations under this subdivision are not conducted in conjunction with any affiliated or associated health clinic or facility defined under this division, except a clinic exempt from licensure under subdivision (m). For purposes of this subparagraph, a freestanding clinic is defined as affiliated only if it directly, or indirectly through one or more intermediaries, controls, or is controlled by, or is under common control with, a clinic or health facility defined under this division, except a clinic exempt from licensure under subdivision (m). For purposes of this subparagraph, a freestanding clinic is defined as associated only if more than 20 percent of the directors or trustees of the clinic are also the directors or trustees of any individual clinic or health facility defined under this division, except a clinic exempt from licensure under subdivision (m). Any activity by a clinic under this subdivision in connection with an affiliated or associated entity shall fully comply with the requirements of this subdivision. This subparagraph shall not apply to agreements between a clinic and any entity for purposes of coordinating medical research.
(2)By January 1, 2007, and every five years thereafter, the Legislature shall receive a report from each clinic meeting the criteria of this subdivision and any other interested party concerning the operation of the clinics activities. The report shall include, but not be limited to, an evaluation of how the clinic impacted competition in the relevant health care market, and a detailed description of the clinics research results and the level of acceptance by the payer community of the procedures performed at the clinic. The report shall also include a description of procedures performed both in clinics governed by this subdivision and those performed in other settings. The cost of preparing the reports shall be borne by the clinics that are required to submit them to the Legislature pursuant to this paragraph.
SEC. 34.Section 1600.3 of the Health and Safety Code is amended to read:1600.3.Blood bank depository means a place other than a blood bank where human whole blood and human whole blood derivatives specified by regulation are stored and held for transfusion. Blood bank depositories shall be clinical laboratories, licensed in accordance with the provisions of federal law, or other places where services essentially equivalent are maintained, as determined by the department.
SEC. 35.Section 14043.27 of the Welfare and Institutions Code is amended to read:14043.27.(a)If an applicant or provider is granted provisional provider status or preferred provisional provider status pursuant to Section 14043.26 and, if at any time during the provisional provider status period or preferred provisional provider status period, the department conducts any announced or unannounced visits or any additional inspections or reviews pursuant to this chapter or Chapter 8 (commencing with Section 14200), or the regulations adopted thereunder, or pursuant to Section 100185.5 of the Health and Safety Code, and discovers or otherwise determines the existence of any ground to deactivate the providers number and business addresses or suspend the provider from the Medi-Cal program pursuant to this chapter or Chapter 8 (commencing with Section 14200), or the regulations adopted thereunder, or pursuant to Section 100185.5 of the Health and Safety Code, or if any of the circumstances listed in subdivision (c) occur, the department shall terminate the provisional provider status or preferred provisional provider status of the provider, regardless of whether the period of time for which the provisional provider status or preferred provisional provider status was granted under Section 14043.26 has elapsed.
(b)Termination of provisional provider status or preferred provisional provider status shall include deactivation of the providers number, including all business addresses used by the provider to obtain reimbursement from the Medi-Cal program and removal of the provider from enrollment in the Medi-Cal program, except where the termination is based upon a ground related solely to a specific location for which provisional provider status was granted. Termination of provisional provider status based upon grounds related solely to a specific location may include failure to have an established place of business, failure to possess the business or zoning permits or other approvals necessary to operate a business, or failure to possess the appropriate licenses, permits, or certificates necessary for the provider of service category or subcategory identified by the provider in its application package. Where the grounds relate solely to a specific location, the termination of provisional provider status shall include only deactivation of the specific locations that the grounds apply to and shall include removal of the provider from enrollment in the Medi-Cal program only if, after deactivation of the specific locations, the provider does not have any business address that is not deactivated.
(c)The following circumstances are grounds for termination of provisional provider status or preferred provisional provider status:
(1)The provider, persons with an ownership or control interest in the provider, or persons who are directors, officers, or managing employees of the provider have been convicted of any felony, or convicted of any misdemeanor involving fraud or abuse in any government program, related to neglect or abuse of a patient in connection with the delivery of a health care item or service, or in connection with the interference with, or obstruction of, any investigation into health care related fraud or abuse, or have been found liable for fraud or abuse in any civil proceeding, or have entered into a settlement in lieu of conviction for fraud or abuse in any government program within 10 years of the date of the application package.
(2)There is a material discrepancy in the information provided to the department, or with the requirements to be enrolled, that is discovered after provisional provider status or preferred provisional provider status has been granted and that cannot be corrected because the discrepancy occurred in the past.
(3)The provider has provided material information that was false or misleading at the time it was provided.
(4)The provider failed to have an established place of business at the business address for which the application package was submitted at the time of any onsite inspection, announced or unannounced visit, or any additional inspection or review conducted pursuant to this article or a statute or regulation governing the Medi-Cal program, unless the practice of the providers profession or delivery of services, goods, supplies, or merchandise is such that services, goods, supplies, or merchandise are rendered or delivered at locations other than the business address and this practice or delivery of services, goods, supplies, or merchandise has been disclosed in the application package approved by the department when the provisional provider status or preferred provisional provider status was granted.
(5)The provider meets the definition of a clinic under Section 1200 of the Health and Safety Code, but is not licensed as a clinic pursuant to Chapter 1 (commencing with Section 1200) of Division 2 of the Health and Safety Code and fails to meet the requirements to qualify for at least one exemption pursuant to Section 1206 or 1206.1 of the Health and Safety Code.
(6)The provider performs clinical laboratory tests or examinations, but it or its personnel do not meet CLIA, and the regulations adopted thereunder, do not possess valid CLIA certificates, or are not exempt pursuant to Section 1241 of the Business and Professions Code.
(7)The provider fails to possess either of the following:
(A)The appropriate licenses, permits, certificates, or other approvals needed to practice the profession or occupation, or provide the services, goods, supplies, or merchandise the provider identified in the application package approved by the department when the provisional provider status or preferred provisional provider status was granted and for the location for which the application was submitted.
(B)The business or zoning permits or other approvals necessary to operate a business at the location identified in its application package approved by the department when the provisional provider status or preferred provisional provider status was granted.
(8)The provider, or if the provider is a clinic, group, partnership, corporation, or other association, any officer, director, or shareholder with a 10 percent or greater interest in that organization, commits two or more violations of the federal or state statutes or regulations governing the Medi-Cal program, and the violations demonstrate a pattern or practice of fraud, abuse, or provision of unnecessary or substandard medical services.
(9)The provider commits any violation of a federal or state statute or regulation governing the Medi-Cal program or of a statute or regulation governing the providers profession or occupation and the violation represents a threat of immediate jeopardy or significant harm to any Medi-Cal beneficiary or to the public welfare.
(10)The provider submits claims for payment that subject a provider to suspension under Section 14043.61.
(11)The provider submits claims for payment for services, goods, supplies, or merchandise rendered at a location other than the business address or addresses listed on the application for enrollment, unless the practice of the providers profession or delivery of services, goods, supplies, or merchandise is such that services, goods, supplies, or merchandise are rendered or delivered at locations other than the business address and this practice or delivery of services, goods, supplies, or merchandise has been disclosed in the application package approved by the department when the provisional provider status was granted.
(12)The provider has not paid its fine, or has a debt due and owing, including overpayments and penalty assessments, to any federal, state, or local government entity that relates to Medicare, medicaid, Medicaid, Medi-Cal, or any other federal or state health care program, and has not made satisfactory arrangements to fulfill the obligation or otherwise been excused by legal process from fulfilling the obligation.
(d)If, during a provisional provider status period or a preferred provisional provider status period, the department conducts any announced or unannounced visits or any additional inspections or reviews pursuant to this chapter or Chapter 8 (commencing with Section 14200), or the regulations adopted thereunder, and commences an investigation for fraud or abuse, or discovers or otherwise determines that the provider is under investigation for fraud or abuse by any other state, local, or federal government law enforcement agency, the provider shall be subject to termination of provisional provider status or preferred provisional provider status, regardless of whether the period of time for which the provisional provider status or preferred provisional provider status was granted under Section 14043.26 has elapsed.
(e)A provider whose provisional provider status or preferred provisional provider status has been terminated pursuant to this section may appeal the termination in accordance with Section 14043.65.
(f)Any department-recovered fine or debt due and owing, including overpayments, that are subsequently determined to have been erroneously collected shall be promptly refunded to the provider, together with interest paid in accordance with subdivision (e) of Section 14171 and Section 14172.5.
(a)A person licensed under Chapter 4 (commencing with Section 1600) of this division or licensed under Chapter 5 (commencing with Section 2000) of this division or licensed under any initiative act referred to in this division relating to osteopaths may not refer patients, clients, or customers to a clinical laboratory in which the licensee has a membership, proprietary interest, or coownership in any form, or has a profit-sharing arrangement, unless the licensee at the time of making the referral discloses in writing the interest to the patient, client, or customer. The written disclosure shall indicate that the patient may choose any clinical laboratory for purposes of having laboratory work or assignment performed.
(b)This does shall not apply to persons who are members of a medical group that contracts to provide medical care to members of a group practice prepayment plan registered under the Knox-Keene Health Care Service Act of 1975 (Chapter 2.2 (commencing with Section 1340) of Division 2 of the Health and Safety Code).
(c)This does shall not apply to a referral to a clinical laboratory that is owned and operated by a health facility licensed pursuant to Chapter 2 (commencing with Section 1250) of Division 2 of the Health and Safety Code.
(d)This section does not prohibit the acceptance of evaluation specimens for proficiency testing or referral of specimens or the assignment from one clinical laboratory to another clinical laboratory, either licensed or exempt under this chapter, providing the report indicates clearly the laboratory performing the test.
(e)Proprietary interest does not include ownership of a building where space is leased to a clinical laboratory at the prevailing rate under a straight lease arrangement.
(f)A violation of this section is a public offense and is punishable upon a first conviction by imprisonment in a county jail for not more than one year, or by imprisonment pursuant to subdivision (h) of Section 1170 of the Penal Code, or by a fine not exceeding ten thousand dollars ($10,000), or by both that imprisonment and fine. A second or subsequent conviction shall be punishable by imprisonment pursuant to subdivision (h) of Section 1170 of the Penal Code.
SEC. 2.Section 655.5 of the Business and Professions Code is amended to read:655.5.(a)It is unlawful for a person licensed under this division or under an initiative act referred to in this division, or a clinical laboratory, or a health facility when billing for a clinical laboratory of the facility, to charge, bill, or otherwise solicit payment from a patient, client, or customer for a clinical laboratory service not actually rendered by the person or clinical laboratory or under his, her or its direct supervision unless the patient, client, or customer is apprised at the first time of the charge, billing, or solicitation of the name, address, and charges of the clinical laboratory performing the service. The first written charge, bill, or other solicitation of payment shall separately set forth the name, address, and charges of the clinical laboratory concerned and shall clearly show whether or not the charge is included in the total of the account, bill, or charge. This subdivision is satisfied if the required disclosures are made to the third-party payer of the patient, client, or customer. If the patient is responsible for submitting the bill for the charges to the third-party payer, the bill provided to the patient for that purpose shall include the disclosures required by this section. This subdivision does not apply to a clinical laboratory of a health facility or a health facility when billing for a clinical laboratory of the facility nor to a person licensed under this division or under any initiative act referred to in this division if the standardized billing form used by the facility or person requires a summary entry for all clinical laboratory charges. For purposes of this subdivision, health facility has the same meaning as defined in Section 1250 of the Health and Safety Code.
(b)A clinical laboratory shall provide to each of its referring providers, upon request, a schedule of fees for services provided to patients of the referring provider. The schedule shall be provided within two working days after the clinical laboratory receives the request. For the purposes of this subdivision, a referring provider means a provider who has referred a patient to the clinical laboratory in the preceding six-month period. A clinical laboratory that provides a list of laboratory services to a referring provider or to a potential referring provider shall include a schedule of fees for the laboratory services listed.
(c)It is also unlawful for a person licensed under this division or under any initiative act referred to in this division to charge additional charges for a clinical laboratory service that is not actually rendered by the licensee to the patient and itemized in the charge, bill, or other solicitation of payment. This section shall not be construed to prohibit any of the following:
(1)An itemized charge for a service actually rendered to the patient by the licensee.
(2)A summary charge for services actually rendered to a patient by a health facility, as defined in Section 1250 of the Health and Safety Code, or by a person licensed under this division or under any initiative act referred to in this division if the standardized billing form used by the facility or person requires a summary entry for all clinical laboratory charges.
(d)As used in this section, the term a person licensed under this division includes a registered laboratory, as defined in Section 1206, all wholly owned subsidiaries of the person, a parent company that wholly owns the person, and any subsidiaries wholly owned by the same parent that wholly owns the person. Wholly owned means ownership directly or through one or more subsidiaries. This section shall not apply to billings by a registered laboratory when the registered laboratory bills for services performed by a laboratory owned or operated by the registered laboratory.
(e)This section does not apply to a person or clinical laboratory who or which contracts directly with a health care service plan licensed pursuant to Section 1349 of the Health and Safety Code, if the services are to be provided to members of the plan on a prepaid basis and without additional charge or liability on account thereof.
(f)A violation of this section is a public offense and is punishable upon a first conviction by imprisonment in a county jail for not more than one year, or by imprisonment pursuant to subdivision (h) of Section 1170 of the Penal Code, or by a fine not exceeding ten thousand dollars ($10,000), or by both that imprisonment and fine. A second or subsequent conviction is punishable by imprisonment pursuant to subdivision (h) of Section 1170 of the Penal Code.
(g)(1)Notwithstanding subdivision (f), a violation of this section by a physician and surgeon for a first offense shall be subject to the exclusive remedy of reprimand by the Medical Board of California if the transaction that is the subject of the violation involves a charge for a clinical laboratory service that is less than the charge would have been if the clinical laboratory providing the service billed a patient, client, or customer directly for the clinical laboratory service, and if that clinical laboratory charge is less than the charge listed in the clinical laboratorys schedule of fees pursuant to subdivision (b).
(2)This subdivision does not permit a physician and surgeon to charge more than he or she was charged for the laboratory service by the clinical laboratory providing the service unless the additional charge is for service actually rendered by the physician and surgeon to the patient.
SEC. 3.Section 1206 of the Business and Professions Code is amended to read:1206.(a)For the purposes of this chapter the following definitions are applicable:
(1)Analyte means the substance or constituent being measured, including, but not limited to, glucose, sodium, or theophylline, or any substance or property whose presence or absence, concentration, activity, intensity, or other characteristics are to be determined.
(2)Biological specimen means any material that is derived from the human body.
(3)Blood electrolyte analysis means the measurement of electrolytes in a blood specimen by means of ion selective electrodes on instruments specifically designed and manufactured for blood gas and acid-base analysis.
(4)Blood gas analysis means a clinical laboratory test or examination that deals with the uptake, transport, and metabolization of oxygen and carbon dioxide in the human body.
(5)Clinical laboratory test or examination means the detection, identification, measurement, evaluation, correlation, monitoring, and reporting of any particular analyte, entity, or substance within a biological specimen for the purpose of obtaining scientific data that may be used as an aid to ascertain the presence, progress, and source of a disease or physiological condition in a human being, or used as an aid in the prevention, prognosis, monitoring, or treatment of a physiological or pathological condition in a human being, or for the performance of nondiagnostic tests for assessing the health of an individual.
(6)Clinical laboratory science means any of the sciences or scientific disciplines used to perform a clinical laboratory test or examination.
(7)Clinical laboratory practice means the application of clinical laboratory sciences or the use of any means that applies the clinical laboratory sciences within or outside of a licensed or registered clinical laboratory. Clinical laboratory practice includes consultation, advisory, and other activities inherent to the profession.
(8)Clinical laboratory means a place used, or an establishment or institution organized or operated, for the performance of clinical laboratory tests or examinations or the practical application of the clinical laboratory sciences. That application may include any means that applies the clinical laboratory sciences.
(9)Direct and constant supervision means personal observation and critical evaluation of the activity of unlicensed laboratory personnel by a physician and surgeon, or by a person licensed under this chapter other than a trainee, during the entire time that the unlicensed laboratory personnel are engaged in the duties specified in Section 1269.
(10)Direct and responsible supervision means both of the following:
(A)Personal observation and critical evaluation of the activity of a trainee by a physician and surgeon, or by a person licensed under this chapter other than a trainee, during the entire time that the trainee is performing clinical laboratory tests or examinations.
(B)Personal review by the physician and surgeon or the licensed person of all results of clinical laboratory testing or examination performed by the trainee for accuracy, reliability, and validity before the results are reported from the laboratory.
(11)Licensed laboratory means a clinical laboratory licensed pursuant to the federal Clinical Laboratory Improvement Amendments of 1988 (CLIA).
(12)Location means either a street and city address, or a site or place within a street and city address, where any of the clinical laboratory sciences or scientific disciplines are practiced or applied, or where clinical laboratory tests or examinations are performed.
(13)Physician office laboratory means a clinical laboratory that is either: (A) owned and operated by a partnership or professional corporation that performs clinical laboratory tests or examinations only for patients of five or fewer physicians and surgeons or podiatrists who are shareholders, partners, or employees of the partnership or professional corporation that owns and operates the clinical laboratory; or (B) owned and operated by an individual licensed physician and surgeon or a podiatrist, and that performs clinical laboratory tests or examinations only for patients of the physician and surgeon or podiatrist who owns and operates the clinical laboratory.
(14)Point-of-care laboratory testing device means a portable laboratory testing instrument to which the following applies:
(A)It is used within the proximity of the patient for whom the test or examination is being conducted.
(B)It is used in accordance with the patient test management system, the quality control program, and the comprehensive quality assurance program established and maintained by the laboratory pursuant to paragraph (2) of subdivision (d) of Section 1220.
(C)It meets the following criteria:
(i)Performs clinical laboratory tests or examinations classified as waived or of moderate complexity under the federal Clinical Laboratory Improvement Amendments of 1988 (CLIA) (42 U.S.C. Sec. 263a).
(ii)Performs clinical laboratory tests or examinations on biological specimens that require no preparation after collection.
(iii)Provides clinical laboratory tests or examination results without calculation or discretionary intervention by the testing personnel.
(iv)Performs clinical laboratory tests or examinations without the necessity for testing personnel to perform calibration or maintenance, except resetting pursuant to the manufacturers instructions or basic cleaning.
(15)Public health laboratory means a laboratory that is operated by a city or county in conformity with Article 5 (commencing with Section 101150) of Chapter 2 of Part 3 of Division 101 of the Health and Safety Code and the regulations adopted thereunder.
(16)Registered laboratory means a clinical laboratory that performs clinical laboratory tests or examinations subject to a certificate of waiver or a certificate of provider-performed microscopy under CLIA.
(17)Specialty means histocompatibility, microbiology, diagnostic immunology, chemistry, hematology, immunohematology, pathology, genetics, or other specialty specified by regulation adopted by the department.
(18)Subspecialty for purposes of microbiology, means bacteriology, mycobacteriology, mycology, parasitology, virology, molecular biology, and serology for diagnosis of infectious diseases, or other subspecialty specified by regulation adopted by the department; for purposes of diagnostic immunology, means syphilis serology, general immunology, or other subspecialty specified by regulation adopted by the department; for purposes of chemistry, means routine chemistry, clinical microscopy, endocrinology, toxicology, or other subspecialty specified by regulation adopted by the department; for purposes of immunohematology, means ABO/Rh Type and Group, antibody detection for transfusion, antibody detection nontransfusion, antibody identification, compatibility, or other subspecialty specified by regulation adopted by the department; for pathology, means tissue pathology, oral pathology, diagnostic cytology, or other subspecialty specified by regulation adopted by the department; for purposes of genetics, means molecular biology related to the diagnosis of human genetic abnormalities, cytogenetics, or other subspecialty specified by regulation adopted by the department.
(b)This chapter does not restrict, limit, or prevent a person licensed to provide health care services under the laws of this state, including, but not limited to, licensed physicians and surgeons and registered nurses, from practicing the profession or occupation for which he or she is licensed.
(c)This chapter does not authorize a person to perform or order health care services, or utilize the results of the clinical laboratory test or examination, unless the person is otherwise authorized to provide that care or utilize the results. The inclusion of a person in Section 1206.5 for purposes of performing a clinical laboratory test or examination shall not be interpreted to authorize a person, who is not otherwise authorized, to perform venipuncture, arterial puncture, or skin puncture.
SEC. 4.Section 1206.6 of the Business and Professions Code is amended to read:1206.6.Subdivision (a) of Section 1206.5 does not apply to a pharmacist at a community pharmacy who, upon customer request, performs only blood glucose, hemoglobin A1c, or cholesterol tests that are classified as waived under CLIA and are approved by the federal Food and Drug Administration for sale to the public without a prescription in the form of an over-the-counter test kit, provided that all of the following requirements are satisfied:
(a)The pharmacy obtains a valid CLIA certificate of waiver and complies with all other requirements for the performance of waived clinical laboratory tests under applicable federal regulations. For purposes of CLIA, the person identified as responsible for directing and supervising testing oversight and decisionmaking shall be the pharmacist-in-charge, as defined in Section 4036.5.
(b)The pharmacy complies with this chapter.
(c)The tests are performed only by a pharmacist, as defined in Section 4036, in the course of performing routine patient assessment procedures in compliance with Section 4052.4.
SEC. 5.Section 1220 of the Business and Professions Code is amended to read:1220.(a)(1)Each clinical laboratory shall maintain records, equipment, and facilities that are adequate and appropriate for the services rendered.
(2)(A)Except for tests or examinations classified as waived under CLIA, each clinical laboratory shall enroll, and demonstrate successful participation, as defined under CLIA, for each specialty and subspecialty in which it performs clinical laboratory tests or examinations, in a proficiency testing program approved by the department or by CMS, to the same extent as required by CLIA in Subpart H (commencing with Section 493.801) of Title 42 of the Code of Federal Regulations. This requirement does not prohibit a clinical laboratory from performing clinical laboratory tests or examinations in a specialty or subspecialty for which there is no department or CMS approved proficiency testing program.
(B)Each clinical laboratory shall authorize its proficiency test results to be reported to the department in an electronic format that is compatible with the departments proficiency testing data monitoring system and shall authorize the release of proficiency tests results to the public to the same extent required by CLIA.
(b)Each clinical laboratory shall be conducted, maintained, and operated without injury to the public health.
(c)The department shall conduct an investigation of complaints received concerning a clinical laboratory that may include an inspection of the laboratory.
(d)(1)Each clinical laboratory shall perform all clinical laboratory tests or examinations classified as waived under CLIA in conformity with the manufacturers instructions.
(2)Except for those clinical laboratories performing only tests or examinations classified as waived under CLIA, each clinical laboratory shall establish and maintain all of the following:
(A)A patient test management system that meets the standards of CLIA in Subpart J (commencing with Section 493.1100) of Title 42 of the Code of Federal Regulations.
(B)A quality control program that meets the requirements of CLIA in Subpart K (commencing with Section 493.1200) of Title 42 of the Code of Federal Regulations as in effect on January 1, 2015, and that may include the clinical laboratorys use of an Individualized Quality Control Plan, as incorporated into Appendix C of the State Operations Manual adopted by the federal Centers for Medicare and Medicaid Services (CMS).
(C)A comprehensive quality assurance program that meets the standards of CLIA in Subpart P (commencing with Section 493.1701) of Title 42 of the Code of Federal Regulations.
SEC. 6.Section 1223 of the Business and Professions Code is repealed.SEC. 7.Section 1223 is added to the Business and Professions Code, to read:1223.Clinical laboratories shall choose to be overseen by the department, pursuant to subdivision (a), or may seek certification of deemed status by an accrediting organization approved under CLIA, pursuant to subdivision (b). The accrediting organization may issue certificates of deemed status and may provide continued oversight to ensure compliance with state law.
(a)The department shall monitor, inspect, and investigate all clinical laboratories that are not accredited by an organization approved under CLIA for compliance with state standards that are in excess of federal standards.
(b)(1)A clinical laboratory that is accredited by an organization approved under CLIA shall be deemed to meet all state standards and shall not require monitoring, inspection, or investigation pursuant to subdivision (a), but may be subject to investigation by the department under other provisions of law.
(2)An accrediting organization shall provide the department with documentation of approval by the federal Centers for Medicare & Medicaid Services as an accrediting body under CLIA, a detailed comparison of the individual accreditation or approval requirements, with the comparable California condition-level requirements, including standards that are in excess of federal law, and a list of all of the clinical laboratories that operate in California, including the CLIA number and the expiration date of their accreditation, as applicable.
(c)The department may concentrate its resources on upholding personnel standards.
SEC. 7.SEC. 8.Section 1227 of the Business and Professions Code is repealed.SEC. 9.Section 1227 is added to the Business and Professions Code, to read:1227.The department shall post on its Internet Web site a comprehensive list of the differences between state and CLIA.
SEC. 8.SEC. 10.Section 1241.1 of the Business and Professions Code is repealed.SEC. 9.SEC. 11.Section 1244 of the Business and Professions Code is amended to read:1244.This chapter does not restrict, limit, or prevent a program of nondiagnostic general health assessment provided that:
(1)The program complies with the requirements of CLIA for waived testing.
(2)The purpose of the program is to screen asymptomatic individuals for chronic health disorders and to refer individuals to licensed sources of care as indicated.
(3)The program does not test for human immunodeficiency virus or any reportable disease or condition identified in Section 120130 of the Health and Safety Code or the regulations adopted under that section.
(4)The program utilizes only those devices that comply with all of the following:
(A)Meet all applicable state and federal performance standards pursuant to Section 111245 of the Health and Safety Code.
(B)Are not adulterated as specified in Article 2 (commencing with Section 111250) of Chapter 6 of Part 5 of Division 104 of the Health and Safety Code.
(C)Are not misbranded as specified in Article 3 (commencing with Section 111330) of Chapter 6 of Part 5 of Division 104 of the Health and Safety Code.
(D)Are not new devices unless they meet the requirements of Section 111550 of the Health and Safety Code.
(E)Are approved as waived tests and are used according to the manufacturers instructions.
(5)Blood collection is performed by skin puncture only.
(6)Testing of a urine specimen is performed by the dipstick method only.
(7)Testing is performed on site and reported directly to the person requesting the test.
(8)The program maintains a supervisory committee consisting of, at a minimum, a licensed physician and surgeon and a clinical laboratory scientist licensed pursuant to this code.
(9)The supervisory committee for the program adopts written protocols that shall be followed in the program and that shall contain all of the following:
(A)Provision of written information to individuals to be assessed that shall include, but not be limited to, the following:
(i)The potential risks and benefits of assessment procedures to be performed in the program.
(ii)The limitations, including the nondiagnostic nature, of assessment examinations of biological specimens performed in the program.
(iii)Information regarding the risk factors or markers targeted by the program.
(iv)The need for followup with licensed sources of care for confirmation, diagnosis, and treatment as appropriate.
(B)Proper use of each device utilized in the program including the operation of analyzers, maintenance of equipment and supplies, and performance of quality control procedures including the determination of both accuracy and reproducibility of measurements in accordance with instructions provided by the manufacturer of the assessment device used.
(C)Proper procedures to be employed when collecting blood, if blood specimens are to be obtained.
(D)Proper procedures to be employed in handling and disposing of all biological specimens to be obtained and material contaminated by those biological specimens. These procedures shall comply with all county and city ordinances for medical waste management and blood-borne pathogen control that apply to the location where the program operates.
(E)Proper procedures to be employed in response to fainting, excessive bleeding, or other medical emergencies.
(F)Documentation that the testing personnel are following the instructions of the instruments manufacturer, are trained in the performance of the test, and are competent to perform the testing without supervision.
(G)Reporting of assessment results to the individual being assessed.
(H)Referral and followup to licensed sources of care as indicated.
(10)(a)The written protocols adopted by the supervisory committee shall be maintained for at least one year following completion of the assessment program, during which period they shall be subject to review by department personnel and the local health officer or his or her designee, including the public health laboratory director.
(b)If skin puncture to obtain a blood specimen is to be performed in a program of nondiagnostic general health assessment, the individual performing the skin puncture shall be authorized to perform skin puncture under this chapter.
(c)A program of nondiagnostic general health assessment that fails to meet the requirements set forth in subdivisions (a) and (b) shall not operate.
(d)For purposes of this section, skin puncture means the collection of a blood specimen by the finger prick method only and does not include venipuncture, arterial puncture, or any other procedure for obtaining a blood specimen.
(e)This chapter does not prohibit a licensed clinical laboratory from operating a program of nondiagnostic general health assessment provided that the clinical laboratory complies with the requirements of this section.
(f)A program for a health fair providing diagnostic or screening tests is not a nondiagnostic general health assessment program if all of the requirements of this chapter are met, and the laboratory performing the testing is licensed by federal law or is operating with a waiver for the applicable procedures. For a test that is not authorized for self-ordering pursuant to Section 1246.5 and that is not for a nondiagnostic general health assessment pursuant to this section, the clinical laboratory participating in the health fair shall assure that the test is ordered onsite only by a person licensed under this division who is authorized under his or her scope of practice to order the test or by a person authorized by that licensee. The results of a test performed at a health fair shall be provided to the test subject along with an explanation of the results.
SEC. 10.SEC. 12.Section 1246.5 of the Business and Professions Code is amended to read:1246.5.(a)Notwithstanding any other law, a person may request, and a licensed clinical laboratory or public health laboratory may perform, the laboratory tests specified in this section. A registered clinical laboratory may perform the laboratory tests specified in this section if the test is subject to a certificate of waiver under CLIA. A program for nondiagnostic general health assessment that includes a laboratory test specified in this section shall comply with the provisions of Section 1244. The results from any test may be provided directly to the person requesting the test if the test is on or for his or her own body. These test results shall be provided in a manner that presents clear information and that identifies results indicating the need for referral to a physician and surgeon.
(b)The tests that may be conducted pursuant to this section are: pregnancy, glucose level, cholesterol, occult blood, and any other test for which there is a test for a particular analyte approved by the federal Food and Drug Administration for sale to the public without a prescription in the form of an over-the-counter test kit. A test approved only as an over-the-counter collection device may not be conducted pursuant to this section.
SEC. 11.SEC. 13.Section 1265 of the Business and Professions Code is repealed.SEC. 12.SEC. 14.Section 1265.1 of the Business and Professions Code is repealed.SEC. 13.SEC. 15.Section 1266 of the Business and Professions Code is repealed.SEC. 14.SEC. 16.Section 1267 of the Business and Professions Code is repealed.SEC. 15.SEC. 17.Section 1268 of the Business and Professions Code is repealed.SEC. 16.SEC. 18.Section 1271.1 of the Business and Professions Code is amended to read:1271.1.(a)A clinical laboratory that provides cytology services shall, if the laboratory ceases operation, preserve records, reports, cytology slides, and cell blocks as prescribed in subdivision (g) of Section 1271 and Section 1274.
(b)A person injured as a result of the laboratorys abandonment of records may bring an action in a court of competent jurisdiction for the amount of damages suffered as a result. If the laboratory was a corporation or partnership that has been dissolved, the person injured may bring an action against that corporations or partnerships principal officers of record at the time of the dissolution.
(c)For purposes of this section, the following definitions shall apply:
(1)Abandonment of records means violating subdivision (a) and thereby leaving patients and physicians and surgeons without access to information to which they are entitled pursuant to this chapter.
(2)Principal officers means:
(A)In the case of a partnership other than a limited partnership, any partner.
(B)In the case of a limited partnership, any general partner, as defined in Section 15904.02 of the Corporations Code.
(C)In the case of a corporation, the chairperson of the board, the chief executive officer, and the president of the corporation.
SEC. 17.SEC. 19.Section 1272 of the Business and Professions Code is amended to read:1272.A clinical laboratory shall participate in a CLIA-approved proficiency testing program and demonstrate satisfactory performance in all of the laboratory specialities that include tests performed in the laboratory. Proficiency shall be tested in the following specialties: microbiology, serology, clinical chemistry, hematology, cytology, and immunohematology.
SEC. 20.Section 1272.1 is added to the Business and Professions Code, to read:1272.1.(a)If a clinical laboratory ceases operations, the laboratory owners, or delegated representatives of the owners, and the laboratory directors shall notify the department of this fact, in writing, within 30 calendar days from the date a clinical laboratory ceases operation. For purposes of this section, a laboratory ceases operations when it suspends the performance of all clinical laboratory tests or examinations for 30 calendar days at the location for which the clinical laboratory is licensed or registered.
(b)(1)Notwithstanding any other law, owners and laboratory directors of all clinical laboratories, including those laboratories that cease operations, shall preserve medical records and laboratory records, as defined in this section, for three years from the date of testing, examination, or purchase, unless a longer retention period is required by any other law, and shall maintain an ability to provide those records when requested by the department or any duly authorized representative of the department.
(2)For purposes of this subdivision, medical records means the test requisition or test authorization, or the patients chart or medical record if used as the test requisition, the final and preliminary test or examination result, and the name of the person contacted if the laboratory test or examination result indicated an imminent life-threatening result or was of panic value.
(3)For purposes of this subdivision, laboratory records means records showing compliance with CLIA and this chapter during a laboratorys operation that are actual or true copies, either photocopies or electronically reproducible copies, of records for patient test management, quality control, quality assurance, and all invoices documenting the purchase or lease of laboratory equipment and test kits, reagents, or media.
(4)Information contained in medical records and laboratory records shall be confidential, and shall be disclosed only to authorized persons in accordance with federal, state, and local laws.
(c)The department or any person injured as a result of a laboratorys abandonment or failure to retain records pursuant to this section may bring an action in a court of proper jurisdiction for any reasonable amount of damages suffered as a result thereof.
SEC. 18.SEC. 21.Section 1272.4 of the Business and Professions Code is repealed.SEC. 19.SEC. 22.Section 1272.6 of the Business and Professions Code is repealed.SEC. 20.SEC. 23.Section 1281 of the Business and Professions Code is repealed.SEC. 21.SEC. 24.Section 1300 of the Business and Professions Code is amended to read:1300.The amount of application and license fees under this chapter shall be as follows:
(a)The application fee for a histocompatibility laboratory directors, clinical laboratory bioanalysts, clinical chemists, clinical microbiologists, clinical laboratory toxicologists, clinical cytogeneticists, or clinical genetic molecular biologists license is sixty-three dollars ($63).
(b)The annual renewal fee for a histocompatibility laboratory directors, clinical laboratory bioanalysts, clinical chemists, clinical microbiologists, clinical laboratory toxicologists, clinical cytogeneticists, or clinical genetic molecular biologists license is sixty-three dollars ($63).
(c)The application fee for a clinical laboratory scientists or limited clinical laboratory scientists license is thirty-eight dollars ($38).
(d)The application and annual renewal fee for a cytotechnologists license is fifty dollars ($50).
(e)The annual renewal fee for a clinical laboratory scientists or limited clinical laboratory scientists license is twenty-five dollars ($25).
(f)The application fee for a trainees license is thirteen dollars ($13).
(g)The annual renewal fee for a trainees license is eight dollars ($8).
(h)The application fee for a duplicate license is five dollars ($5).
(i)The personnel licensing delinquency fee is equal to the annual renewal fee.
(j)The director may establish a fee for examinations required under this chapter. The fee shall not exceed the total cost to the department in conducting the examination.
(k)The state, a district, city, county, city and county, or other political subdivision, or a public officer or body shall be subject to the payment of fees established pursuant to this chapter or regulations adopted thereunder.
(l)The department shall establish an application fee and a renewal fee for a medical laboratory technician license, the total fees collected not to exceed the costs of the department for the implementation and operation of the program licensing and regulating medical laboratory technicians pursuant to Section 1260.3.
SEC. 22.SEC. 25.Section 1300.1 of the Business and Professions Code is repealed.SEC. 23.SEC. 26.Section 1301 of the Business and Professions Code is amended to read:1301.(a)The department shall give written notice to all persons licensed pursuant to Section 1260, 1260.1, 1261, 1261.5, 1262, 1264, or 1270 at least 30 days in advance of the regular renewal date that a renewal fee has not been paid. In addition, the department shall give written notice to licensed clinical laboratory bioanalysts or doctoral degree specialists and clinical laboratory scientists or limited clinical laboratory scientists by registered or certified mail 90 days in advance of the expiration of the fifth year that a renewal fee has not been paid and, if not paid before the expiration of the fifth year of delinquency, the licensee may be subject to reexamination.
(b)If the renewal fee is not paid for five or more years, the department may require an examination before reinstating the license, except that an examination shall not be required as a condition for reinstatement if the original license was issued without an examination. An examination shall not be required for reinstatement if the license was forfeited solely by reason of nonpayment of the renewal fee if the nonpayment was for less than five years.
(c)If the license is not renewed within 60 days after its expiration, the licensee, as a condition precedent to renewal, shall pay the delinquency fee identified in subdivision (i) of Section 1300, in addition to the renewal fee in effect on the last preceding regular renewal date. Payment of the delinquency fee is not necessary if, within 60 days of the license expiration date, the licensee files an application for inactive status.
SEC. 24.SEC. 27.Section 1310 of the Business and Professions Code is repealed.SEC. 28.Section 1310 is added to the Business and Professions Code, to read:1310.(a)If the department determines that a clinical laboratory does not substantially meet the requirements of this chapter or federal law, the department may impose any of the following:
(1)Directed plans of correction, as defined under CLIA.
(2)Civil money penalties in an amount ranging from fifty dollars ($50) to three thousand dollars ($3,000) per day of noncompliance, or per violation, for a condition-level deficiency that does not pose immediate jeopardy, to an amount ranging from three thousand fifty dollars ($3,050) to ten thousand dollars ($10,000) per day of noncompliance, or per violation, for a condition-level deficiency that poses immediate jeopardy, but only after notice and an opportunity to respond in accordance with Section 100171 of the Health and Safety Code, and consideration of facts enumerated in CLIA in Section 493.1834 of Title 42 of the Code of Federal Regulations.
(3)Civil money penalties in an amount ranging from fifty dollars ($50) to three thousand dollars ($3,000) per day of noncompliance, or per violation, for failure to comply with disease reporting requirements, but only after notice and an opportunity to respond in accordance with Section 100171 of the Health and Safety Code.
(4)Onsite monitoring, as defined under CLIA, and payment for the costs of onsite monitoring.
(5)Any combination of the actions described in paragraphs (1) to (4), inclusive.
(b)The department or its agents may enter and inspect a clinical laboratory at any time to enforce state laws and regulations, including, but not limited to, state standards that are more stringent than federal standards.
SEC. 25.SEC. 29.Section 1320 of the Business and Professions Code is amended to read:1320.The department may deny, suspend, or revoke a license issued pursuant to this chapter for any of the following reasons:
(a)Conduct involving moral turpitude or dishonest reporting of tests.
(b)Violation by the applicant or licensee of this chapter or a rule or regulation adopted pursuant thereto.
(c)Aiding, abetting, or permitting the violation of this chapter, the rules or regulations adopted pursuant to this chapter, or the Medical Practice Act (Chapter 5 (commencing with Section 2000) of Division 2).
(d)Permitting a licensed trainee to perform tests or procure specimens unless under direct and responsible supervision.
(e)Violation of any provision of this code governing the practice of medicine and surgery.
(f)Proof that an applicant or licensee has made false statements in any material regard on the application for a license or renewal issued pursuant to this chapter.
(g)Conduct inimical to the public health, morals, welfare, or safety of the people of the State of California in the provision of services for which a license is issued pursuant to this chapter.
(h)Proof that the applicant or licensee has used a degree or certificate as a means of qualifying for licensure that has been purchased or procured by barter or by any unlawful means or obtained from an institution that, at the time the degree, certificate, or title was obtained, was not recognized or accredited by the department of education of the state where the institution is or was located to give training in the field of study in which the degree, certificate, or title is claimed.
(i)Violation of any of the prenatal laws or regulations pertaining thereto in Chapter 2 (commencing with Section 120675) of Part 3 of Division 105 of the Health and Safety Code and Article 1 (commencing with Section 1125) of Group 4 of Subchapter 1 of Chapter 2 of Part 1 of Title 17 of the California Code of Regulations.
(j)Knowingly accepting an assignment for clinical laboratory tests or specimens from, and the rendering of a report thereon to, persons not authorized by law to submit those specimens or assignments.
(k)Rendering a report on clinical laboratory work actually performed in another clinical laboratory without designating clearly the name and address of the laboratory in which the test was performed.
(l)Conviction of a felony or misdemeanor involving moral turpitude under the laws of any state or of the United States arising out of or in connection with the practice of clinical laboratory technology. The record of conviction or a certified copy thereof shall be conclusive evidence of that conviction.
(m)Unprofessional conduct.
(n)The use of drugs or alcoholic beverages to the extent or in a manner as to be dangerous to a person licensed under this chapter, or any other person to the extent that use impairs the ability of the licensee to conduct, with safety to the public, the practice of clinical laboratory technology.
(o)Misrepresentation in obtaining a license.
(p)Performance of a clinical laboratory test or examination or other procedure that is not within the specialties or subspecialties, or category of laboratory procedures authorized by the license.
SEC. 26.SEC. 30.Section 1324 of the Business and Professions Code is repealed.SEC. 27.SEC. 31.Section 1325 of the Business and Professions Code is repealed.SEC. 28.SEC. 32.Section 9272 of the Food and Agricultural Code is amended to read:9272.The provisions of this chapter shall not apply (1) to facilities primarily engaged in the collection, preparation, testing, processing, storage, or distribution of human blood or blood products, provided the facility is licensed pursuant to Chapter 4 (commencing with Section 1600) of Division 2 of the Health and Safety Code and any biologic, as defined in Section 9203, produced by the facility is sold or distributed only to an establishment licensed by this chapter or (2) to clinical laboratories whose only biologics are autogenous bacterins prepared at the request of licensed veterinarians.
SEC. 29.SEC. 33.Section 1206 of the Health and Safety Code is amended to read:1206.This chapter does not apply to the following:
(a)Except with respect to the option provided with regard to surgical clinics in paragraph (1) of subdivision (b) of Section 1204 and, further, with respect to specialty clinics specified in paragraph (2) of subdivision (b) of Section 1204, a place or establishment owned or leased and operated as a clinic or office by one or more licensed health care practitioners and used as an office for the practice of their profession, within the scope of their license, regardless of the name used publicly to identify the place or establishment.
(b)A clinic directly conducted, maintained, or operated by the United States or by any of its departments, officers, or agencies, and any primary care clinic specified in subdivision (a) of Section 1204 that is directly conducted, maintained, or operated by this state or by any of its political subdivisions or districts, or by any city. Nothing in this subdivision precludes the department from adopting regulations that utilize clinic licensing standards as eligibility criteria for participation in programs funded wholly or partially under Title XVIII or XIX of the federal Social Security Act.
(c)(1)A clinic conducted, maintained, or operated by a federally recognized Indian tribe or tribal organization, as defined in Section 450 or 1603 of Title 25 of the United States Code, that is located on land recognized as tribal land by the federal government.
(2)A clinic conducted, maintained, or operated by a federally recognized Indian tribe or tribal organization, as defined in Section 450 or 1603 of Title 25 of the United States Code, under a contract with the United States pursuant to the Indian Self-Determination and Education Assistance Act (Public Law 93-638), regardless of the location of the clinic, except that if the clinic chooses to apply to the State Department of Public Health for a state facility license, then the State Department of Public Health will retain authority to regulate that clinic as a primary care clinic as defined by subdivision (a) of Section 1204.
(d)Clinics conducted, operated, or maintained as outpatient departments of hospitals.
(e)A facility licensed as a health facility under Chapter 2 (commencing with Section 1250).
(f)A freestanding clinical or pathological laboratory.
(g)A clinic operated by, or affiliated with, an institution of learning that teaches a recognized healing art and is approved by the state board or commission vested with responsibility for regulation of the practice of that healing art.
(h)A clinic that is operated by a primary care community or free clinic and that is operated on separate premises from the licensed clinic and is only open for limited services of no more than 30 hours a week. An intermittent clinic, as described in this subdivision, shall meet all other requirements of law, including administrative regulations and requirements, pertaining to fire and life safety.
(i)The offices of physicians in group practice who provide a preponderance of their services to members of a comprehensive group practice prepayment health care service plan subject to Chapter 2.2 (commencing with Section 1340).
(j)Student health centers operated by public institutions of higher education.
(k)Nonprofit speech and hearing centers, as defined in Section 1201.5. A nonprofit speech and hearing clinic desiring an exemption under this subdivision shall apply to the director, who shall grant the exemption to any facility meeting the criteria of Section 1201.5. Notwithstanding the licensure exemption contained in this subdivision, a nonprofit speech and hearing center shall be deemed to be an organized outpatient clinic for purposes of qualifying for reimbursement as a rehabilitation center under the Medi-Cal Act (Chapter 7 (commencing with Section 14000) of Part 3 of Division 9 of the Welfare and Institutions Code).
(l)A clinic operated by a nonprofit corporation exempt from federal income taxation under paragraph (3) of subsection (c) of Section 501 of the Internal Revenue Code of 1954, as amended, or a statutory successor thereof, that conducts medical research and health education and provides health care to its patients through a group of 40 or more physicians and surgeons, who are independent contractors representing not less than 10 board-certified specialties, and not less than two-thirds of whom practice on a full-time basis at the clinic.
(m)A clinic, limited to in vivo diagnostic services by magnetic resonance imaging functions or radiological services under the direct and immediate supervision of a physician and surgeon who is licensed to practice in California. This shall not be construed to permit cardiac catheterization or any treatment modality in these clinics.
(n)A clinic operated by an employer or jointly by two or more employers for their employees only, or by a group of employees, or jointly by employees and employers, without profit to the operators thereof or to any other person, for the prevention and treatment of accidental injuries to, and the care of the health of, the employees comprising the group.
(o)A community mental health center, as defined in Section 5667 of the Welfare and Institutions Code.
(p)(1)A clinic operated by a nonprofit corporation exempt from federal income taxation under paragraph (3) of subsection (c) of Section 501 of the Internal Revenue Code of 1954, as amended, or a statutory successor thereof, as an entity organized and operated exclusively for scientific and charitable purposes and that satisfied all of the following requirements on or before January 1, 2005:
(A)Commenced conducting medical research on or before January 1, 1982, and continues to conduct medical research.
(B)Conducted research in, among other areas, prostatic cancer, cardiovascular disease, electronic neural prosthetic devices, biological effects and medical uses of lasers, and human magnetic resonance imaging and spectroscopy.
(C)Sponsored publication of at least 200 medical research articles in peer-reviewed publications.
(D)Received grants and contracts from the National Institutes of Health.
(E)Held and licensed patents on medical technology.
(F)Received charitable contributions and bequests totaling at least five million dollars ($5,000,000).
(G)Provides health care services to patients only:
(i)In conjunction with research being conducted on procedures or applications not approved or only partially approved for payment (I) under the Medicare program pursuant to Section 1359y(a)(1)(A) of Title 42 of the United States Code, or (II) by a health care service plan registered under Chapter 2.2 (commencing with Section 1340), or a disability insurer regulated under Chapter 1 (commencing with Section 10110) of Part 2 of Division 2 of the Insurance Code; provided that services may be provided by the clinic for an additional period of up to three years following the approvals, but only to the extent necessary to maintain clinical expertise in the procedure or application for purposes of actively providing training in the procedure or application for physicians and surgeons unrelated to the clinic.
(ii)Through physicians and surgeons who, in the aggregate, devote no more than 30 percent of their professional time for the entity operating the clinic, on an annual basis, to direct patient care activities for which charges for professional services are paid.
(H)Makes available to the public the general results of its research activities on at least an annual basis, subject to good faith protection of proprietary rights in its intellectual property.
(I)Is a freestanding clinic, whose operations under this subdivision are not conducted in conjunction with any affiliated or associated health clinic or facility defined under this division, except a clinic exempt from licensure under subdivision (m). For purposes of this subparagraph, a freestanding clinic is defined as affiliated only if it directly, or indirectly through one or more intermediaries, controls, or is controlled by, or is under common control with, a clinic or health facility defined under this division, except a clinic exempt from licensure under subdivision (m). For purposes of this subparagraph, a freestanding clinic is defined as associated only if more than 20 percent of the directors or trustees of the clinic are also the directors or trustees of any individual clinic or health facility defined under this division, except a clinic exempt from licensure under subdivision (m). Any activity by a clinic under this subdivision in connection with an affiliated or associated entity shall fully comply with the requirements of this subdivision. This subparagraph shall not apply to agreements between a clinic and any entity for purposes of coordinating medical research.
(2)By January 1, 2007, and every five years thereafter, the Legislature shall receive a report from each clinic meeting the criteria of this subdivision and any other interested party concerning the operation of the clinics activities. The report shall include, but not be limited to, an evaluation of how the clinic impacted competition in the relevant health care market, and a detailed description of the clinics research results and the level of acceptance by the payer community of the procedures performed at the clinic. The report shall also include a description of procedures performed both in clinics governed by this subdivision and those performed in other settings. The cost of preparing the reports shall be borne by the clinics that are required to submit them to the Legislature pursuant to this paragraph.
SEC. 30.SEC. 34.Section 1600.3 of the Health and Safety Code is amended to read:1600.3.Blood bank depository means a place other than a blood bank where human whole blood and human whole blood derivatives specified by regulation are stored and held for transfusion. Blood bank depositories shall be clinical laboratories, licensed in accordance with the provisions of federal law, or other places where services essentially equivalent are maintained, as determined by the department.
SEC. 31.SEC. 35.Section 14043.27 of the Welfare and Institutions Code is amended to read:14043.27.(a)If an applicant or provider is granted provisional provider status or preferred provisional provider status pursuant to Section 14043.26 and, if at any time during the provisional provider status period or preferred provisional provider status period, the department conducts any announced or unannounced visits or any additional inspections or reviews pursuant to this chapter or Chapter 8 (commencing with Section 14200), or the regulations adopted thereunder, or pursuant to Section 100185.5 of the Health and Safety Code, and discovers or otherwise determines the existence of any ground to deactivate the providers number and business addresses or suspend the provider from the Medi-Cal program pursuant to this chapter or Chapter 8 (commencing with Section 14200), or the regulations adopted thereunder, or pursuant to Section 100185.5 of the Health and Safety Code, or if any of the circumstances listed in subdivision (c) occur, the department shall terminate the provisional provider status or preferred provisional provider status of the provider, regardless of whether the period of time for which the provisional provider status or preferred provisional provider status was granted under Section 14043.26 has elapsed.
(b)Termination of provisional provider status or preferred provisional provider status shall include deactivation of the providers number, including all business addresses used by the provider to obtain reimbursement from the Medi-Cal program and removal of the provider from enrollment in the Medi-Cal program, except where the termination is based upon a ground related solely to a specific location for which provisional provider status was granted. Termination of provisional provider status based upon grounds related solely to a specific location may include failure to have an established place of business, failure to possess the business or zoning permits or other approvals necessary to operate a business, or failure to possess the appropriate licenses, permits, or certificates necessary for the provider of service category or subcategory identified by the provider in its application package. Where the grounds relate solely to a specific location, the termination of provisional provider status shall include only deactivation of the specific locations that the grounds apply to and shall include removal of the provider from enrollment in the Medi-Cal program only if, after deactivation of the specific locations, the provider does not have any business address that is not deactivated.
(c)The following circumstances are grounds for termination of provisional provider status or preferred provisional provider status:
(1)The provider, persons with an ownership or control interest in the provider, or persons who are directors, officers, or managing employees of the provider have been convicted of any felony, or convicted of any misdemeanor involving fraud or abuse in any government program, related to neglect or abuse of a patient in connection with the delivery of a health care item or service, or in connection with the interference with, or obstruction of, any investigation into health care related fraud or abuse, or have been found liable for fraud or abuse in any civil proceeding, or have entered into a settlement in lieu of conviction for fraud or abuse in any government program within 10 years of the date of the application package.
(2)There is a material discrepancy in the information provided to the department, or with the requirements to be enrolled, that is discovered after provisional provider status or preferred provisional provider status has been granted and that cannot be corrected because the discrepancy occurred in the past.
(3)The provider has provided material information that was false or misleading at the time it was provided.
(4)The provider failed to have an established place of business at the business address for which the application package was submitted at the time of any onsite inspection, announced or unannounced visit, or any additional inspection or review conducted pursuant to this article or a statute or regulation governing the Medi-Cal program, unless the practice of the providers profession or delivery of services, goods, supplies, or merchandise is such that services, goods, supplies, or merchandise are rendered or delivered at locations other than the business address and this practice or delivery of services, goods, supplies, or merchandise has been disclosed in the application package approved by the department when the provisional provider status or preferred provisional provider status was granted.
(5)The provider meets the definition of a clinic under Section 1200 of the Health and Safety Code, but is not licensed as a clinic pursuant to Chapter 1 (commencing with Section 1200) of Division 2 of the Health and Safety Code and fails to meet the requirements to qualify for at least one exemption pursuant to Section 1206 or 1206.1 of the Health and Safety Code.
(6)The provider performs clinical laboratory tests or examinations, but it or its personnel do not meet CLIA, and the regulations adopted thereunder, do not possess valid CLIA certificates, or are not exempt pursuant to Section 1241 of the Business and Professions Code.
(7)The provider fails to possess either of the following:
(A)The appropriate licenses, permits, certificates, or other approvals needed to practice the profession or occupation, or provide the services, goods, supplies, or merchandise the provider identified in the application package approved by the department when the provisional provider status or preferred provisional provider status was granted and for the location for which the application was submitted.
(B)The business or zoning permits or other approvals necessary to operate a business at the location identified in its application package approved by the department when the provisional provider status or preferred provisional provider status was granted.
(8)The provider, or if the provider is a clinic, group, partnership, corporation, or other association, any officer, director, or shareholder with a 10 percent or greater interest in that organization, commits two or more violations of the federal or state statutes or regulations governing the Medi-Cal program, and the violations demonstrate a pattern or practice of fraud, abuse, or provision of unnecessary or substandard medical services.
(9)The provider commits any violation of a federal or state statute or regulation governing the Medi-Cal program or of a statute or regulation governing the providers profession or occupation and the violation represents a threat of immediate jeopardy or significant harm to any Medi-Cal beneficiary or to the public welfare.
(10)The provider submits claims for payment that subject a provider to suspension under Section 14043.61.
(11)The provider submits claims for payment for services, goods, supplies, or merchandise rendered at a location other than the business address or addresses listed on the application for enrollment, unless the practice of the providers profession or delivery of services, goods, supplies, or merchandise is such that services, goods, supplies, or merchandise are rendered or delivered at locations other than the business address and this practice or delivery of services, goods, supplies, or merchandise has been disclosed in the application package approved by the department when the provisional provider status was granted.
(12)The provider has not paid its fine, or has a debt due and owing, including overpayments and penalty assessments, to any federal, state, or local government entity that relates to Medicare, medicaid, Medi-Cal, or any other federal or state health care program, and has not made satisfactory arrangements to fulfill the obligation or otherwise been excused by legal process from fulfilling the obligation.
(d)If, during a provisional provider status period or a preferred provisional provider status period, the department conducts any announced or unannounced visits or any additional inspections or reviews pursuant to this chapter or Chapter 8 (commencing with Section 14200), or the regulations adopted thereunder, and commences an investigation for fraud or abuse, or discovers or otherwise determines that the provider is under investigation for fraud or abuse by any other state, local, or federal government law enforcement agency, the provider shall be subject to termination of provisional provider status or preferred provisional provider status, regardless of whether the period of time for which the provisional provider status or preferred provisional provider status was granted under Section 14043.26 has elapsed.
(e)A provider whose provisional provider status or preferred provisional provider status has been terminated pursuant to this section may appeal the termination in accordance with Section 14043.65.
(f)Any department-recovered fine or debt due and owing, including overpayments, that are subsequently determined to have been erroneously collected shall be promptly refunded to the provider, together with interest paid in accordance with subdivision (e) of Section 14171 and Section 14172.5.
(a)Persons A person licensed under Chapter 4 (commencing with Section 1600) of this division or licensed under Chapter 5 (commencing with Section 2000) of this division or licensed under any initiative act referred to in this division relating to osteopaths may not refer patients, clients, or customers to any a clinical laboratory licensed under Section 1265 in which the licensee has any a membership, proprietary interest, or coownership in any form, or has any a profit-sharing arrangement, unless the licensee at the time of making such the referral discloses in writing such the interest to the patient, client, or customer. The written disclosure shall indicate that the patient may choose any clinical laboratory for purposes of having any laboratory work or assignment performed.
This
(b)This section does shall not apply to persons who are members of a medical group which that contracts to provide medical care to members of a group practice prepayment plan registered under the Knox-Keene Health Care Service Act of 1975, Chapter 1975 (Chapter 2.2 (commencing with Section 1340) of Division 2 of the Health and Safety Code. Code).
This
(c)This section does shall not apply to any a referral to a clinical laboratory which that is owned and operated by a health facility licensed pursuant to Chapter 2 (commencing with Section 1250) of Division 2 of the Health and Safety Code.
This
(d)This section does not prohibit the acceptance of evaluation specimens for proficiency testing or referral of specimens or such the assignment from one clinical laboratory to another clinical laboratory, either licensed or exempt under this chapter, providing the report indicates clearly the laboratory performing the test.
Proprietary
(e)Proprietary interest does not include ownership of a building where space is leased to a clinical laboratory at the prevailing rate under a straight lease arrangement.
A
(f)A violation of this section is a public offense and is punishable upon a first conviction by imprisonment in a county jail for not more than one year, or by imprisonment pursuant to subdivision (h) of Section 1170 of the Penal Code, or by a fine not exceeding ten thousand dollars ($10,000), or by both that imprisonment and fine. A second or subsequent conviction shall be punishable by imprisonment pursuant to subdivision (h) of Section 1170 of the Penal Code.
SEC. 2.Section 655.5 of the Business and Professions Code is amended to read:655.5.(a)It is unlawful for any a person licensed under this division or under any an initiative act referred to in this division, or any a clinical laboratory, or any a health facility when billing for a clinical laboratory of the facility, to charge, bill, or otherwise solicit payment from any a patient, client, or customer for any a clinical laboratory service not actually rendered by the person or clinical laboratory or under his, her or its direct supervision unless the patient, client, or customer is apprised at the first time of the charge, billing, or solicitation of the name, address, and charges of the clinical laboratory performing the service. The first such written charge, bill, or other solicitation of payment shall separately set forth the name, address, and charges of the clinical laboratory concerned and shall clearly show whether or not the charge is included in the total of the account, bill, or charge. This subdivision shall be is satisfied if the required disclosures are made to the third-party payer of the patient, client, or customer. If the patient is responsible for submitting the bill for the charges to the third-party payer, the bill provided to the patient for that purpose shall include the disclosures required by this section. This subdivision shall does not apply to a clinical laboratory of a health facility or a health facility when billing for a clinical laboratory of the facility nor to a person licensed under this division or under any initiative act referred to in this division if the standardized billing form used by the facility or person requires a summary entry for all clinical laboratory charges. For purposes of this subdivision, health facility has the same meaning as defined in Section 1250 of the Health and Safety Code.
(b)Commencing July 1, 1994, a A clinical laboratory shall provide to each of its referring providers, upon request, a schedule of fees for services provided to patients of the referring provider. The schedule shall be provided within two working days after the clinical laboratory receives the request. For the purposes of this subdivision, a referring provider means any a provider who has referred a patient to the clinical laboratory in the preceding six-month period. Commencing July 1, 1994, a A clinical laboratory that provides a list of laboratory services to a referring provider or to a potential referring provider shall include a schedule of fees for the laboratory services listed.
(c)It is also unlawful for any a person licensed under this division or under any initiative act referred to in this division to charge additional charges for any a clinical laboratory service that is not actually rendered by the licensee to the patient and itemized in the charge, bill, or other solicitation of payment. This section shall not be construed to prohibit any of the following:
(1)Any An itemized charge for any a service actually rendered to the patient by the licensee.
(2)Any A summary charge for services actually rendered to a patient by a health facility, as defined in Section 1250 of the Health and Safety Code, or by a person licensed under this division or under any initiative act referred to in this division if the standardized billing form used by the facility or person requires a summary entry for all clinical laboratory charges.
(d)As used in this section, the term any a person licensed under this division includes a person licensed under paragraph (1) of subdivision (a) of Section 1265, registered laboratory, as defined in Section 1206, all wholly owned subsidiaries of the person, a parent company that wholly owns the person, and any subsidiaries wholly owned by the same parent that wholly owns the person. Wholly owned means ownership directly or through one or more subsidiaries. This section shall not apply to billings by a person licensed under paragraph (1) of subdivision (a) of Section 1265 registered laboratory when the person licensed under paragraph (1) of subdivision (a) of Section 1265 registered laboratory bills for services performed by any a laboratory owned or operated by the person licensed under paragraph (1) of subdivision (a) of Section 1265. registered laboratory.
(e)This section shall does not apply to any a person or clinical laboratory who or which contracts directly with a health care service plan licensed pursuant to Section 1349 of the Health and Safety Code, if the services are to be provided to members of the plan on a prepaid basis and without additional charge or liability on account thereof.
(f)A violation of this section is a public offense and is punishable upon a first conviction by imprisonment in a county jail for not more than one year, or by imprisonment pursuant to subdivision (h) of Section 1170 of the Penal Code, or by a fine not exceeding ten thousand dollars ($10,000), or by both that imprisonment and fine. A second or subsequent conviction is punishable by imprisonment pursuant to subdivision (h) of Section 1170 of the Penal Code.
(g)(1)Notwithstanding subdivision (f), a violation of this section by a physician and surgeon for a first offense shall be subject to the exclusive remedy of reprimand by the Medical Board of California if the transaction that is the subject of the violation involves a charge for a clinical laboratory service that is less than the charge would have been if the clinical laboratory providing the service billed a patient, client, or customer directly for the clinical laboratory service, and if that clinical laboratory charge is less than the charge listed in the clinical laboratorys schedule of fees pursuant to subdivision (b).
(2)Nothing in this This subdivision shall be construed to does not permit a physician and surgeon to charge more than he or she was charged for the laboratory service by the clinical laboratory providing the service unless the additional charge is for service actually rendered by the physician and surgeon to the patient.
SEC. 3.Section 1206 of the Business and Professions Code is amended to read:1206.(a)For the purposes of this chapter the following definitions are applicable:
(1)Analyte means the substance or constituent being measured measured, including, but not limited to, glucose, sodium, or theophyline, or any substance or property whose presence or absence, concentration, activity, intensity, or other characteristics are to be determined.
(2)Biological specimen means any material that is derived from the human body.
(3)Blood electrolyte analysis means the measurement of electrolytes in a blood specimen by means of ion selective electrodes on instruments specifically designed and manufactured for blood gas and acid-base analysis.
(4)Blood gas analysis means a clinical laboratory test or examination that deals with the uptake, transport, and metabolism metabolization of oxygen and carbon dioxide in the human body.
(5)Clinical laboratory test or examination means the detection, identification, measurement, evaluation, correlation, monitoring, and reporting of any particular analyte, entity, or substance within a biological specimen for the purpose of obtaining scientific data which that may be used as an aid to ascertain the presence, progress, and source of a disease or physiological condition in a human being, or used as an aid in the prevention, prognosis, monitoring, or treatment of a physiological or pathological condition in a human being, or for the performance of nondiagnostic tests for assessing the health of an individual.
(6)Clinical laboratory science means any of the sciences or scientific disciplines used to perform a clinical laboratory test or examination.
(7)Clinical laboratory practice means the application of clinical laboratory sciences or the use of any means that applies the clinical laboratory sciences within or outside of a licensed or registered clinical laboratory. Clinical laboratory practice includes consultation, advisory, and other activities inherent to the profession.
(8)Clinical laboratory means any a place used, or any an establishment or institution organized or operated, for the performance of clinical laboratory tests or examinations or the practical application of the clinical laboratory sciences. That application may include any means that applies the clinical laboratory sciences.
(9)Direct and constant supervision means personal observation and critical evaluation of the activity of unlicensed laboratory personnel by a physician and surgeon, or by a person licensed under this chapter other than a trainee, during the entire time that the unlicensed laboratory personnel are engaged in the duties specified in Section 1269.
(10)Direct and responsible supervision means both of the following:
(A)Personal observation and critical evaluation of the activity of a trainee by a physician and surgeon, or by a person licensed under this chapter other than a trainee, during the entire time that the trainee is performing clinical laboratory tests or examinations.
(B)Personal review by the physician and surgeon or the licensed person of all results of clinical laboratory testing or examination performed by the trainee for accuracy, reliability, and validity before the results are reported from the laboratory.
(11)Licensed laboratory means a clinical laboratory licensed pursuant to paragraph (1) of subdivision (a) of Section 1265. pursuant to the federal Clinical Laboratory Improvement Amendments of 1988 (CLIA).
(12)Location means either a street and city address, or a site or place within a street and city address, where any of the clinical laboratory sciences or scientific disciplines are practiced or applied, or where any clinical laboratory tests or examinations are performed.
(13)Physician office laboratory means a clinical laboratory that is licensed or registered under Section 1265, and that is either: (A) a clinical laboratory that is owned and operated by a partnership or professional corporation that performs clinical laboratory tests or examinations only for patients of five or fewer physicians and surgeons or podiatrists who are shareholders, partners, or employees of the partnership or professional corporation that owns and operates the clinical laboratory; or (B) a clinical laboratory that is owned and operated by an individual licensed physician and surgeon or a podiatrist, and that performs clinical laboratory tests or examinations only for patients of the physician and surgeon or podiatrist who owns and operates the clinical laboratory.
(14)Point-of-care laboratory testing device means a portable laboratory testing instrument to which the following applies:
(A)It is used within the proximity of the patient for whom the test or examination is being conducted.
(B)It is used in accordance with the patient test management system, the quality control program, and the comprehensive quality assurance program established and maintained by the laboratory pursuant to paragraph (2) of subdivision (d) of Section 1220.
(C)It meets the following criteria:
(i)Performs clinical laboratory tests or examinations classified as waived or of moderate complexity under the federal Clinical Laboratory Improvement Amendments of 1988 (CLIA) (42 U.S.C. Sec. 263a).
(ii)Performs clinical laboratory tests or examinations on biological specimens that require no preparation after collection.
(iii)Provides clinical laboratory tests or examination results without calculation or discretionary intervention by the testing personnel.
(iv)Performs clinical laboratory tests or examinations without the necessity for testing personnel to perform calibration or maintenance, except resetting pursuant to the manufacturers instructions or basic cleaning.
(15)Public health laboratory means a laboratory that is operated by a city or county in conformity with Article 5 (commencing with Section 101150) of Chapter 2 of Part 3 of Division 101 of the Health and Safety Code and the regulations adopted thereunder.
(16)Registered laboratory means a clinical laboratory registered pursuant to paragraph (2) of subdivision (a) of Section 1265. that performs clinical laboratory tests or examinations subject to a certificate of waiver or a certificate of provider-performed microscopy under CLIA.
(17)Specialty means histocompatibility, microbiology, diagnostic immunology, chemistry, hematology, immunohematology, pathology, genetics, or other specialty specified by regulation adopted by the department.
(18)Subspecialty for purposes of microbiology, means bacteriology, mycobacteriology, mycology, parasitology, virology, molecular biology, and serology for diagnosis of infectious diseases, or other subspecialty specified by regulation adopted by the department; for purposes of diagnostic immunology, means syphilis serology, general immunology, or other subspecialty specified by regulation adopted by the department; for purposes of chemistry, means routine chemistry, clinical microscopy, endocrinology, toxicology, or other subspecialty specified by regulation adopted by the department; for purposes of immunohematology, means ABO/Rh Type and Group, antibody detection for transfusion, antibody detection nontransfusion, antibody identification, compatibility, or other subspecialty specified by regulation adopted by the department; for pathology, means tissue pathology, oral pathology, diagnostic cytology, or other subspecialty specified by regulation adopted by the department; for purposes of genetics, means molecular biology related to the diagnosis of human genetic abnormalities, cytogenetics, or other subspecialty specified by regulation adopted by the department.
(b)Nothing in this This chapter shall does not restrict, limit, or prevent any a person licensed to provide health care services under the laws of this state, including, but not limited to, licensed physicians and surgeons and registered nurses, from practicing the profession or occupation for which he or she is licensed.
(c)Nothing in this This chapter shall does not authorize any a person to perform or order health care services, or utilize the results of the clinical laboratory test or examination, unless the person is otherwise authorized to provide that care or utilize the results. The inclusion of a person in Section 1206.5 for purposes of performing a clinical laboratory test or examination shall not be interpreted to authorize a person, who is not otherwise authorized, to perform venipuncture, arterial puncture, or skin puncture.
SEC. 4.Section 1206.6 of the Business and Professions Code is amended to read:1206.6.Subdivision (a) of Section 1206.5 shall does not apply to a pharmacist at a community pharmacy who, upon customer request, performs only blood glucose, hemoglobin A1c, or cholesterol tests that are classified as waived under CLIA and are approved by the federal Food and Drug Administration for sale to the public without a prescription in the form of an over-the-counter test kit, provided that all of the following requirements are satisfied:
(a)The pharmacy obtains a valid CLIA certificate of waiver and complies with all other requirements for the performance of waived clinical laboratory tests under applicable federal regulations. For purposes of CLIA, the person identified as responsible for directing and supervising testing oversight and decisionmaking shall be the pharmacist-in-charge, as defined in Section 4036.5.
(b)The pharmacy obtains a registration from the department pursuant to Section 1265 and complies with this chapter.
(c)The tests are performed only by a pharmacist, as defined in Section 4036, in the course of performing routine patient assessment procedures in compliance with Section 4052.4.
SEC. 5.Section 1220 of the Business and Professions Code is amended to read:1220.(a)(1)Each clinical laboratory shall maintain records, equipment, and facilities that are adequate and appropriate for the services rendered.
(2)(A)Except for tests or examinations classified as waived under CLIA, each clinical laboratory shall enroll, and demonstrate successful participation, as defined under CLIA, for each specialty and subspecialty in which it performs clinical laboratory tests or examinations, in a proficiency testing program approved by the department or by HCFA, CMS, to the same extent as required by CLIA in Subpart H (commencing with Section 493.801) of Title 42 of the Code of Federal Regulations. This requirement shall does not be interpreted to prohibit a clinical laboratory from performing clinical laboratory tests or examinations in a specialty or subspecialty for which there is no department or HCFA CMS approved proficiency testing program.
(B)Each clinical laboratory shall authorize its proficiency test results to be reported to the department in an electronic format that is compatible with the departments proficiency testing data monitoring system and shall authorize the release of proficiency tests results to the public to the same extent required by CLIA.
(b)Each clinical laboratory shall be conducted, maintained, and operated without injury to the public health.
(c)(1)The department shall conduct inspections of licensed clinical laboratories no less than once every two years. The department shall maintain a record of those inspections and shall ensure that every licensed clinical laboratory in California is inspected at least that often.
(2)Registered clinical laboratories shall not be routinely inspected by the department.
(3)
(c)The department shall conduct an investigation of complaints received concerning any a clinical laboratory, which laboratory that may include an inspection of the laboratory.
(4)Each licensed or registered clinical laboratory shall be subject to inspections by HCFA or HCFA agents, as defined by CLIA, as a condition of licensure or registration.
(d)(1)Each clinical laboratory shall perform all clinical laboratory tests or examinations classified as waived under CLIA in conformity with the manufacturers instructions.
(2)Except for those clinical laboratories performing only tests or examinations classified as waived under CLIA, each clinical laboratory shall establish and maintain all of the following:
(A)A patient test management system that meets the standards of CLIA in Subpart J (commencing with Section 493.1100) of Title 42 of the Code of Federal Regulations.
(B)A quality control program that meets the requirements of CLIA in Subpart K (commencing with Section 493.1200) of Title 42 of the Code of Federal Regulations as in effect on January 1, 2015, and that may include the clinical laboratorys use of the following alternative quality control testing procedures recognized an Individualized Quality Control Plan, as incorporated into Appendix C of the State Operations Manual adopted by the federal Centers for Medicare and Medicaid Services (CMS): (CMS).
(i)Until December 31, 2015, equivalent quality control procedures.
(ii)Commencing January 1, 2016, an Individualized Quality Control Plan, as incorporated in Appendix C of the State Operations Manual adopted by CMS.
(C)A comprehensive quality assurance program that meets the standards of CLIA in Subpart P (commencing with Section 493.1701) of Title 42 of the Code of Federal Regulations.
SEC. 6.Section 1223 of the Business and Professions Code is repealed.1223.(a)The Legislature finds and declares that it is the public policy of the state to ensure that Californias laboratory standards, including its laboratory personnel standards, be sustained in order to provide accurate, reliable, and necessary test results. The Legislature further finds that inspections are the most effective means of furthering this policy. It is not the intent of the Legislature to reduce in any way the resources available to the department for inspections, but rather to provide the department with the greatest flexibility to concentrate its resources where they can be most effective. It is the intent of the Legislature to provide for an inspection process that includes state-based inspection components and that determines compliance with federal and state requirements for clinical laboratories.
(b)The department shall employ, or contract for, inspectors, special agents, and investigators, and provide any clerical and technical assistance as necessary to administer this chapter and may incur other expenses as necessary.
(c)Laboratories accredited by a private, nonprofit organization shall be deemed by the department to meet state licensure or registration requirements, and shall be issued a certificate of that deemed status by the department, provided that both of the following conditions are met:
(1)The private, nonprofit organization meets all of the following requirements:
(A)Is approved by the federal Center for Medicare and Medicaid Services as an accreditation body under CLIA and provides the department with the following information:
(i)A detailed comparison of the individual accreditation or approval requirements, with the comparable condition-level requirements.
(ii)A detailed description of its inspection process, including all of the following:
(I)Frequency of inspections.
(II)Copies of inspection forms.
(III)Instructions and guidelines.
(IV)A description of the review and decisionmaking process of inspections.
(V)A statement concerning whether inspections are announced or unannounced.
(VI)A description of the steps taken to monitor the correction of deficiencies.
(iii)A description of the process for monitoring proficiency testing performance, including action to be taken in response to unsuccessful participation.
(iv)A list of all of its current California licensed or registered laboratories and the expiration date of their accreditation, licensure, or registration, as applicable.
(B)Is approved by the department as having accreditation standards that are equal to, or more stringent than, state requirements for licensure and registration.
(C)Conducts inspections of clinical laboratories in a manner that will determine compliance with federal standards and California laws to the extent that California laws provide greater protection to residents, or are more stringent than federal standards, as determined by the department. Notwithstanding any other provision of law, the department may, without taking regulatory action pursuant to Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, implement or interpret this section by means of an All Clinical Laboratories Letter (ACLL). The department shall post the ACLL on its Internet Web site so that any person may observe which California laws are more stringent than federal standards, and which accreditation bodies have been approved to conduct inspections. Public comment on the ACLL shall be accepted by the department for 30 days after posting and shall become final 45 days after the posting. Comments received shall be considered by the department. Nothing in this subdivision is intended to change existing statutory or regulatory requirements governing the operation of clinical laboratories or their personnel.
(D)Is approved by the department as meeting the requirements of this paragraph. The department shall begin accepting applications for approval, in a form and manner prescribed by the department, by January 1, 2011. The department shall make a determination on an application submitted pursuant to this subparagraph within 180 days of receiving the application.
(2)The laboratory meets all of the following requirements:
(A)Meets the accreditation standards of the private, nonprofit organization.
(B)Agrees to permit the private, nonprofit organization to provide any records or other information to the department, its agents, or contractors, as the department may require.
(C)Pays the applicable fees required under Section 1300.
(D)Authorizes its proficiency testing organization to furnish to the department and the private, nonprofit organization the results of the laboratorys participation in an approved proficiency testing program, as defined in 42 C.F.R. 493.2, for the purpose of monitoring the laboratorys proficiency testing, along with explanatory information needed to interpret the proficiency testing results, upon request of the department.
(E)Authorizes the private, nonprofit organization to release to the department a notification of every violation of condition-level requirements, including the actions taken by the organization as a result of the violation, within 30 days of the initiation of the action.
(F)Authorizes the private, nonprofit organization to give notice to the department of any withdrawal of the laboratorys accreditation.
(d)If the private, nonprofit organization described in subdivision (c) has withdrawn or revoked its accreditation of a laboratory, the laboratory shall retain its certificate of deemed status issued pursuant to subdivision (c) for 45 days after the laboratory receives notice of the withdrawal or revocation of the accreditation, or the effective date of any action taken by the department, whichever is earlier.
(e)A certificate of deemed status issued pursuant to subdivision (c) shall be renewed annually provided that the conditions for issuance specified in subdivision (c) are still met. Except as authorized under subdivision (f), the department shall not conduct routine inspections of a laboratory issued a certificate of deemed status pursuant to subdivision (c). Each application for a certificate of deemed status issued under subdivision (c) and each request for renewal of that certificate shall be accompanied by the fees set forth in Section 1300. The total of those certificate application and renewal fees collected by the department shall be sufficient to cover the cost of issuing the certificate. If the department determines that those certificate fees do not fully support the costs of these activities, it shall report that determination to the Legislature.
(f)Nothing in this section shall be construed to prohibit the exercise of the departments authority to conduct complaint investigations, sample validation inspections, or require submission of proficiency testing results to the department to ensure compliance of any clinical laboratory with state standards.
SEC. 7.Section 1227 of the Business and Professions Code is repealed.1227.Every person or clinical laboratory licensed or registered under this chapter shall report to the department, within 30 days thereof, any change of name or address.
SEC. 8.Section 1241.1 of the Business and Professions Code is repealed.1241.1.(a)A primary care clinic, licensed pursuant to subdivision (a) of Section 1204 of the Health and Safety Code, that is operating within a network of primary care clinics, may be issued a license to operate a clinical laboratory pursuant to Section 1265, which authorizes the conduct of clinical laboratory tests and examinations from its network of primary care clinics, if all of the following conditions are met:
(1)The central laboratorys sole purpose is performing moderate or high complexity clinical laboratory tests and examinations, or both, for the patients of the clinics in the network.
(2)Prior to performing any tests or examinations, the central laboratory obtains a certificate under the federal Clinical Laboratory Improvement Amendments of 1988 (42 U.S.C. 263a) (CLIA) and a state laboratory license for the appropriate complexity level of clinical laboratory testing pursuant to Section 1265.
(b)For purposes of this section, network of primary care clinics means two or more primary care clinics operated by the same nonprofit corporation with the same board of directors and the same corporate officers, and operating under the same procedures and protocols.
SEC. 9.Section 1244 of the Business and Professions Code is amended to read:1244.(a)Nothing in this This chapter shall does not restrict, limit, or prevent a program of nondiagnostic general health assessment provided that:
(1)The program meets the requirements of Section 1265 and complies with the requirements of CLIA for waived testing.
(2)The purpose of the program is to screen asymptomatic individuals for chronic health disorders and to refer individuals to licensed sources of care as indicated.
(3)The program does not test for human immunodeficiency virus or any reportable disease or condition identified in Section 120130 of the Health and Safety Code or the regulations adopted under that section.
(4)The program utilizes only those devices that comply with all of the following:
(A)Meet all applicable state and federal performance standards pursuant to Section 111245 of the Health and Safety Code.
(B)Are not adulterated as specified in Article 2 (commencing with Section 111250) of Chapter 6 of Part 5 of Division 104 of the Health and Safety Code.
(C)Are not misbranded as specified in Article 3 (commencing with Section 111330) of Chapter 6 of Part 5 of Division 104 of the Health and Safety Code.
(D)Are not new devices unless they meet the requirements of Section 111550 of the Health and Safety Code.
(E)Are approved as waived tests and are used according to the manufacturers instructions.
(5)Blood collection is performed by skin puncture only.
(6)Testing of a urine specimen is performed by the dipstick method only.
(7)Testing is performed on site and reported directly to the person requesting the test.
(8)The program maintains a supervisory committee consisting of, at a minimum, a licensed physician and surgeon and a clinical laboratory scientist licensed pursuant to this code.
(9)The supervisory committee for the program adopts written protocols that shall be followed in the program and that shall contain all of the following:
(A)Provision of written information to individuals to be assessed that shall include, but not be limited to, the following:
(i)The potential risks and benefits of assessment procedures to be performed in the program.
(ii)The limitations, including the nondiagnostic nature, of assessment examinations of biological specimens performed in the program.
(iii)Information regarding the risk factors or markers targeted by the program.
(iv)The need for followup with licensed sources of care for confirmation, diagnosis, and treatment as appropriate.
(B)Proper use of each device utilized in the program including the operation of analyzers, maintenance of equipment and supplies, and performance of quality control procedures including the determination of both accuracy and reproducibility of measurements in accordance with instructions provided by the manufacturer of the assessment device used.
(C)Proper procedures to be employed when collecting blood, if blood specimens are to be obtained.
(D)Proper procedures to be employed in handling and disposing of all biological specimens to be obtained and material contaminated by those biological specimens. These procedures shall comply with all county and city ordinances for medical waste management and blood-borne pathogen control that apply to the location where the program operates.
(E)Proper procedures to be employed in response to fainting, excessive bleeding, or other medical emergencies.
(F)Documentation that the testing personnel are following the instructions of the instruments manufacturer, are trained in the performance of the test, and are competent to perform the testing without supervision.
(G)Reporting of assessment results to the individual being assessed.
(H)Referral and followup to licensed sources of care as indicated.
The
(10)(a)The written protocols adopted by the supervisory committee shall be maintained for at least one year following completion of the assessment program program, during which period they shall be subject to review by department personnel and the local health officer or his or her designee, including the public health laboratory director.
(b)If skin puncture to obtain a blood specimen is to be performed in a program of nondiagnostic general health assessment, the individual performing the skin puncture shall be authorized to perform skin puncture under this chapter.
(c)A program of nondiagnostic general health assessment that fails to meet the requirements set forth in subdivisions (a) and (b) shall not operate.
(d)For purposes of this section, skin puncture means the collection of a blood specimen by the finger prick method only and does not include venipuncture, arterial puncture, or any other procedure for obtaining a blood specimen.
(e)Nothing in this This chapter shall be interpreted as prohibiting does not prohibit a licensed clinical laboratory from operating a program of nondiagnostic general health assessment provided that the clinical laboratory complies with the requirements of this section.
(f)A program for a health fair providing diagnostic or screening tests is not a nondiagnostic general health assessment program if all of the requirements of this chapter are met, and the laboratory performing the testing is licensed or registered under subdivision (a) of Section 1265. by federal law or is operating with a waiver for the applicable procedures. For a test that is not authorized for self-ordering pursuant to Section 1246.5 and that is not for a nondiagnostic general health assessment pursuant to this section, the licensed or registered clinical laboratory participating in the health fair shall assure that the test is ordered on-site onsite only by a person licensed under this division who is authorized under his or her scope of practice to order the test or by a person authorized by that licensee. The results of a test performed at a health fair shall be provided to the test subject along with an explanation of the results.
SEC. 10.Section 1246.5 of the Business and Professions Code is amended to read:1246.5.(a)Notwithstanding any other provision of law, any a person may request, and any a licensed clinical laboratory or public health laboratory may perform, the laboratory tests specified in this section. A registered clinical laboratory may perform the laboratory tests specified in this section if the test is subject to a certificate of waiver under CLIA and the laboratory has registered with the department under paragraph (2) of subdivision (a) of Section 1265. CLIA. A program for nondiagnostic general health assessment that includes a laboratory test specified in this section shall comply with the provisions of Section 1244. The results from any test may be provided directly to the person requesting the test if the test is on or for his or her own body. These test results shall be provided in a manner that presents clear information and that identifies results indicating the need for referral to a physician and surgeon.
The
(b)The tests that may be conducted pursuant to this section are: pregnancy, glucose level, cholesterol, occult blood, and any other test for which there is a test for a particular analyte approved by the federal Food and Drug Administration for sale to the public without a prescription in the form of an over-the-counter test kit. A test approved only as an over-the-counter collection device may not be conducted pursuant to this section.
SEC. 11.Section 1265 of the Business and Professions Code is repealed.1265.(a)(1)A clinical laboratory performing clinical laboratory tests or examinations classified as of moderate or of high complexity under CLIA shall obtain a clinical laboratory license pursuant to this chapter. The department shall issue a clinical laboratory license to any person who has applied for the license on forms provided by the department and who is found to be in compliance with this chapter and the regulations pertaining thereto. No clinical laboratory license shall be issued by the department unless the clinical laboratory and its personnel meet the CLIA requirements for laboratories performing tests or examinations classified as of moderate or high complexity, or both.
(2)A clinical laboratory performing clinical laboratory tests or examinations subject to a certificate of waiver or a certificate of provider-performed microscopy under CLIA, shall register with the department. The department shall issue a clinical laboratory registration to any person who has applied for the registration on forms provided by the department and is found to be in compliance with this chapter, the regulations pertaining thereto, and the CLIA requirements for either a certificate of waiver or a certificate of provider-performed microscopy.
(b)An application for a clinical laboratory license or registration shall include the name or names of the owner or the owners, the name or names of the laboratory director or directors, the name and location of the laboratory, a list of the clinical laboratory tests or examinations performed by the laboratory by name and total number of test procedures and examinations performed annually (excluding tests the laboratory may run for quality control, quality assurance, or proficiency testing purposes). The application shall also include a list of the tests and the test kits, methodologies, and laboratory equipment used, and the qualifications (educational background, training, and experience) of the personnel directing and supervising the laboratory and performing the laboratory examinations and test procedures, and any other relevant information as may be required by the department. If the laboratory is performing tests subject to a provider-performed microscopy certificate, the name of the provider or providers performing those tests shall be included on the application. Application shall be made by the owners of the laboratory and the laboratory directors prior to its opening. A license or registration to conduct a clinical laboratory if the owners are not the laboratory directors shall be issued jointly to the owners and the laboratory directors and the license or registration shall include any information as may be required by the department. The owners and laboratory directors shall be severally and jointly responsible to the department for the maintenance and conduct thereof or for any violations of this chapter and regulations pertaining thereto.
(c)The department shall not issue a license or registration until it is satisfied that the clinical laboratory will be operated within the spirit and intent of this chapter, that the owners and laboratory directors are each of good moral character, and that the granting of the license will not be in conflict with the interests of public health.
(d)A separate license or registration shall be obtained for each laboratory location, with the following exceptions:
(1)Laboratories that are not at a fixed location, that is, laboratories that move from one testing site to another, such as mobile units providing laboratory testing, health screening fairs, or other temporary testing locations, may apply for and obtain one license or registration for the designated primary site or home base, using the address of that primary site.
(2)Not-for-profit, or federal, state, or local government laboratories that engage in limited (not more than a combination of 15 moderately complex or waived tests, as defined under CLIA, per license) public health testing may apply for and obtain a single license or registration.
(3)Laboratories within a hospital that are located at contiguous buildings on the same campus and under common direction, may file a single application or multiple applications for a license or registration of laboratory locations within the same campus or street address.
(4)Locations within a single street and city address that are under common ownership may apply for and obtain a single license or registration or multiple licenses or registrations, at the discretion of the owner or owners.
(e)(1)A license or registration shall be valid for one year unless revoked or suspended. A clinical laboratory license or registration shall be automatically revoked 30 days from a major change of laboratory directorship or ownership. The clinical laboratory shall be required to submit a completed application for a new clinical laboratory license or registration within those 30 days or cease engaging in clinical laboratory practice.
(2)If a clinical laboratory intends to continue to engage in clinical laboratory practice during the 30 days after a major change in directorship occurs and before the laboratory license or registration is automatically revoked, the laboratory owner may appoint an interim director who meets the requirements of this chapter and CLIA. The interim director shall be appointed within five business days of the major change of the directorship. Written notice shall be provided to the department of the appointment of the laboratory director pursuant to this paragraph within five business days of the appointment.
(f)If the department does not within 60 days after the date of receipt of the application issue a license or registration, it shall state the grounds and reasons for its refusal in writing, serving a copy upon the applicant by certified mail addressed to the applicant at his or her last known address.
(g)The department shall be notified in writing by the laboratory owners or delegated representatives of the owners and the laboratory directors of any change in ownership, directorship, name, or location, including the addition or deletion of laboratory owners or laboratory directors within 30 days. However, notice of change in ownership shall be the responsibility of both the current and new owners. Laboratory owners and directors to whom the current license or registration is issued shall remain jointly and severally responsible to the department for the operation, maintenance, and conduct of the clinical laboratory and for any violations of this chapter or the regulations adopted thereunder, including any failure to provide the notifications required by this subdivision, until proper notice is received by the department. In addition, failure of the laboratory owners and directors to notify the department within 30 days of any change in laboratory directors, including any additions or deletions, shall result in the automatic revocation of the clinical laboratorys license or registration.
(h)The withdrawal of an application for a license or registration or for a renewal of a license, or registration, issuable under this chapter, shall not, after the application has been filed with the department, deprive the department of its authority to institute or continue a proceeding against the applicant for denial of the license, registration, or renewal upon any ground provided by law or to enter an order denying the license, registration, or renewal upon any such ground, unless the department consents in writing to the withdrawal.
(i)The suspension, expiration, or forfeiture by operation of law of a license or registration issued under this chapter, or its suspension, forfeiture, or cancellation by order of the department or by order of a court of law, or its surrender without the written consent of the department, shall not deprive the department of its authority to institute or continue an action against a license or registration issued under this chapter or against the laboratory owner or laboratory director upon any ground provided by law or to enter an order suspending or revoking the license or registration issued under this chapter.
(j)(1)Whenever a clinical laboratory ceases operations, the laboratory owners, or delegated representatives of the owners, and the laboratory directors shall notify the department of this fact, in writing, within 30 calendar days from the date a clinical laboratory ceases operation. For purposes of this subdivision, a laboratory ceases operations when it suspends the performance of all clinical laboratory tests or examinations for 30 calendar days at the location for which the clinical laboratory is licensed or registered.
(2)(A)Notwithstanding any other provision of law, owners and laboratory directors of all clinical laboratories, including those laboratories that cease operations, shall preserve medical records and laboratory records, as defined in this section, for three years from the date of testing, examination, or purchase, unless a longer retention period is required pursuant to any other provision of law, and shall maintain an ability to provide those records when requested by the department or any duly authorized representative of the department.
(B)For purposes of this subdivision, medical records means the test requisition or test authorization, or the patients chart or medical record, if used as the test requisition, the final and preliminary test or examination result, and the name of the person contacted if the laboratory test or examination result indicated an imminent life-threatening result or was of panic value.
(C)For purposes of this subdivision, laboratory records means records showing compliance with CLIA and this chapter during a laboratorys operation that are actual or true copies, either photocopies or electronically reproducible copies, of records for patient test management, quality control, quality assurance, and all invoices documenting the purchase or lease of laboratory equipment and test kits, reagents, or media.
(D)Information contained in medical records and laboratory records shall be confidential, and shall be disclosed only to authorized persons in accordance with federal, state, and local laws.
(3)The department or any person injured as a result of a laboratorys abandonment or failure to retain records pursuant to this section may bring an action in a court of proper jurisdiction for any reasonable amount of damages suffered as a result thereof.
(k)For purposes of this section, in the case of a pharmacy that applies for a registration pursuant to Section 1206.6, laboratory director means the pharmacist-in-charge identified pursuant to subdivision (a) of Section 1206.6.
SEC. 12.Section 1265.1 of the Business and Professions Code is repealed.1265.1.(a)A primary care clinic that submits an application to the State Department of Public Health for clinic licensure pursuant to subdivision (a) of Section 1204 of the Health and Safety Code may submit prior to that submission, or concurrent therewith, an application for licensure or registration of a clinical laboratory to be operated by the clinic.
(b)An application for licensure of a clinical laboratory submitted pursuant to this section shall be subject to all applicable laboratory licensing laws and regulations, including, but not limited to, any statutory or regulatory timelines and processes for review of a clinical laboratory application.
SEC. 13.Section 1266 of the Business and Professions Code is repealed.1266.The clinical laboratory license and the license or current renewal permit of each person performing tests shall be conspicuously posted in the clinical laboratory.
SEC. 14.Section 1267 of the Business and Professions Code is repealed.1267.Any denial, suspension, or revocation of a license under this chapter shall be conducted in compliance with Section 100171 of the Health and Safety Code.
SEC. 15.Section 1268 of the Business and Professions Code is repealed.1268.Upon filing application therefor, containing such information as the department may require, and the payment of the license fee, the department shall issue to any person duly licensed under this chapter a duplicate license for one previously issued or, where there has been a change of name, another license in lieu of one previously issued.
SEC. 16.Section 1271.1 of the Business and Professions Code is amended to read:1271.1.(a)Clinical laboratories which are licensed pursuant to this chapter and provide A clinical laboratory that provides cytology services shall, if the licensee laboratory ceases operation, preserve records, reports, cytology slides, and cell blocks as prescribed in subdivision (g) of Section 1271 and Section 1274.
(b)Any A person injured as a result of the licensees laboratorys abandonment of records may bring an action in any a court of competent jurisdiction for the amount of any damages suffered as a result. In the event the licensee If the laboratory was a corporation or partnership which that has been dissolved, the person injured may bring an action against that corporations or partnerships principal officers of record at the time of the dissolution.
(c)For purposes of this section, the following definitions shall apply:
(1)Abandonment of records means violating subdivision (a) and thereby leaving patients and physicians and surgeons without access to information to which they are entitled pursuant to this chapter.
(2)Principal officers means:
(A)In the case of a partnership other than a limited partnership, any partner.
(B)In the case of a limited partnership, any general partner, as defined in subdivision (i) of Section 15611 15904.02 of the Corporations Code.
(C)In the case of a corporation, the chairperson of the board, the chief executive officer, and the president of the corporation.
SEC. 17.Section 1272 of the Business and Professions Code is amended to read:1272.A clinical laboratory shall participate in a state-approved CLIA-approved proficiency testing program and demonstrate satisfactory performance in all of the laboratory specialities that include tests performed in the laboratory. Proficiency shall be tested in the following specialties: microbiology, serology, clinical chemistry, hematology, cytology, and immunohematology.
SEC. 18.Section 1272.4 of the Business and Professions Code is repealed.1272.4.The department shall establish standards for the evaluation of cytologic slides, for reporting the adequacy of cytologic slides, for a cytotechnologist competency program, and for a proficiency testing program for clinical laboratories providing cytology services.
SEC. 19.Section 1272.6 of the Business and Professions Code is repealed.1272.6.The department shall, on or before January 1, 1992, develop or adopt a proficiency testing program for laboratories providing cytology services which may be administered by the department or by a proficiency testing service or program approved by the department. The proficiency program established pursuant to this section shall include announced and unannounced onsite proficiency testing, with that testing to take place, to the extent practicable, under normal working conditions.
SEC. 20.Section 1281 of the Business and Professions Code is repealed.1281.It is unlawful for any person to own, operate, maintain, direct, or engage in the business of operating a clinical laboratory, as defined in this chapter, unless he or she possesses a valid clinical laboratory license issued by the department. In the event a health facility does not perform clinical laboratory services, but provides laboratory services to its patients under an agreement with another person or entity that holds and is operating under a valid clinical laboratory license, the health facility shall not be required to obtain a clinical laboratory license.
SEC. 21.Section 1300 of the Business and Professions Code is amended to read:1300.The amount of application, registration, application and license fees under this chapter shall be as follows:
(a)The application fee for a histocompatibility laboratory directors, clinical laboratory bioanalysts, clinical chemists, clinical microbiologists, clinical laboratory toxicologists, clinical cytogeneticists, or clinical genetic molecular biologists license is sixty-three dollars ($63) commencing on July 1, 1983. ($63).
(b)The annual renewal fee for a histocompatibility laboratory directors, clinical laboratory bioanalysts, clinical chemists, clinical microbiologists, clinical laboratory toxicologists, clinical cytogeneticists, or clinical genetic molecular biologists license is sixty-three dollars ($63) commencing on July 1, 1983. ($63).
(c)The application fee for a clinical laboratory scientists or limited clinical laboratory scientists license is thirty-eight dollars ($38) commencing on July 1, 1983. ($38).
(d)The application and annual renewal fee for a cytotechnologists license is fifty dollars ($50) commencing on January 1, 1991. ($50).
(e)The annual renewal fee for a clinical laboratory scientists or limited clinical laboratory scientists license is twenty-five dollars ($25) commencing on July 1, 1983. ($25).
(f)A clinical laboratory applying for a license to perform tests or examinations classified as of moderate or of high complexity under CLIA and a clinical laboratory applying for certification under subdivision (c) of Section 1223 shall pay an application fee for that license or certification based on the number of tests it performs or expects to perform in a year, as follows:
(1)Less than 2,001 tests: two hundred seventy dollars ($270).
(2)Between 2,001 and 10,000, inclusive, tests: eight hundred twenty dollars ($820).
(3)Between 10,001 and 25,000, inclusive, tests: one thousand three hundred fifteen dollars ($1,315).
(4)Between 25,001 and 50,000, inclusive, tests: one thousand five hundred eighty dollars ($1,580).
(5)Between 50,001 and 75,000, inclusive, tests: one thousand nine hundred sixty dollars ($1,960).
(6)Between 75,001 and 100,000, inclusive, tests: two thousand three hundred forty dollars ($2,340).
(7)Between 100,001 and 500,000, inclusive, tests: two thousand seven hundred forty dollars ($2,740).
(8)Between 500,001 and 1,000,000, inclusive, tests: four thousand nine hundred ten dollars ($4,910).
(9)More than 1,000,000 tests: five thousand two hundred sixty dollars ($5,260) plus three hundred fifty dollars ($350) for every 500,000 tests over 1,000,000, up to a maximum of 15,000,000 tests.
(g)A clinical laboratory performing tests or examinations classified as of moderate or of high complexity under CLIA and a clinical laboratory with a certificate issued under subdivision (c) of Section 1223 shall pay an annual renewal fee based on the number of tests it performed in the preceding calendar year, as follows:
(1)Less than 2,001 tests: one hundred seventy dollars ($170).
(2)Between 2,001 and 10,000, inclusive, tests: seven hundred twenty dollars ($720).
(3)Between 10,001 and 25,000, inclusive, tests: one thousand one hundred fifteen dollars ($1,115).
(4)Between 25,001 and 50,000, inclusive, tests: one thousand three hundred eighty dollars ($1,380).
(5)Between 50,001 and 75,000, inclusive, tests: one thousand seven hundred sixty dollars ($1,760).
(6)Between 75,001 and 100,000, inclusive, tests: two thousand forty dollars ($2,040).
(7)Between 100,001 and 500,000, inclusive, tests: two thousand four hundred forty dollars ($2,440).
(8)Between 500,001 and 1,000,000, inclusive, tests: four thousand six hundred ten dollars ($4,610).
(9)More than 1,000,000 tests per year: four thousand nine hundred sixty dollars ($4,960) plus three hundred fifty dollars ($350) for every 500,000 tests over 1,000,000, up to a maximum of 15,000,000 tests.
(h)
(f)The application fee for a trainees license is thirteen dollars ($13) commencing on July 1, 1983. ($13).
(i)
(g)The annual renewal fee for a trainees license is eight dollars ($8) commencing on July 1, 1983. ($8).
(j)
(h)The application fee for a duplicate license is five dollars ($5) commencing on July 1, 1983. ($5).
(k)
(i)The personnel licensing delinquency fee is equal to the annual renewal fee.
(l)
(j)The director may establish a fee for examinations required under this chapter. The fee shall not exceed the total cost to the department in conducting the examination.
(m)A clinical laboratory subject to registration under paragraph (2) of subdivision (a) of Section 1265 and performing only those clinical laboratory tests or examinations considered waived under CLIA shall pay an annual fee of one hundred dollars ($100). A clinical laboratory subject to registration under paragraph (2) of subdivision (a) of Section 1265 and performing only provider-performed microscopy, as defined under CLIA, shall pay an annual fee of one hundred fifty dollars ($150). A clinical laboratory performing both waived and provider-performed microscopy shall pay an annual registration fee of one hundred fifty dollars ($150).
(n)The costs of the department in conducting a complaint investigation, imposing sanctions, or conducting a hearing under this chapter shall be paid by the clinical laboratory. The fee shall be no greater than the fee the laboratory would pay under CLIA for the same type of activities and shall not be payable if the clinical laboratory would not be required to pay those fees under CLIA.
(o)
(k)The state, a district, city, county, city and county, or other political subdivision, or any a public officer or body shall be subject to the payment of fees established pursuant to this chapter or regulations adopted thereunder.
(p)In addition to the payment of registration or licensure fees, a clinical laboratory located outside the State of California shall reimburse the department for travel and per diem to perform any necessary onsite inspections at the clinical laboratory in order to ensure compliance with this chapter.
(q)
(l)The department shall establish an application fee and a renewal fee for a medical laboratory technician license, the total fees collected not to exceed the costs of the department for the implementation and operation of the program licensing and regulating medical laboratory technicians pursuant to Section 1260.3.
(r)The costs of the department to conduct any reinspections to ensure compliance of a laboratory applying for initial licensure shall be paid by the laboratory. This additional cost for each visit shall be equal to the initial application fee and shall be paid by the laboratory prior to issuance of a license. The department shall not charge a reinspection fee if the reinspection is due to error or omission on the part of the department.
(s)A fee of twenty-five dollars ($25) shall be assessed for approval of each additional location authorized by paragraph (2) of subdivision (d) of Section 1265.
(t)On or before July 1, 2013, the department shall report to the Legislature during the annual legislative budget hearing process the extent to which the state oversight program meets or exceeds federal oversight standards and the extent to which the federal Department of Health and Human Services is accepting exemption applications and the potential cost to the state for an exemption.
SEC. 22.Section 1300.1 of the Business and Professions Code is repealed.1300.1.The application and renewal fees for clinical laboratory licenses specified in Section 1300 shall be adjusted annually in the manner specified in Section 100450 of the Health and Safety Code. The adjustments shall be rounded off to the nearest whole dollar amount.
SEC. 23.Section 1301 of the Business and Professions Code is amended to read:1301.(a)The annual renewal fee for a clinical laboratory license or registration set under this chapter shall be paid during the 30-day period before the expiration date of the license or registration. If the license or registration is not renewed before the expiration date, the licensee or registrant, as a condition precedent to renewal, shall pay a delinquency fee equal to 25 percent of the annual renewal fee for up to 60 days after the expiration date, in addition to the annual renewal fee in effect on the last preceding regular renewal date. Failure to pay the annual renewal fee in advance during the time the license or registration remains in force shall, ipso facto, work a forfeiture of the license or registration after a period of 60 days from the expiration date of the license or registration.
(b)(1)(a)The department shall give written notice to all persons licensed pursuant to Section 1260, 1260.1, 1261, 1261.5, 1262, 1264, or 1270 at least 30 days in advance of the regular renewal date that a renewal fee has not been paid. In addition, the department shall give written notice to licensed clinical laboratory bioanalysts or doctoral degree specialists and clinical laboratory scientists or limited clinical laboratory scientists by registered or certified mail 90 days in advance of the expiration of the fifth year that a renewal fee has not been paid and and, if not paid before the expiration of the fifth year of delinquency delinquency, the licensee may be subject to reexamination.
(2)
(b)If the renewal fee is not paid for five or more years, the department may require an examination before reinstating the license, except that no an examination shall not be required as a condition for reinstatement if the original license was issued without an examination. No An examination shall not be required for reinstatement if the license was forfeited solely by reason of nonpayment of the renewal fee if the nonpayment was for less than five years.
(3)
(c)If the license is not renewed within 60 days after its expiration, the licensee, as a condition precedent to renewal, shall pay the delinquency fee identified in subdivision (k) (i) of Section 1300, in addition to the renewal fee in effect on the last preceding regular renewal date. Payment of the delinquency fee will not be is not necessary if if, within 60 days of the license expiration date date, the licensee files with the department an application for inactive status.
SEC. 24.Section 1310 of the Business and Professions Code is repealed.1310.If the department determines that a laboratory that has been issued a license or registration under this chapter, except for a laboratory only performing tests or examinations classified as waived under CLIA, no longer substantially meets the requirements of this chapter or the regulations adopted thereunder, the department, in lieu of, or in addition to, revocation or suspension of the license or registration under Section 1320 or 1323, may impose any of the following:
(a)Directed plans of correction, as defined under CLIA.
(b)Civil money penalties in an amount ranging from fifty dollars ($50) to three thousand dollars ($3,000) per day of noncompliance, or per violation, for a condition-level deficiency that does not pose immediate jeopardy, to an amount ranging from three thousand fifty dollars ($3,050) to ten thousand dollars ($10,000) per day of noncompliance, or per violation, for a condition-level deficiency that poses immediate jeopardy, but only after notice and an opportunity to respond in accordance with Section 100171 of the Health and Safety Code, and consideration of facts enumerated in CLIA in Section 493.1834 of Title 42 of the Code of Federal Regulations.
(c)Civil money penalties in an amount ranging from fifty dollars ($50) to three thousand dollars ($3,000) per day of noncompliance, or per violation, for a violation of subdivision (t) of Section 1320, for failure to comply with disease reporting requirements, but only after notice and an opportunity to respond in accordance with Section 100171 of the Health and Safety Code.
(d)Onsite monitoring, as defined under CLIA, and payment for the costs of onsite monitoring.
(e)Any combination of the actions described in subdivisions (a), (b), (c), and (d).
SEC. 25.Section 1320 of the Business and Professions Code is amended to read:1320.The department may deny, suspend, or revoke any a license or registration issued under pursuant to this chapter for any of the following reasons:
(a)Conduct involving moral turpitude or dishonest reporting of tests.
(b)Violation by the applicant, licensee, or registrant applicant or licensee of this chapter or any a rule or regulation adopted pursuant thereto.
(c)Aiding, abetting, or permitting the violation of this chapter, the rules or regulations adopted under pursuant to this chapter chapter, or the Medical Practice Act, Chapter Act (Chapter 5 (commencing with Section 2000) of Division 2. 2).
(d)Permitting a licensed trainee to perform tests or procure specimens unless under the direct and responsible supervision of a person duly licensed under this chapter or physician and surgeon other than another licensed trainee. supervision.
(e)Violation of any provision of this code governing the practice of medicine and surgery.
(f)Proof that an applicant, licensee, or registrant applicant or licensee has made false statements in any material regard on the application for a license, registration, license or renewal issued under pursuant to this chapter.
(g)Conduct inimical to the public health, morals, welfare, or safety of the people of the State of California in the maintenance or operation of the premises or provision of services for which a license or registration is issued under pursuant to this chapter.
(h)Proof that the applicant or licensee has used any degree, or certificate, a degree or certificate as a means of qualifying for licensure that has been purchased or procured by barter or by any unlawful means or obtained from any an institution that that, at the time the degree, certificate, or title was obtained obtained, was not recognized or accredited by the department of education of the state where the institution is or was located to give training in the field of study in which the degree, certificate, or title is claimed.
(i)Violation of any of the prenatal laws or regulations pertaining thereto in Chapter 2 (commencing with Section 120675) of Part 3 of Division 105 of the Health and Safety Code and Article 1 (commencing with Section 1125) of Group 4 of Subchapter 1 of Chapter 2 of Part 1 of Title 17 of the California Code of Regulations.
(j)Knowingly accepting an assignment for clinical laboratory tests or specimens from from, and the rendering of a report thereon to to, persons not authorized by law to submit those specimens or assignments.
(k)Rendering a report on clinical laboratory work actually performed in another clinical laboratory without designating clearly the name and address of the laboratory in which the test was performed.
(l)Conviction of a felony or of any misdemeanor involving moral turpitude under the laws of any state or of the United States arising out of or in connection with the practice of clinical laboratory technology. The record of conviction or a certified copy thereof shall be conclusive evidence of that conviction.
(m)Unprofessional conduct.
(n)The use of drugs or alcoholic beverages to the extent or in a manner as to be dangerous to a person licensed under this chapter, or any other person to the extent that that use impairs the ability of the licensee to conduct conduct, with safety to the public public, the practice of clinical laboratory technology.
(o)Misrepresentation in obtaining a license or registration. license.
(p)Performance of, or representation of the laboratory as entitled to perform, of a clinical laboratory test or examination or other procedure that is not within the specialties or subspecialties, or category of laboratory procedures authorized by the license or registration. license.
(q)Refusal of a reasonable request of HCFA, a HCFA agent, the department, or any employee, agent, or contractor of the department, for permission to inspect, pursuant to this chapter, the laboratory and its operations and pertinent records during the hours the laboratory is in operation.
(r)Failure to comply with reasonable requests of the department for any information, work, or materials that the department concludes is necessary to determine the laboratorys continued eligibility for its license or registration, or its continued compliance with this chapter or the regulations adopted under this chapter.
(s)Failure to comply with a sanction imposed under Section 1310.
(t) Failure to comply with the disease reporting requirements adopted pursuant to Section 120130 of the Health and Safety Code. However, when a laboratory is not able to obtain complete information for a patient within the reporting timeframes, it shall document that it made a good faith effort to do so and it shall submit the report with the available information within the required reporting timeframes and, in that case, the laboratory shall not be subject to sanctions for failure to submit complete patient information.
SEC. 26.Section 1324 of the Business and Professions Code is repealed.1324.Except for a person or entity whose license was revoked automatically under Section 1265, no person or entity who has owned or operated a clinical laboratory that had its license or registration revoked may, within two years of the revocation of the license or registration, own or operate a laboratory for which a license or registration has been issued under this chapter.
SEC. 27.Section 1325 of the Business and Professions Code is repealed.1325.Notwithstanding Sections 1267 and 1322, the license or registration of a clinical laboratory that has been excluded from participation under the Medicare program (Title XVIII of the Social Security Act (42 U.S.C. Sec. 1395 et seq.)), under the Medicaid Program (Title XIX of the Social Security Act (42 U.S.C. Sec. 1396 et seq.)), or that had its certificate revoked under CLIA, shall be automatically suspended by the department for the period the laboratory is so excluded or has its certificate revoked.
SEC. 28.Section 9272 of the Food and Agricultural Code is amended to read:9272.The provisions of this chapter shall not apply (1) to facilities primarily engaged in the collection, preparation, testing, processing, storage, or distribution of human blood or blood products, provided such the facility is licensed pursuant to Section 1601 or 1602 Chapter 4 (commencing with Section 1600) of Division 2 of the Health and Safety Code and any biologic biologic, as defined in Section 9203 9203, produced by such the facility is sold or distributed only to an establishment licensed by this chapter or (2) to clinical laboratories licensed pursuant to Chapter 3 (commencing with Section 1200) of Division 2 of the Business and Professions Code whose only biologics are autogenous bacterins prepared at the request of licensed veterinarians.
SEC. 29.Section 1206 of the Health and Safety Code is amended to read:1206.This chapter does not apply to the following:
(a)Except with respect to the option provided with regard to surgical clinics in paragraph (1) of subdivision (b) of Section 1204 and, further, with respect to specialty clinics specified in paragraph (2) of subdivision (b) of Section 1204, any a place or establishment owned or leased and operated as a clinic or office by one or more licensed health care practitioners and used as an office for the practice of their profession, within the scope of their license, regardless of the name used publicly to identify the place or establishment.
(b)Any A clinic directly conducted, maintained, or operated by the United States or by any of its departments, officers, or agencies, and any primary care clinic specified in subdivision (a) of Section 1204 that is directly conducted, maintained, or operated by this state or by any of its political subdivisions or districts, or by any city. Nothing in this subdivision precludes the state department from adopting regulations that utilize clinic licensing standards as eligibility criteria for participation in programs funded wholly or partially under Title XVIII or XIX of the federal Social Security Act.
(c)(1)Any A clinic conducted, maintained, or operated by a federally recognized Indian tribe or tribal organization, as defined in Section 450 or 1603 of Title 25 of the United States Code, that is located on land recognized as tribal land by the federal government.
(2)Any A clinic conducted, maintained, or operated by a federally recognized Indian tribe or tribal organization, as defined in Section 450 or 1603 of Title 25 of the United States Code, under a contract with the United States pursuant to the Indian Self-Determination and Education Assistance Act (Public Law 93-638), regardless of the location of the clinic, except that if the clinic chooses to apply to the State Department of Public Health for a state facility license, then the State Department of Public Health will retain authority to regulate that clinic as a primary care clinic as defined by subdivision (a) of Section 1204.
(d)Clinics conducted, operated, or maintained as outpatient departments of hospitals.
(e)Any A facility licensed as a health facility under Chapter 2 (commencing with Section 1250).
(f)Any A freestanding clinical or pathological laboratory licensed under Chapter 3 (commencing with Section 1200) of Division 2 of the Business and Professions Code. laboratory.
(g)A clinic operated by, or affiliated with, any an institution of learning that teaches a recognized healing art and is approved by the state board or commission vested with responsibility for regulation of the practice of that healing art.
(h)A clinic that is operated by a primary care community or free clinic and that is operated on separate premises from the licensed clinic and is only open for limited services of no more than 30 hours a week. An intermittent clinic clinic, as described in this subdivision shall, however, subdivision, shall meet all other requirements of law, including administrative regulations and requirements, pertaining to fire and life safety.
(i)The offices of physicians in group practice who provide a preponderance of their services to members of a comprehensive group practice prepayment health care service plan subject to Chapter 2.2 (commencing with Section 1340).
(j)Student health centers operated by public institutions of higher education.
(k)Nonprofit speech and hearing centers, as defined in Section 1201.5. Any A nonprofit speech and hearing clinic desiring an exemption under this subdivision shall make application therefor apply to the director, who shall grant the exemption to any facility meeting the criteria of Section 1201.5. Notwithstanding the licensure exemption contained in this subdivision, a nonprofit speech and hearing center shall be deemed to be an organized outpatient clinic for purposes of qualifying for reimbursement as a rehabilitation center under the Medi-Cal Act (Chapter 7 (commencing with Section 14000) of Part 3 of Division 9 of the Welfare and Institutions Code).
(l)A clinic operated by a nonprofit corporation exempt from federal income taxation under paragraph (3) of subsection (c) of Section 501 of the Internal Revenue Code of 1954, as amended, or a statutory successor thereof, that conducts medical research and health education and provides health care to its patients through a group of 40 or more physicians and surgeons, who are independent contractors representing not less than 10 board-certified specialties, and not less than two-thirds of whom practice on a full-time basis at the clinic.
(m)Any A clinic, limited to in vivo diagnostic services by magnetic resonance imaging functions or radiological services under the direct and immediate supervision of a physician and surgeon who is licensed to practice in California. This shall not be construed to permit cardiac catheterization or any treatment modality in these clinics.
(n)A clinic operated by an employer or jointly by two or more employers for their employees only, or by a group of employees, or jointly by employees and employers, without profit to the operators thereof or to any other person, for the prevention and treatment of accidental injuries to, and the care of the health of, the employees comprising the group.
(o)A community mental health center, as defined in Section 5667 of the Welfare and Institutions Code.
(p)(1)A clinic operated by a nonprofit corporation exempt from federal income taxation under paragraph (3) of subsection (c) of Section 501 of the Internal Revenue Code of 1954, as amended, or a statutory successor thereof, as an entity organized and operated exclusively for scientific and charitable purposes and that satisfied all of the following requirements on or before January 1, 2005:
(A)Commenced conducting medical research on or before January 1, 1982, and continues to conduct medical research.
(B)Conducted research in, among other areas, prostatic cancer, cardiovascular disease, electronic neural prosthetic devices, biological effects and medical uses of lasers, and human magnetic resonance imaging and spectroscopy.
(C)Sponsored publication of at least 200 medical research articles in peer-reviewed publications.
(D)Received grants and contracts from the National Institutes of Health.
(E)Held and licensed patents on medical technology.
(F)Received charitable contributions and bequests totaling at least five million dollars ($5,000,000).
(G)Provides health care services to patients only:
(i)In conjunction with research being conducted on procedures or applications not approved or only partially approved for payment (I) under the Medicare program pursuant to Section 1359y(a)(1)(A) of Title 42 of the United States Code, or (II) by a health care service plan registered under Chapter 2.2 (commencing with Section 1340), or a disability insurer regulated under Chapter 1 (commencing with Section 10110) of Part 2 of Division 2 of the Insurance Code; provided that services may be provided by the clinic for an additional period of up to three years following the approvals, but only to the extent necessary to maintain clinical expertise in the procedure or application for purposes of actively providing training in the procedure or application for physicians and surgeons unrelated to the clinic.
(ii)Through physicians and surgeons who, in the aggregate, devote no more than 30 percent of their professional time for the entity operating the clinic, on an annual basis, to direct patient care activities for which charges for professional services are paid.
(H)Makes available to the public the general results of its research activities on at least an annual basis, subject to good faith protection of proprietary rights in its intellectual property.
(I)Is a freestanding clinic, whose operations under this subdivision are not conducted in conjunction with any affiliated or associated health clinic or facility defined under this division, except a clinic exempt from licensure under subdivision (m). For purposes of this subparagraph, a freestanding clinic is defined as affiliated only if it directly, or indirectly through one or more intermediaries, controls, or is controlled by, or is under common control with, a clinic or health facility defined under this division, except a clinic exempt from licensure under subdivision (m). For purposes of this subparagraph, a freestanding clinic is defined as associated only if more than 20 percent of the directors or trustees of the clinic are also the directors or trustees of any individual clinic or health facility defined under this division, except a clinic exempt from licensure under subdivision (m). Any activity by a clinic under this subdivision in connection with an affiliated or associated entity shall fully comply with the requirements of this subdivision. This subparagraph shall not apply to agreements between a clinic and any entity for purposes of coordinating medical research.
(2)By January 1, 2007, and every five years thereafter, the Legislature shall receive a report from each clinic meeting the criteria of this subdivision and any other interested party concerning the operation of the clinics activities. The report shall include, but not be limited to, an evaluation of how the clinic impacted competition in the relevant health care market, and a detailed description of the clinics research results and the level of acceptance by the payer community of the procedures performed at the clinic. The report shall also include a description of procedures performed both in clinics governed by this subdivision and those performed in other settings. The cost of preparing the reports shall be borne by the clinics that are required to submit them to the Legislature pursuant to this paragraph.
SEC. 30.Section 1600.3 of the Health and Safety Code is amended to read:1600.3.Blood bank depository means any a place other than a blood bank where human whole blood and human whole blood derivatives specified by regulation are stored and held for transfusion. Such blood Blood bank depositories shall be clinical laboratories, licensed in accordance with the provisions of Chapter 3 (commencing with Section 1200), Division 2 of the Business and Professions Code, federal law, or such other places where services essentially equivalent are maintained, as determined by the department.
SEC. 31.Section 14043.27 of the Welfare and Institutions Code is amended to read:14043.27.(a)If an applicant or provider is granted provisional provider status or preferred provisional provider status pursuant to Section 14043.26 and, if at any time during the provisional provider status period or preferred provisional provider status period, the department conducts any announced or unannounced visits or any additional inspections or reviews pursuant to this chapter or Chapter 8 (commencing with Section 14200), or the regulations adopted thereunder, or pursuant to Section 100185.5 of the Health and Safety Code, and discovers or otherwise determines the existence of any ground to deactivate the providers number and business addresses or suspend the provider from the Medi-Cal program pursuant to this chapter or Chapter 8 (commencing with Section 14200), or the regulations adopted thereunder, or pursuant to Section 100185.5 of the Health and Safety Code, or if any of the circumstances listed in subdivision (c) occur, the department shall terminate the provisional provider status or preferred provisional provider status of the provider, regardless of whether the period of time for which the provisional provider status or preferred provisional provider status was granted under Section 14043.26 has elapsed.
(b)Termination of provisional provider status or preferred provisional provider status shall include deactivation of the providers number, including all business addresses used by the provider to obtain reimbursement from the Medi-Cal program and removal of the provider from enrollment in the Medi-Cal program, except where the termination is based upon a ground related solely to a specific location for which provisional provider status was granted. Termination of provisional provider status based upon grounds related solely to a specific location may include failure to have an established place of business, failure to possess the business or zoning permits or other approvals necessary to operate a business, or failure to possess the appropriate licenses, permits, or certificates necessary for the provider of service category or subcategory identified by the provider in its application package. Where the grounds relate solely to a specific location, the termination of provisional provider status shall include only deactivation of the specific locations that the grounds apply to and shall include removal of the provider from enrollment in the Medi-Cal program only if, after deactivation of the specific locations, the provider does not have any business address that is not deactivated.
(c)The following circumstances are grounds for termination of provisional provider status or preferred provisional provider status:
(1)The provider, persons with an ownership or control interest in the provider, or persons who are directors, officers, or managing employees of the provider have been convicted of any felony, or convicted of any misdemeanor involving fraud or abuse in any government program, related to neglect or abuse of a patient in connection with the delivery of a health care item or service, or in connection with the interference with, or obstruction of, any investigation into health care related fraud or abuse, or have been found liable for fraud or abuse in any civil proceeding, or have entered into a settlement in lieu of conviction for fraud or abuse in any government program within 10 years of the date of the application package.
(2)There is a material discrepancy in the information provided to the department, or with the requirements to be enrolled, that is discovered after provisional provider status or preferred provisional provider status has been granted and that cannot be corrected because the discrepancy occurred in the past.
(3)The provider has provided material information that was false or misleading at the time it was provided.
(4)The provider failed to have an established place of business at the business address for which the application package was submitted at the time of any onsite inspection, announced or unannounced visit, or any additional inspection or review conducted pursuant to this article or a statute or regulation governing the Medi-Cal program, unless the practice of the providers profession or delivery of services, goods, supplies, or merchandise is such that services, goods, supplies, or merchandise are rendered or delivered at locations other than the business address and this practice or delivery of services, goods, supplies, or merchandise has been disclosed in the application package approved by the department when the provisional provider status or preferred provisional provider status was granted.
(5)The provider meets the definition of a clinic under Section 1200 of the Health and Safety Code, but is not licensed as a clinic pursuant to Chapter 1 (commencing with Section 1200) of Division 2 of the Health and Safety Code and fails to meet the requirements to qualify for at least one exemption pursuant to Section 1206 or 1206.1 of the Health and Safety Code.
(6)The provider performs clinical laboratory tests or examinations, but it or its personnel do not meet CLIA, and the regulations adopted thereunder, and the state clinical laboratory law, thereunder, do not possess valid CLIA certificates and clinical laboratory registrations or licenses pursuant to Chapter 3 (commencing with Section 1200) of Division 2 of the Business and Professions Code, certificates, or are not exempt from licensure as a clinical laboratory under pursuant to Section 1241 of the Business and Professions Code.
(7)The provider fails to possess either of the following:
(A)The appropriate licenses, permits, certificates, or other approvals needed to practice the profession or occupation, or provide the services, goods, supplies, or merchandise the provider identified in the application package approved by the department when the provisional provider status or preferred provisional provider status was granted and for the location for which the application was submitted.
(B)The business or zoning permits or other approvals necessary to operate a business at the location identified in its application package approved by the department when the provisional provider status or preferred provisional provider status was granted.
(8)The provider, or if the provider is a clinic, group, partnership, corporation, or other association, any officer, director, or shareholder with a 10 percent or greater interest in that organization, commits two or more violations of the federal or state statutes or regulations governing the Medi-Cal program, and the violations demonstrate a pattern or practice of fraud, abuse, or provision of unnecessary or substandard medical services.
(9)The provider commits any violation of a federal or state statute or regulation governing the Medi-Cal program or of a statute or regulation governing the providers profession or occupation and the violation represents a threat of immediate jeopardy or significant harm to any Medi-Cal beneficiary or to the public welfare.
(10)The provider submits claims for payment that subject a provider to suspension under Section 14043.61.
(11)The provider submits claims for payment for services, goods, supplies, or merchandise rendered at a location other than the business address or addresses listed on the application for enrollment, unless the practice of the providers profession or delivery of services, goods, supplies, or merchandise is such that services, goods, supplies, or merchandise are rendered or delivered at locations other than the business address and this practice or delivery of services, goods, supplies, or merchandise has been disclosed in the application package approved by the department when the provisional provider status was granted.
(12)The provider has not paid its fine, or has a debt due and owing, including overpayments and penalty assessments, to any federal, state, or local government entity that relates to Medicare, medicaid, Medi-Cal, or any other federal or state health care program, and has not made satisfactory arrangements to fulfill the obligation or otherwise been excused by legal process from fulfilling the obligation.
(d)If, during a provisional provider status period or a preferred provisional provider status period, the department conducts any announced or unannounced visits or any additional inspections or reviews pursuant to this chapter or Chapter 8 (commencing with Section 14200), or the regulations adopted thereunder, and commences an investigation for fraud or abuse, or discovers or otherwise determines that the provider is under investigation for fraud or abuse by any other state, local, or federal government law enforcement agency, the provider shall be subject to termination of provisional provider status or preferred provisional provider status, regardless of whether the period of time for which the provisional provider status or preferred provisional provider status was granted under Section 14043.26 has elapsed.
(e)A provider whose provisional provider status or preferred provisional provider status has been terminated pursuant to this section may appeal the termination in accordance with Section 14043.65.
(f)Any department-recovered fine or debt due and owing, including overpayments, that are subsequently determined to have been erroneously collected shall be promptly refunded to the provider, together with interest paid in accordance with subdivision (e) of Section 14171 and Section 14172.5.
|
Date
|
Status
|
|---|---|
| Feb 3, 2016 | Read first time. To print. |
| Feb 4, 2016 | From printer. May be heard in committee March 5. |
| Feb 18, 2016 | Referred to Com. on B. & P. |
| Apr 21, 2016 | From committee: Amend, and do pass as amended and re-refer to Com. on APPR. (Ayes 15. Noes 0.) (April 19). |
| Apr 25, 2016 | Read second time and amended. |
| Apr 26, 2016 | Re-referred to Com. on APPR. |
| May 11, 2016 | From committee chair, with author's amendments: Amend, and re-refer to Com. on APPR. Read second time and amended. |
| May 12, 2016 | Re-referred to Com. on APPR. |
| May 18, 2016 | In committee: Set, first hearing. Referred to APPR. suspense file. |
| May 27, 2016 | In committee: Held under submission. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Apr 19, 2016 | Do pass as amended and be re-referred to the Committee on [Appropriations] | Assembly Standing Committee on Business and Professions |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
Date of Hearing: May 18, 2016
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Lorena Gonzalez, Chair
ABPCA Bill Id:AB 1774
Author:(Bonilla) – As Amended Ver:May 11, 2016
Policy Committee: | Business and Professions | Vote: | 15 - 0 |
Urgency: No State Mandated Local Program: No Reimbursable: No
SUMMARY:
This bill repeals state licensure and registration requirements for clinical laboratories (labs), including laboratory inspections, issuance of licenses and registration, and associated fees. Specifically, this bill:
- Repeals requirements including:
- Licensure and registration of labs by the state.
- Licensure and registration fees, including provisions for adjusting such fees.
- Requirements that out-of-state labs performing tests on California specimens reimburse the department for travel and per diem to perform any necessary onsite inspections in order to ensure compliance with state law.
- Biennial inspections and proficiency testing requirements for licensed labs.
- A number of provisions related to licensure and registration procedures.
- A requirement that the California Department of Public Health (CDPH) report to the Legislature, on or before July 1, 2013, on the extent to which the state oversight program meets or exceeds federal oversight standards, the extent to which the federal Department of Health and Human Services is accepting exemption applications, and the potential cost to the state for an exemption from the federal Clinical Laboratory Improvement Act (CLIA).
- Repeals language granting CDPH the ability to approve and rely on accreditation organizations to assess compliance with state licensure requirements, and specifies clinical laboratories may choose to be overseen by CDPH, or by an accrediting organization, as follows:
- For unaccredited labs: Requires CDPH to monitor, inspect, and investigate all unaccredited clinical laboratories for compliance with state standards that are in excess of federal standards. Allows CDPH to levy an inspection fee, not to exceed $1,050, for such inspection, but only when it has spent all but $1 million of the fees collected previously from clinical laboratories.
- For accredited labs: Deems a laboratory accredited by an accrediting organization approved by the Centers for Medicare and Medicaid Services (CMS) to meet all state standards.
- Reduces fee levels for personnel licensure and removes authority to adjust such fees.
- Requires CDPH to post on its website a comprehensive list of the differences between CLIA and state law.
- Retains numerous standards for clinical laboratories, including requirements for quality control, compliance with personnel standards, and participation in proficiency testing, among others.
- Authorizes the department or its agents to enter and inspect a clinical laboratory at any time to enforce state laws and regulations, including, but not limited to, state standards that are more stringent than federal standards.
- Loosens supervision requirements for licensed trainees performing tests or procuring specimens.
- Includes a number of technical and conforming changes.
FISCAL EFFECT:
- This bill allows LFS to levy a fee for inspection with state standards only when it has spent all but $1 million of the fees collected previously from clinical laboratories. This bill also reduces clinical laboratory personnel fees to pre-2009 levels, prior to their last increase, resulting in reduced revenue. It also allows the department to recover costs for certain activities, but does not allow cost recovery for inspections if a lab is accredited, and limits the cost recovery for inspections to $1,050 if a lab is not accredited.
There is a significant reserve of over $20 million in the LFS Clinical Laboratory Improvement Fund, which could mitigate an expected sharp reduction in revenue for a year or two. On an ongoing basis, however, this bill may results in unknown fiscal risk because the ongoing balance between fee revenue and workload is unclear.
- By repealing lab licensure and registration, this bill should reduce LFS workload. However, given LFS has not performed many enforcement activities expected under current law with existing staff, it is unclear what the appropriate staffing level to meet current-law expectations, nor what it would be under this bill with different, reduced workload.
COMMENTS:
- Purpose. According to the author, this bill implements the State Auditor’s recommendation to repeal state clinical laboratory licensing, because federal government oversight is highly similar and well-implemented. This bill will free up state resources to focus on personnel standards which are unique to California, while ensuring a continued level of consumer protection in clinical laboratories.
- Background. Clinical laboratories analyze human specimens such as blood, tissue, and urine so that medical professionals can make diagnoses, prescribe treatment, and perform research. There are approximately 2,800 laboratories licensed by Laboratory Field Services (LFS) within CDPH, and approximately 19,300 registered labs. A lab’s license or registration is separate from personnel licenses or other certifications. LFS also licenses and certifies lab personnel, including clinical laboratory scientists and trainees, phlebotomists, and cytotechnologists. Labs are also governed by federal law, and state law and federal law in California can be enforced by LFS or private accrediting organizations, as explained below.
- Federal versus state standards. The federal Clinical Laboratory Improvement Act (CLIA) establishes minimum standards for laboratories to ensure the accuracy, reliability, and timeliness of patient test results. All labs must maintain a CLIA certificate under federal law. The federal CMS administers CLIA, and enforces requirements through accrediting organizations or through state agencies. California law also specifies a number of requirements that are the same as, or similar to, CLIA.[1]
In addition to CLIA standards and CLIA-like standards that were adopted in state law, California clinical labs and out-of-state labs performing tests on California specimens must meet other California-specific standards in order to operate. These include a variety of personnel standards specifying which professional may perform what type of test, and requirements related to education and supervision. There are also a number of other provisions, including limitations on cytology laboratories, requirements related to proficiency testing, and actions that constitute unlawful practice. CDPH administers state clinical laboratory law, and enforces requirements through LFS staff and, more recently, through an approved accrediting organizations.
- Licensed versus Registered Labs. All laboratories must maintain either a registration or a license under state law, depending on if they perform simple or more complex tests. Federal law separates labs into two categories: those performing simple tests, and those performing moderate- to high-complexity tests.
Labs performing only simple tests, often physician offices, must be registered with LFS, but are not required to be licensed. They must also maintain a CLIA certificate and pay a biennial fee, and are subject to complaint investigations and sanctions.
Labs performing moderate- to high-complexity testing, however, are subject to more stringent standards under CLIA and under state law. To become certified under CLIA, these labs must pay a fee to CMS and meet all applicable standards, including biennial surveys, proficiency testing, and personnel requirements. This group of labs is also subject to state licensure. Similar to CLIA, state licensing law requires biennial surveys, proficiency testing, and personnel requirements. As noted, state law establishes certain standards that differ from, or exceed, CLIA standards.
- Accredited labs versus Nonaccredited. Licensed labs, those performing complex tests, either be accredited by private organizations, or nonaccredited. About half of the licensed clinical labs in California are accredited. Accreditation can demonstrate compliance with state or federal standards, if the accrediting organization is approved by CDPH or CMS, respectively. Six accreditation organizations have been approved by CMS, and one has been approved by CDPH.
For accredited labs, the accrediting organizations perform the inspections, monitor proficiency testing, and oversee compliance with applicable standards. The lab provides the state and/or federal government with proof of accreditation and is deemed in compliance with state and/or federal law.
For nonaccredited labs, the federal government contracts with LFS as the oversight entity to ensure compliance with federal CLIA law. LFS verifies compliance with CLIA and uses a "state checklist addendum" to examine compliance with state law. According to the State Auditor, the state checklist of additional requirements in state law includes 15 criteria, most of which relate to personnel standards.
- Scathing State Audits. The California State Auditor found in 2008, and again in September 2015, severe deficiencies plaguing CDPH's laboratory oversight through LFS. The 2008 audit found LFS inconsistently monitored laboratory proficiency testing, was not inspecting laboratories every two years as required, closed many complaints without taking action, only sporadically imposed sanctions against laboratories for violations, and incorrectly adjusted licensing fees. In response, CDPH sponsored and the Legislature passed SB 744 (Strickland), Chapter 201, Statutes of 2009, which authorized LFS to contract with accreditation organizations to serve as the state inspecting agent, and adjusted lab licensure fees to account for testing volume. The stated purpose of the increased fee revenue pursuant to SB 744 was to allow CDPH to hire needed staff at competitive salaries to carry out oversight duties.
More recently, the 2015 audit found lab inspections were still not occurring, and the exact same issues related to proficiency testing, sanctions, and complaints remained. Staffing issues that were supposed to be resolved by increasing revenues pursuant to SB 744 were not resolved. Positions were eliminated in 2012 due to excessive vacancies and hiring for authorized positions did not occur due to other administrative failures. Finally, the 2015 audit noted that since much of state law is duplicative of the federal CLIA, and given the multitude of problems at LFS, the Legislature should repeal state licensure and registration as well as the associated fees.
- Staff Comments. The state auditor and many stakeholders believe many state licensure and registration standards are duplicative of federal law. Thus, this bill repeals them. However, in so doing, this bill raises other issues, including the following:
- Enforcement of State Standards. It is the author's stated intention to uphold state standards that are stricter than federal standards. However, this bill would create challenges in doing so. If state standards are important to maintain, the issues below should be addressed.
- Unaccredited Labs: De Facto Modified Compliance Structure is Weak and Not Clearly Specified. The new Section 1223 (Business and Professions Code) of this bill states for unaccredited labs, the state shall monitor, inspect, and investigate for compliance with state standards that are in excess of federal standards. Compliance with state standards would not result in a state license, but the department could inspect, investigate complaints, and cite and fine facilities. By retaining some state-specific standards, this bill creates a de facto modified compliance structure for these state standards. Generally, state facility standards are enforced through a license. For example, there is duplication between CMS certification standards and state licensure standards for other health facilities like hospitals and skilled nursing facilities, but the state still issues licenses to these facilities. Without licensure and the "stick" of licensure revocation, it appears as though the lab could still legally operate in violation of state standards. In addition, the bill gives inadequate direction to the department as to how it should enforce state-specific standards (e.g., via inspections? via a sampling methodology?). Given LFS's difficulty in enforcing current law, clarifying enforcement expectations seems paramount.
- Accredited Labs: Deemed as Meeting State Standards with no Verification. Unlike (2) above, the compliance structure for state standards with respect to accredited labs is clear: there is none. The bill repeals the existing Section 1223, which gives CDPH the ability to approve accrediting organizations that demonstrate their standards meet or exceed state standards, and the requirement to meet or exceed state standards is not present in the new Section 1223. The new Section 1223 of this bill states for labs accredited by an organization approved under federal CLIA, that accreditation shall be deemed to meet all state standards. Essentially, under this bill's language, federally accredited labs would be "deemed" in compliance with state standards, such as personnel standards, without verification of compliance
- Out-of-State Labs: Not Subject to State Personnel Standards. Staff notes repealing licensure requirements for out-of-state labs subjects in-state labs to stricter standards than out-of-state labs.
- Ongoing balance of revenue and workload unclear. This bill eliminates licensure fees, limiting the department's ability to generate revenue to enforce the remaining requirements in state law. This bill also reduces unrelated personnel application and license fees from their current levels and deletes authority to adjust them in the future, without providing a workload justification and evidence that fee revenue matches ongoing workload. Additionally, given such uncertainty, the restriction on levying fees until LFS has spent all but $1 million of the previously collected fees may not be practicable.
- Lack of Clarity About Which Standards are Duplicative. This bill retains all current state standards for clinical laboratories— some of which are duplicative of federal law, some of which are similar to federal law, and some of which are state-specific. There is no effort made to distinguish in the law which standards are considered duplicative, and which are state-specific. The differences could be clarified in the law so the public, the department, clinical laboratories, and other stakeholders can clearly identify what is being deferred to federal or third-party oversight versus what the state is expected to enforce. In addition, current state law is aligned with a prior version of federal law, suggesting a more comprehensive statutory overhaul is warranted.
- Makes Other, Unrelated Changes. This bill repeals language that applies to personnel and registered labs as well as licensed labs. For example, it repeals requirements that persons or laboratories report name changes to the department. It repeals standards for cytotechnologist competency. It changes supervision standards for lab personnel. It is unclear whether these changes are inadvertent or support the bill's main intent.
- Removes, and Does not Replace, Certain Provisions Regulating Conduct of Laboratories. Since this bill removes code related to licensure, this bill also removes some licensure-related provisions. For example, this bill repeals a provision that allows CDPH to deny, suspend, or revoke a license based on a refusal of a reasonable request to allow the department to inspect the laboratory, its operations, and pertinent records. If there is no licensure, there could instead be a provision that would allow CDPH to impose a fine for such conduct.
Although consistent with the auditor's recommendation to reduce duplication, the blunt nature of the bill's approach results in unintended changes, unspecified enforcement of state-specific standards, and reduced revenue to support any remaining oversight work. The change in fee structure without sufficient workload justification results in unknown fiscal risk and likely inability to perform oversight. Despite LFS's utter failure to perform state-mandated workload, a more deliberative approach to recasting state law in this complex area seems warranted.
Analysis Prepared by: Lisa Murawski / APPR. / (916) 319-2081
According to CDPH, California has incorporated federal CLIA law as published on January 1, 1994, which is different from CLIA as finally adopted in April 2003. The Clinical Laboratory Technology Advisory Committee, which advises CDPH on lab issues, is currently performing a crosswalk of these differences. ↑
Date of Hearing:
ASSEMBLY COMMITTEE ON BUSINESS AND PROFESSIONS
Rudy Salas, Chair
ABPCA Bill Id:AB 1774
Author:(Bonilla) – As Introduced Ver:February 3, 2016
SUBJECT: Clinical laboratories: licensure.
SUMMARY: Repeals the laws requiring a clinical laboratory to be licensed and inspected by the California Department of Public Health (CDPH), including the licensing fees associated with licensure of clinical laboratories; provides that clinical laboratories in this state are still subject to the federal Clinical Laboratory Improvement Amendments of 1988 (CLIA), including the fees and enforcement policies set forth by CLIA.
EXISTING STATE LAW:
- Provides for the licensure, registration, and regulation of clinical laboratories and various clinical laboratory personnel by the CDPH and authorizes the CDPH to inspect clinical laboratories and assesses a fee for licensure of those facilities. (Business and Professions Code (BPC) Section 1200, et seq.)
- Defines several terms, among others, for the purposes of governing clinical laboratories: (BPC Section 1206(a)(5)-1206(a)(16))
- “Clinical laboratory test or examination” means the detection, identification, measurement, evaluation, correlation, monitoring, and reporting of any particular analyte, entity, or substance within a biological specimen for the purpose of obtaining scientific data that may be used as an aid to ascertain the presence, progress, and source of a disease or physiological condition in a human being, or used as an aid in the prevention, prognosis, monitoring, or treatment of a physiological or pathological condition in a human being, or for the performance of nondiagnostic tests for assessing the health of an individual.
- “Clinical laboratory science” means any of the sciences or scientific disciplines used to perform a clinical laboratory test or examination.
- “Clinical laboratory practice” means the application of clinical laboratory sciences or the use of any means that applies the clinical laboratory sciences within or outside of a licensed or registered clinical laboratory. Clinical laboratory practice includes consultation, advisory, and other activities inherent to the profession.
- “Clinical laboratory” means a place used, or an establishment or institution organized or operated, for the performance of clinical laboratory tests or examinations or the practical application of the clinical laboratory sciences. That application may include any means that applies the clinical laboratory sciences.
- “Direct and constant supervision” means personal observation and critical evaluation of the activity of unlicensed laboratory personnel by a physician and surgeon, or by a person licensed under this chapter other than a trainee, during the entire time that the unlicensed laboratory personnel are engaged in the duties, as specified.
- “Direct and responsible supervision” means both of the following:
- Personal observation and critical evaluation of the activity of a trainee by a physician and surgeon, or by a person licensed under this chapter other than a trainee, during the entire time that the trainee is performing clinical laboratory tests or examinations.
- Personal review by the physician and surgeon or the licensed person of all results of clinical laboratory testing or examination performed by the trainee for accuracy, reliability, and validity before the results are reported from the laboratory.
- “Licensed laboratory” means a clinical laboratory licensed, as specified, pursuant to state law.
- “Location” means either a street and city address, or a site or place within a street and city address, where any of the clinical laboratory sciences or scientific disciplines are practiced or applied, or where clinical laboratory tests or examinations are performed.
- “Physician office laboratory” means a clinical laboratory that is licensed pursuant to state law and is either: (A) a clinical laboratory that is owned and operated by a partnership or professional corporation that performs clinical laboratory tests or examinations only for patients of five or fewer physicians and surgeons or podiatrists who are shareholders, partners, or employees of the partnership or professional corporation that owns and operates the clinical laboratory; or (B) a clinical laboratory that is owned and operated by an individual licensed physician and surgeon or a podiatrist, and that performs clinical laboratory tests or examinations only for patients of the physician and surgeon or podiatrist who owns and operates the clinical laboratory.
- “Point-of-care laboratory testing device” means a portable laboratory testing instrument that is used within the proximity of the patient for whom the test or examination is being conducted; is used in accordance with the patient test management system, the quality control program, and the comprehensive quality assurance program established and maintained by the laboratory, as specified; it performs clinical laboratory tests or examinations classified as waived or of moderate complexity under the federal CLIA; performs clinical laboratory tests or examinations on biological specimens that require no preparation after collection; or, provides clinical laboratory tests or examination results without calculation or discretionary intervention by the testing personnel; performs clinical laboratory tests or examinations without the necessity for testing personnel to perform calibration or maintenance, except resetting pursuant to the manufacturer’s instructions or basic cleaning.
- “Public health laboratory” means a laboratory that is operated by a city or county, as specified.
- “Registered laboratory” means a clinical laboratory pursuant to BPC Section 1265(a)(2).
- Specifies that a person licensed to provide health care services under the laws of this state, as specified, is not prohibited from practicing the profession or occupation for which he or she is licensed, nor does it authorize a person licensed under the laws of this state to perform or order services for which he or she is not licensed to perform or order. (BPC Section 1206)
- Exempts specified pharmacy clinical laboratory settings from inspection by CDPH if the laboratory only performs specified tests classified as waived under CLIA and are approved by the federal Food and Drug Administration (FDA) for sale to the public without a prescription in the form of an over-the-counter test kit, as specified. (BPC Section 1206.6)
- Defines “unlicensed laboratory personnel” to mean a laboratory aide, histocompatibility technician, cardiopulmonary technician, or other person performing the activities authorized by Section 1269. (BPC Section 1212)
- Requires each clinical laboratory to maintain records, equipment, and facilities that are adequate and appropriate for the services rendered and operated without injury to the public health; requires the CDPH to inspect laboratories no less than once every two years if licensed, maintain a record of those inspections, ensure that every licensed clinical laboratory in California is inspected at least that often; provides that registered clinical laboratories shall not be routinely inspected by CDPH; requires a clinical laboratory to perform all clinical laboratory tests or examinations classified as waived under CLIA in conformity with the manufacturer’s instructions; clinical laboratories performing tests or examinations not waived under CLIA must establish and maintain a patient test management system, as specified, must establish and maintain a quality control program, and may use alternative quality control testing procedures recognized CMS or an Individualized Quality Control Plan and a comprehensive quality assurance program, as specified. (BPC Section 1220)
- Declares that it is the public policy of the state to ensure that California’s laboratory standards, including its laboratory personnel standards, be sustained in order to provide accurate, reliable, and necessary test results; that inspections are the most effective means of furthering this policy; that it is not the intent of the Legislature to reduce in any way the resources available to the department for inspections, but rather to provide the department with the greatest flexibility to concentrate its resources where they can be most effective; that it is the intent of the Legislature to provide for an inspection process that includes state-based inspection components and that determines compliance with federal and state requirements for clinical laboratories. (BPC Section 1223(a))
- Authorizes the CDPH to employ, or contract for, inspectors, special agents, and investigators, and provide any clerical and technical assistance as necessary to administer this chapter and may incur other expenses as necessary. (BPC Section 1223(b))
- Provides that laboratories accredited by a private, nonprofit organization shall be deemed by the CDPH to meet state licensure or registration requirements, and be issued a certificate of that deemed status by the CDPH, provided that both the organization and the laboratory meet specified requirements. (BPC Section 1223(c))
- Requires every person or clinical laboratory licensed or registered under California clinical laboratory requirements to report to the CDPH within 30 days of any change of name or address. (BPC Section 1227)
- Requires a clinical laboratory performing clinical laboratory tests or examinations classified as of moderate or of high complexity under CLIA to obtain a clinical laboratory license as specified; provides that no clinical laboratory license shall be issued by the CDPH unless the clinical laboratory and its personnel meet the CLIA requirements for laboratories performing tests or examinations classified as of moderate or high complexity, or both; requires a clinical laboratory performing tests or examinations subject to a certificate of waiver or a certificate of provider-performed microscopy under CLIA, to register with the CDPH; provides that a license or registration is valid for one year unless revoked or suspended; provides that whenever a clinical laboratory ceases operations, the laboratory owners, as specified, must notify the CDPH of this fact, in writing, within 30 calendar days from the date a clinical laboratory ceases operation and maintain all medical records and laboratory records, as defined, for specified timeframes; provides that a separate license is required for each location except as specified; provides that the CDPH must state in writing the reason for denying an applicant for clinical laboratory licensure; provides that a withdrawal of application for clinical laboratory licensure does not deprive the CDPH to institute or continue with a proceeding for denial; and provides that the suspension, expiration, or forfeiture by operation of law of a license or registration does not deprive the CDPH’s authority to institute or continue an action against a license or registration. (BPC Section 1265)
- Provides that a primary care clinic that submits an application to the CDPH for a clinic license pursuant to Health and Safety Code (HSC) 1204(a) may submit before or along with the clinic application an application for a license to conduct clinical laboratory tests and examinations, as specified. (BPC Section 1265.1)
- Requires a clinical laboratory’s license and the license or renewal permit of each person performing tests to be conspicuously posted. (BPC Section 1266)
- Provides that any denial, suspension, or revocation of a license must be conducted in compliance with HSC Section 100171. (BPC Section 1267)
- Requires the CDPH to establish standards for the evaluation of cytologic slides, reporting of slides, personnel competency standards and a proficiency testing program for clinical laboratories offering cytology services. (BPC Section 1272.4)
- Requires the CDPH to develop or adopt a CDPH-administered proficiency testing program for laboratories offering cytology services to be administered by the CDPH or by a proficiency testing program approved by the CDPH; provides that the program conduct announced and unannounced onsite proficiency testing under normal working conditions. (BPC Section 1272.6)
- Specifies that it is unlawful for a person to own, operate, maintain, direct, or engage in the business of operating a clinical laboratory, as defined, unless he or she possess a valid clinical laboratory license; provides that a health facility, as specified, is not required to obtain a clinical laboratory license. (BPC Section 1281)
- Authorizes the CDPH to establish and charge fees, as specified, for licensing activities, including: (BPC Section 1300 – 1302)
- Issuing a duplicate license for a change of name; (BPC Section 1268)
- Application for licensure, renewal, and delinquency for personnel and trainee licenses; (BPC Sections 1260.3, 1270.5,
- Application for a license to perform moderate or high complexity tests, as defined under CLIA, based on the number of tests performed annually;
- Renewal of a license to perform moderate or high complexity tests, as defined under CLIA, based on the number of tests performed annually;
- Examinations pursuant to this chapter, as specified;
- Application for registration to perform tests or examinations considered waived under CLIA or provider-performed microscopy;
- Cost recovery for CDPH to conduct a complaint investigation, impose sanctions, or conduct a hearing, as specified; specifies that the amount paid by a laboratory for these enforcement activities is limited to no more than the amount a laboratory would pay under CLIA for the same actions; requires a laboratory applying for initial licensures to pay for the CDPH to conduct any re-inspections to ensure compliance;
- Continuing education; (BPC Section 1275)
- Cost recovery for an inspector to travel to a clinical laboratory outside of California to ensure compliance; and,
- Additional laboratory locations, as specified. (BPC Section 1300)
- Provides that the fees specified in BPC Section 1300 are adjusted annually pursuant to HSC Section 100450. (BPC Section 1300.1)
- Requires the CDPH to give written notice prior to a license or registration expiring, as specified, and authorizes the CDPH to require an examination as a condition for reinstatement if the licenses renewal fee is not paid, as specified. (BPC Section 1301)
- Provides that CDPH may revoke or suspend a clinical laboratory license if the laboratory does not meet the requirements to operate, as specified; provides that CDPH may impose directed plans of corrections, as defined under CLIA; impose civil money penalties in specified amounts for each day of noncompliance; and impose onsite monitoring, as defined under CLIA, and recover costs associated with onsite monitoring. (BPC Section 1310)
EXISTING FEDERAL LAW:
- Establishes CLIA, which regulates clinical laboratories that perform tests on human specimens and sets standards for facility administration, personnel qualifications and quality control. These standards apply to all laboratory settings, including commercial, hospital or physician office laboratories. (Title 42 of the Code of Federal Regulations (CFR), Part 493)
THIS BILL:
- Repeals state mandates for CDPH to conduct laboratory inspections and contract with accreditation organizations. (BPC Section 1223)
- Repeals reporting requirements for a licensed clinical laboratory when the laboratory changes a name or address. (BPC Section 1227)
- Repeals provisions allowing a primary care clinic, or a network of primary care clinics, as defined, to obtain a license to operate a clinical laboratory that conducts moderate to high complexity tests or examinations; repeals application provisions for these primary care clinics to apply for licensure. (BPC Sections 1241.1, 1265.1)
- Repeals provisions requiring a clinical laboratory performing moderate or high complexity tests or examinations to be licensed by CDPH; repeals provisions requiring clinical laboratories performing tests or examinations considered waived under CLIA to register with CDPH; repeals provisions describing the application process, lifetime of a license or registration, notices required of CDPH as they relate to licensed clinical laboratories, withdrawal and renewal of a clinical laboratory license, suspension, expiration, and forfeiture of a clinical laboratory license; and repeals requirements for a licensed clinical laboratory to maintain medical and laboratory records, as specified. Repeals provisions making it unlawful for a person to own, operate, maintain, direct, or engage in the business of operating a clinical laboratory, as defined, unless he or she possess a valid clinical laboratory license. (BPC Section 1265 and 1281)
- Repeals requirements relating to the display of a clinical laboratory license and the license or current renewal permit of each person performing tests. (BPC Section 1266)
- Repeals requirements for a denial, suspension, or revocation of a license to be in compliance with HSC Section 100171. (BPC Section 1267)
- Repeals fees associated with clinical laboratory licensing or registration. (BPC Sections 1268, 1300(p), and 1300.1)
- Repeals requirements relating to standards and requirements for cytology programs, including proficiency testing and reporting to the CDPH. (BPC Section 1272.4 and 1272.6)
- Repeals authorization for CDPH to impose, instead of suspension or revocation of a license, directed plans of corrections, as defined under CLIA; impose civil money penalties in specified amounts for each day of noncompliance; and impose onsite monitoring, as defined under CLIA, and recover costs associated with onsite monitoring. (BPC Section 1310)
- Specifies that clinical laboratories must continue to comply with federal provisions specified in CLIA and must adhere to quality control plans, inspections, and enforcement policies set forth by CMS.
- Makes other conforming, technical, non-substantive changes.
FISCAL EFFECT: Unknown. This bill is marked fiscal by the Legislative Counsel.
COMMENTS:
Purpose. This bill repeals the laws requiring a clinical laboratory to be licensed and inspected by the CDPH, including the licensing fees associated with licensure of clinical laboratories and provides that clinical laboratories in this state are still subject to the federal CLIA, including the fees and enforcement policies set forth by CLIA.
This bill is sponsored by the author. According to the author, “Laboratory Field Services (LFS) is the state entity responsible for licensing clinical laboratories and clinical laboratory personnel in California. In two successive audits over [eight] years, the State Auditor has found that LFS is woefully neglecting its state mandate. Despite past Legislative efforts to increase its budget, allow for additional staffing, and reduce workload through a mechanism to contract [with] accrediting bodies, [LFS] continues to fail to meet the majority of its mandates. In the Auditor’s September 2015 report, she noted that state and federal law regarding clinical labs is highly duplicative. In fact, in the mid 1990’s, California made strides to try to become exempt from federal oversight. In this process, the Legislature passed laws which were purposely duplicative of federal standards [(SB 113 (Maddy), Chapter 510, Statutes of 1995)]. However, in 1999, the State decided not to move forward with the exemption process. This has left us with a statutory and regulatory structure that largely copies the federal structure. AB 1774 implements the State Auditor’s recommendation that we repeal state clinical laboratory licensing because the federal government oversight is highly similar and also well implemented. AB 1774 will free up state resources to focus on personnel standards which are unique to California, while ensuring a continued level of consumer protection in clinical laboratories.”
Background. Clinical laboratories analyze human specimens such as blood, tissue, and urine so that medical professionals can make diagnoses, prescribe treatment, and perform research. The CDPH oversees these laboratories through licensing, proficiency testing, and inspections by the LFS within the CDPH. Oversight responsibilities for the LFS cover licensing of personnel, such as clinical lab scientists and phlebotomists, and in-state laboratories as well as out-of-state laboratories that test specimens originating within California. There are approximately 2,800 licensed laboratories and approximately 19,300 registered labs. A lab’s license or registration is separate from personnel licenses or other certifications.
The difference between a licensed laboratory and a registered laboratory is determined by the complexity of the tests performed by the lab. A laboratory must be licensed to perform tests of moderate to high complexity, such as testing for hepatitis or certain sexually transmitted diseases by DNA probe, but is authorized to perform all tests. Registered laboratories may perform waived tests, which are simple tests with less chance of error or risk, such as prepackaged manufactured tests. A license or registration is valid for one year and must be renewed annually for the laboratory to continue operating. Additionally, laboratories must pay a set licensing or registration fee determined by the volume and type of tests performed. Licensed laboratories must be inspected by the LFS every two years and be notified of any deficiencies revealed by an inspection. Registered laboratories need not be inspected every two years, but may be inspected as part of a complaint investigation.
The state has overseen laboratories since 1926 and has licensed laboratories since the 1950s. In addition to meeting state requirements, all laboratories that the LFS licenses or registers must adhere to federal regulations outlined in the CLIA which was enacted to ensure the accuracy and reliability of laboratory testing. The federal Centers for Medicare and Medicaid Services (CMS) has primary responsibility under the CLIA to regulate laboratories across the nation.
The CLIA groups laboratories into two categories based on the complexity of the tests performed. Laboratories that perform complex tests are subject to ongoing oversight in the form of biennial inspections and proficiency testing. At the federal level, these laboratories can choose to be overseen by the CMS or by an accreditation organization that is approved by the CMS. Laboratories that perform waived tests are overseen by the CMS.
Inspections by Accreditation Organizations. The federal government contracts with the LFS or with CMS-approved accredited organizations to carry out its inspection mandate. Pursuant to a recommendation by the State Auditor in 2008, the LFS began using a state checklist addendum while conducting the federal CLIA inspections, which would incorporate additional state laws into the CLIA inspection and qualify the one inspection for both the CLIA and state requirements. According to the Auditor, the state checklist includes 15 criteria, most of which relate to personnel standards.
Approved accredited organizations are national accrediting organizations that the CMS has vetted and determined to possess high standards and quality when conducting its accreditation process. Accreditation by one of these organizations meets the federal CLIA inspection requirements.
Although the LFS has been accepting applications since January 1, 2011, only one organization has been approved, two have been pending for the last five years, and one was withdrawn. The LFS is required to approve (or deny) an application within six months; however, the first application was under review for almost two years. The organization was approved in August 2013, but the LFS still has not entered into an agreement to specify its role and responsibilities.
The LFS inspects less than 20% of the laboratories that the LFS has not contracted with the federal government to inspect. In the Northern California LFS office, one staff person is assigned to inspect all 250 Northern California labs; however, only eight inspections were conducted in 2013-2014. In Southern California, only 195 of 600 laboratories were inspected in the same timeframe.
Exemption to Federal Oversight. A state can request to be exempted from all or part of CLIA’s requirements in order to retain full oversight over the laboratories within its jurisdiction. Senate Bill 113 (Maddy), Chapter 510, Statutes of 1995 made several changes to state law to incorporate CLIA standards and facilitate a CLIA exemption. California earned the CLIA exemption in 1999 but declined to pursue it because of concerns regarding an annual $2.4 million overhead fee paid to the federal Department of Health and Human Services. As a result, the state has been operating under a largely duplicative set of state and federal standards.
In order to be exempted, the state must establish standards that are equal to or more stringent than federal CLIA. CDPH has highlighted some of the major differences between the CLIA law and California law shown in the chart below:
Subject Matter | CLIA law | California law |
Laboratory Directors | Requires all laboratories to have a qualified director who is a state licensed physician and surgeon, bioanalyst, or doctoral scientist (not limited by specific specialty areas). | Requires all laboratories to have a director who is qualified as a California licensed physician and surgeon, clinical laboratory bioanalyst, or doctoral scientist in specific specialty areas. |
Allows only one person to serve as director. | Allows multiple directors. | |
Does not require a qualified pathologist to direct a hospital laboratory. | Requires a pathologist director for acute care hospitals. | |
Does not mandate any requirements for an individual in charge of a waived laboratory. | Requires a laboratory director for a waived laboratory. | |
Requires notification to CMS within 30 days of change of director. | Requires appointment of an interim laboratory director within 5 days of major change and notification to CDPH within 30 days. | |
Laboratory Supervisors | Does not require licensure for laboratory supervisors but requires that supervisors possess a current state license if state licensure is required. | Requires laboratory supervisors to pass an examination and have licensure by state. |
Clinical Consultant | Does not have category of technical consultant for waived tests. | Recognizes a waived laboratory technical consultant for waived tests. |
Requires clinical consultant to meet qualifications but they do not require licensure, but requires that consultants possess a current state license if state licensure is required. | Requires clinical consultant to be licensed to direct a clinical laboratory or have California licensure as a physician and surgeon. | |
Testing Personnel | Does not specify education requirements other than a minimum of an associate degree for high complexity, and high school graduation for moderate and waived testing. | Specifies education requirements including courses and credit hours: baccalaureate degree, except for US military training and experience, for high complexity; associate degree for moderate and waived. |
Does not require licensure for testing personnel but requires that testing personnel possess a current state license if state licensure is required. | Requires licensure for testing personnel. | |
Does not require continuing education (CE). | Requires CE for renewal of license. | |
Cytology | Does not require licensure of cytotechnologists. | Requires licensure of cytotechnologists. |
Limits a cytotechnologist to reading 100 Pap slides per day, or perform 200 automated screenings. | Limits a cytotechnologist to reading 80 Pap slides per day, or perform 160 automated screenings, less if adjusted for other duties. | |
N/A | Requires a cytotechnologist to record the number of Pap slides read each day at all locations at which they work. | |
Requires an authorized testing person to sign all results. | Requires a licensed person to review and release all results. | |
Phlebotomy | Does not address issues of phlebotomy. | Explains who may perform phlebotomy and under what conditions, and sets requirements of education and training to be certified by CDPH to collect blood for testing. |
Requires approval of phlebotomy training programs by CDPH. | ||
Unlicensed Personnel as Laboratory Aides | Does not have category of laboratory aide. | Requires documentation of competence of unlicensed laboratory aides, limits their activities, and specifies supervision requirements. |
Personnel Licensure Enforcement | Does not inspect for or enforce state personnel requirements; if personnel violations are found, they are referred to state program. | Checks compliance with state personnel requirements, and sanctions or penalizes for violations. |
Laboratory Owners | Does not define ownership or set qualifications for ownership. | Defines who can own and operate a laboratory, requires ownership disclosure down to 5% interest. |
Tracks change of ownership and requires notification of CDPH within 30 days. | ||
Holds owner and director jointly and severally responsible for actions of the lab. | ||
Physician Office Laboratories (POL) | Defines POL as a self-designated status. Does not specify limits to number of physicians or receipt of referral specimens from outside physicians. | Closely defines POL and allows up to 5 doctors to oversee a POL to test on their own patients. More than 5 owners are required to register or be licensed as a laboratory. |
Complaints | CLIA does not address business processes other than Medicare, doesn’t certify or inspect stand-alone specimen collection sites, and does not address inducement issues, such as the provision of personnel or supplies in exchange for referrals of laboratory work. | Performs complaint investigations of laboratories, offsite collection stations, inducement issues, or personnel issues. |
Reporting of Infectious Diseases | Do not require reporting of infectious diseases as a condition of licensure. | Requires laboratories to report infectious diseases as a condition of licensure. |
Payment for Blood Specimens | Does not address fraudulent collection of blood samples. | Prohibits soliciting, selling, or buying blood or other biological specimens to laboratories, except for research, teaching, or quality assurance purposes. |
Autoverification | Does not have a provision for autoverification using a computer algorithm in conjunction with automated instrumentation to review and verify the results of clinical laboratory tests for accuracy and reliability. | Allows autoverification using a computer algorithm in conjunction with automated instrumentation to review and verify the results of clinical laboratory tests for accuracy and reliability. Requires annual review by director. |
Posting of Personnel Licenses | Does not require posting of personnel licenses in a clinical laboratory. | Requires personnel laboratory licenses to be posted in a clinical laboratory. |
Certificate and Licensure Period | Biennial certificate. | Annual license and registration renewal. |
Histopathology | Does not require direct supervision of personnel performing dissection, slide preparation or staining of specimens for histological examination because CLIA does not consider these technical components to be testing. | Requires direct supervision by a pathologist of a person engaged in histological dissection when the person assisting a pathologist is not board-certified. |
Control | Federal government sets rules through regulation and publication of guidelines. | California controls statutes and regulations, with statutory changes subject to legislative authority and review. |
State Audit Reports. In 2008, the California Bureau of State Audits published an audit report on the effectiveness of LFS titled Department of Public Health: Laboratory Field Services’ Lack of Clinical Laboratory Oversight Places the Public at Risk. The report concluded that the LFS had not provided its state mandated oversight of labs, struggled to respond to complaints, and did not have sufficient controls for its policies and procedures. The LFS attributes these issues to a lack of funding, but failed to properly increase fees. The report further detailed missed opportunities for the LFS to leverage its resources to help meet their state mandated requirements.
The State Auditor recently published its 2015 update report (Follow-up – California Department of Public Health: Laboratory Field Services is Unable to Oversee Clinical Laboratories Effectively, but a Feasible Alternative Exists). The update concluded that the LFS is still not performing its mandated oversight requirements. Although the LFS has made progress in rectifying issues raised in the 2008 report, the LFS continues to be ineffective in maintaining laboratory oversight. Additionally, the LFS made an unauthorized fee increase in 2015 that resulted in laboratories overpaying by more than $1 million. Since the 2008 report, the LFS has collected more than $12 million in laboratory fees that have not been spent. Despite this surplus, the LFS still faces personnel shortages and continues to miss inspections, handle complaints and conduct proficiency testing.
The LFS has also demonstrated problems with its proficiency testing program, sanctioning program, and complaint inspection. According to the State Auditor, the LFS has not established timeframes for complaint investigation, resolution, or follow up. The LFS has only sanctioned four facilities since 2007 and did not collect any civil money penalties during the audit period. In one case, the LFS took more than 15 months to fine a laboratory after investigating and confirming use of unlicensed laboratory personnel. Furthermore, the Auditor found that the LFS has not inspected half of the required laboratories in the State, and has not inspected any of the required out-of-state labs. State law has required inspection of out-of-state laboratories since 1996, but LFS did not begin inspecting them until November 2014. In 2014, the LFS failed to inspect 93% of these labs.
According to the State Auditor, “we believe Laboratory Services’ workload largely duplicates federal oversight with no meaningful benefit to consumers. State law and CLIA are nearly equivalent in their mandates, and the oversight each requires is redundant: Both Laboratory Services and CMS collect fees from laboratories to perform inspections, monitor proficiency testing, investigate complaints, and issue sanctions. Eliminating the portion of Laboratory Services that we have found to be exceedingly deficient for many years would end the duplicate oversight and the duplicate fees. CMS has processes in place to ensure that it effectively administers CLIA; therefore, relying on CLIA would keep the public health benefits of laboratory monitoring intact, as they are today, while reducing the regulatory burden on California’s clinical labs.”
In short, the current system of state licensure for clinical laboratories may not provide any additional benefits or protections to consumers.
Prior Related Legislation. SB 744 (Strickland), Chapter 201, Statutes of 2009, authorized LFS to contract with accreditation organizations, if approved by LFS, to serve as the state inspecting agent. If a laboratory earned accreditation from one of these organizations, the laboratory would meet the state inspection requirement. This bill was sponsored by the CDPH.
ARGUMENTS IN SUPPORT:
The California Society of Pathologists writes in support, “[This bill] does not disrupt current unique California personnel standards or the enforcement of those standards. The specifics of the reform can be debated but it is clear that reform of the current LFS licensing authority is long overdue.”
The California Society of Dermatology & Dermatological Surgery (CalDerm) writes in support, “This bill would save precious health care resources by ending the State’s redundant licensing requirements – including ending the cost of redundant licenses and enabling inspection and enforcement personnel to focus on more critical issues.”
The California Chapters of American College of Physicians write in support, “This bill would save precious health care resources by ending the State’s redundant licensing requirements – including ending the cost of redundant licenses and enabling inspection and enforcement personnel to focus on more critical issues.”
The California Hospital Association writes in support, “The [2015 State Auditor’s report states] that since the problems that have plagued LFS have persisted, the state’s consumers have, in effect, been relying on federal oversight from the [CMS] through its administration of [CLIA]. LFS’ oversight of laboratory facilities largely duplicates federal oversight with no meaningful benefit to consumers, yet both LFS and CMS collect fees from laboratories to perform inspections, monitor proficiency testing, investigate complaints, and issue sanctions. [This bill] would repeal state law requiring that laboratory facilities be licensed by the state, thus reducing the regulatory and financial burden on laboratory facilities. CHA does support the continuation of the personnel standards and any efforts to ensure the enforcement of these standards.”
ARGUMENTS IN OPPOSITION:
The Engineers and Scientists of California, IFPTE Local 20 writes in opposition, “Federal law is different in this area and the feds are not going to enforce this state’s laws. Rather, we should be providing more stringent direction to the [CDPH] and [LFS] to ensure that they do their job protecting patients.”
The California Labor Federation writes in opposition, “[T]he repeal of California laws regulating clinical laboratories would only erode quality standards. California’s regulations were put into place to respond to specific concerns, and despite the regulator’s lack of oversight, those laws are still needed. We cannot depend on the federal government to enforce state law. Rather than throw out state law, we should work to find a way to make the state regulator more effective and thereby preserve important state protections for patients and workers.”
The California Association of Bioanalysts (CAB) writes in concern, “We urge you to address the root cause for the unfavorable State audit, rather than reacting hastily to abolish a licensure that, as far as the CAB is concerned, has provided the clinical laboratories in the State of California with much needed oversight and accountability.”
IMPLEMENTATION ISSUES:
- If the state clinical laboratory license requirements are removed, all medical and laboratory records should be maintained.
- If state licensure of a clinical laboratory is repealed, CDPH should maintain its authority to inspect labs for personnel standards and impose corrective actions or citations and fines, as appropriate. The appropriate number and frequency of inspections is debatable and the practicality of surprise inspections versus scheduled biennial inspections may not be implemented in such a way that clinical laboratories maintain the highest level of consumer protection in regards to tests and examinations, record maintenance, and proper training of employees.
- It may be useful to amend the current state licensure structure to a modified compliance structure. This modified structure would require CDPH to recognize accreditation organizations that are approved under the federal CLIA and require CDPH to monitor labs for compliance with state standards that are more stringent than federal standards. This modified structure would also authorize the state to concentrate its resources on upholding personnel standards, allowing the CDPH to focus on the provisions that go above and beyond what is required by the federal CLIA, during inspections and complaint investigations.
- Although stakeholders maintain there are distinct and stringent differences between state and federal law, it is unclear what those differences actually are, and can make inspections, mandated or not, difficult to conduct consistently. The author should consider requiring CDPH to make these differences available to the public.
Amendments:
- To address the maintenance of records issue raised above, the bill should be amended as follows:
On page 25 after lines 1-6, insert:
“1272.1(a) Whenever a clinical laboratory ceases operations, the laboratory owners, or delegated representatives of the owners, and the laboratory directors shall notify the department of this fact, in writing, within 30 calendar days from the date a clinical laboratory ceases operation. For purposes of this subdivision, a laboratory ceases operations when it suspends the performance of all clinical laboratory tests or examinations for 30 calendar days at the location for which the clinical laboratory is licensed or registered.
(b)(1) Notwithstanding any other provision of law, owners and laboratory directors of all clinical laboratories, including those laboratories that cease operations, shall preserve medical records and laboratory records, as defined in this section, for three years from the date of testing, examination, or purchase, unless a longer retention period is required pursuant to any other provision of law, and shall maintain an ability to provide those records when requested by the department or any duly authorized representative of the department.
(2) For purposes of this subdivision, “medical records” means the test requisition or test authorization, or the patient’s chart or medical record, if used as the test requisition, the final and preliminary test or examination result, and the name of the person contacted if the laboratory test or examination result indicated an imminent life-threatening result or was of panic value.
(3)For purposes of this subdivision, “laboratory records” means records showing compliance with CLIA and this chapter during a laboratory’s operation that are actual or true copies, either photocopies or electronically reproducible copies, of records for patient test management, quality control, quality assurance, and all invoices documenting the purchase or lease of laboratory equipment and test kits, reagents, or media.
(4)Information contained in medical records and laboratory records shall be confidential, and shall be disclosed only to authorize persons in accordance with federal, state, and local laws.
(c)The department or any person injured as a result of a laboratory’s abandonment or failure to retain records pursuant to this section may bring an action in a court of proper jurisdiction for any reasonable amount of damages suffered as a result thereof.”
- To address the issue of enforcement authority, the author should amend the bill to include:
- Authority for CDPH to impose corrective actions, citations and fines, and sanctions; and,
- Authority for CDPH to enter clinical laboratories to enforce state law and regulation including, but not limited to, state standards that are more stringent than federal standards.
- To address the issue of a modified compliance structure, the author should amend the bill to:
- Require CDPH to recognize accreditation organizations that are approved under the federal CLIA;
- Require CDPH to monitor, inspect and investigate unaccredited laboratories for compliance with state standards that are more stringent than federal standards; and,
- Authorize the state to concentrate its resources on upholding personnel standards
- To address the issue of transparency in differences between state and federal law with respect to clinical laboratories, the author should amend the bill to:
Require CDPH post on its Internet web site, a comprehensive list of the differences between state and federal law.
REGISTERED SUPPORT:
California Society of Pathologists
California Society of Dermatology & Dermatologic Surgery (CalDerm)
California Chapters of American College of Physicians
California Hospital Association
REGISTERED OPPOSITION:
Engineers and Scientists of California, IFPTE Local 20
California Labor Federation
California Association of Bioanalysts
Analysis Prepared by: Gabby Nepomuceno / B. & P. / (916) 319-3301, Vincent Chee / B. & P. / (916) 319-3301
Discussed in Hearing
Assembly Standing Committee on Business and Professions
Bill Author
Bill Co-Author(s):